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Retroviruses are a family of clinically significant and scientifically fascinating
viruses that infect a wide array of organisms from all vertebrate classes. The two
hallmark events in the life cycle of retroviruses are the reverse transcription of the single
stranded RNA (ssRNA) genome generating a double stranded DNA (dsDNA) and the
integration of this dsDNA into the host genome. Because integration is irreversible and
the infected cells are usually difficult to target for elimination in the host, the infection is
generally permanent. HIV-1, the most important and well-studied member of all
retroviruses, is the causative agent of acquired immune deficiency syndrome (AIDS) for
which no vaccine or cure is known. Since recognition of the AIDS epidemic, around 25
million people have died from HIV-1 related causes, including 2 million in 2007.
Currently, 33 million people are believed to be living with the virus, with most of these
people living in sub-Saharan Africa, where 67% of all infected people reside and 75% of
AIDS deaths occurred in 2007.
When retroviruses infect germ cells or germ cell progenitors, the virus can
become endogenized. These viruses, called endogenous retroviruses (ERV), make up
more than 8% of the human genome. The integrated virus will be present in the genome

of all cells of the individual derived from the infected germ cell, and be passed on to
progeny in a Mendelian manner to following generations. Both chance and the insertion’s
effect on the fitness of the host can determine the allelic frequency in the population.
Hence, elements which produce large quantities of viral proteins and progeny or elements
that insert into a necessary gene will likely reduce the fitness of the host and as an allele
will be negatively selected in the host population.
Currently, there is no known replication competent HERV, as most proviruses are
filled with deletions and premature stop codons. However, one family of Class II HERV,
HERV-K(HML-2), seems to have been replicating until recently. The HERV-K(HML-2)
family includes human specific members and elements that are polymorphic in the human
population, suggesting replication since the divergence of humans from chimpanzees 6
million years ago and potentially more recently as well.
In this body of work, the problem of the lack of a replication competent virus
sequence is circumvented by deducing a consensus sequence from the youngest set of
HERV proviruses. Named HERV-KCON, we find that many of its components are
functional individually and together enable infection of target cells in a single-cycle
infection system. Using this system, we have characterized the previously unknown
aspects of HERV-K(HML-2) life cycle, such as location of assembly and budding,
dependency on cell replication, and more extensively, its integration site preference.
HERV-KCON’s interaction with current anti-retroviral host proteins is accessed, and
evidence of the same interaction occurring in vivo is presented in the context of
APOBEC3G.

I would like to dedicate this work to my family. My parents, who started with very little,
have always provided me with a supportive and loving environment, and instilled in me
the value of education and hard work. My sister has always been kind, and despite our
divergent professional and personal paths, still represents in many ways what I strive
toward. They enabled everything I have done.

iii

ACKNOWLEDGMENTS
I would like to acknowledge the people my laboratories, past and present, for their
scientific and personal support. Thank you for making late nights and weekends fun, in
and out of lab.
I would also like to acknowledge my friends. Thank you for your patience, your
company, and your support. You made the unbearable moments pass and happier
moments last.
I also appreciate the help and support of my committee, Dr. Charles Rice, Dr. Jack Lenz,
and Dr. Nina Papavasiliou, and my collaborators, Dr. Mike Malim (UCL), Dr. Fredrick
Bushman (University of Pennsylvania), and Dr. Troy Brady (University of
Pennsylvania).
The Dean’s office members and the administrative staff of Rockefeller University and
ADARC have been tremendously helpful over the years in multiple aspects of my life.
Thank you.
Lastly, I would like to acknowledge the city. I love New York. It is the only home I have
known in my adult life. I pray that I will be back one day.

iv

TABLE OF CONTENTS

Dedication
Acknowledgements
Table of Contents
Table of Figures
Table of Tables
List of Publications

iii
iv
v
vii
ix
x

I. INTRODUCTION

1

1. Retroviridae
2. Integration site preference of retroviruses
3. Endogenous retroviruses
4. History of the discovery of HERV-K superfamily
5. Activity and replication potential of HERV-K(HML-2)
6. Restriction factors

II. MATERIALS AND METHODS

1
14
15
20
23
28

37

1. Cloning of endogenous HERV-K proviruses
2. Derivation and synthesis of HERV-KCON
3. HERV-KCON–derived expression plasmids
4. Other expression plasmids
5. Cell lines
6. Transfection
7. Infection
8. Reverse Transcription Assay
9. Generation of anti-HERV-K CA antibody
10. HERV-K protein analysis
11. Analysis of de novo integrated HERV-KCON proviral DNA
12. HERV- K sequence analysis
13. HERV-K hypermutation assay
14. Aphidicolin induced cell arrest and infection
15. Infection and recovery of integration sites
16. Analysis of integration site distributions

III. RESULTS

37
38
40
43
43
44
44
45
45
46
47
48
49
50
50
52

53

Chapter 1. Endogenous HERV-K proviruses
1. Introduction to human endogenous retroviruses
2. HERV-K(HML-2)
v

53
53
54

3. HERV-K113 LTR
4. HERV-K113 and YY2
5. Replication capacity of K113 and K108

66
67
70

Chapter 2. Derivation of HERV-KCON and the single-cycle infection system
1. Derivation of HERV-KCON
2. HERV-KCON sequence
3. HERV-KCON proteins
4. Establishment of single-cycle infection system

74
74
75
89
96

Chapter 3. Restriction factors and HERV-K
1. Introduction to restriction factors
2. Effects of TRIM proteins on HERV-KCON infection
3. Effect of tetherin on HERV-KCON release
4. Effect of APOBEC proteins on HERV-KCON infection
5. Hypermutated HERV-K proviruses in modern human DNA
6. Flanking nucleotide characteristics of G-to-A changes in hypermutated
HERV-K proviruses
7. Hypermutation of HERV-K by APOBEC3 proteins during in vitro
replication

109
109
110
112
115
117
120
122

Chapter 4. Integration of HERV-KCON
1. Introduction to retrovirus integration
2. HERV-K integration preference relative to genomic markers
3. HERV-KCON integration preference relative to endogenous HERV-K
integration sites

129
129
130

IV. DISCUSSION

143

V. REFERENCES

162

vi

137

LIST OF FIGURES
Figure 1 Phylogenetic analysis of Retrovirus family.......................................................... 2
Figure 2 Basic genomic layout of retroviruses ................................................................... 4
Figure 3 Life cycle of HIV-1 .............................................................................................. 5
Figure 4 Reverse transcription of retroviruses .................................................................... 7
Figure 5 Retrovirus integration ........................................................................................... 9
Figure 6 Location of restriction sites in HERV-K(HML-2) ............................................. 38
Figure 7 Map of pCRVI .................................................................................................... 42
Figure 8 Chromosomal distribution of HERV-K(HML-2) LTRs. ................................... 62
Figure 9 The activity of HERV-K(HML-2) LTR inducing factor or factors in NCCIT
cells ................................................................................................................................... 68
Figure 10 The modest transcription enhancing activity of YY2....................................... 70
Figure 11 K113 and K108 derived proviral constructs ..................................................... 72
Figure 12 Undisrupted open reading frames in HERV-K proviruses ............................... 75
Figure 13 Phylogenetic analysis of HERV-K proviruses and HERV-KCON ..................... 76
Figure 14 Sequence of HERV-KCON ................................................................................. 88
Figure 15 Expression of HERV-K proteins and release of virus-like particles ................ 90
Figure 16 RT activity of HERV-KCON VLPs .................................................................... 91
Figure 17 In vitro purification of HERV-KCON CA .......................................................... 93
Figure 18 Efficacy of polyclonal HERV-KCON CA antibody ........................................... 94
Figure 19 Plasma membrane localization of HERV-KCON Gag ....................................... 94
Figure 20 Electron microscopy of HERV-KCON VLPs ..................................................... 95
Figure 21 Diagram of HERV-KCON derived packageable genome constructs ................. 97
Figure 22 Generation of single cycle infectious HERV-KCON VLPs ............................... 99
Figure 23 Lack of infection by RT mutant HERV-KCON VLPs ..................................... 100
Figure 24 Infection of HERV-KCON VLPs with RT mutation ........................................ 101
Figure 25 AZT sensitivity of HERV-KCON infection...................................................... 102
Figure 26 Transduction by HERV-KCON Gag-PR-Pol and genomes .............................. 102
Figure 27 Identification and confirmation of HERV-KCON integration sites.................. 104
Figure 28 Tropism of HERV-KCON ................................................................................ 106
Figure 29 Cell cycle dependency of HERV-KCON .......................................................... 108
Figure 30 Effect of TRIM5 proteins on HERV-KCON infection ..................................... 111
Figure 31 Localization and effect of TRIM22 on HERV-KCON infection ...................... 113
Figure 32 Effect of tetherin on HERV-KCON VLP release ............................................. 114
Figure 33 Expression and effect of human APOBEC3 proteins on HERV-KCON infection
......................................................................................................................................... 116
Figure 34 Nucleotide changes in human-specific HERV-K proviruses relative to HERVKCON ................................................................................................................................ 118
Figure 35 Flanking nucleotides of C-to-T and G-to-A changes in non-hypermutated
HERV-K ......................................................................................................................... 121
Figure 36 Flanking nucleotides of G-to-A changes in hypermutated HERV-K ............. 123
Figure 37 Frequency of di- and trinucleotide for all G-to-A and GG-to-AG changes ... 124
Figure 38 Hypermutation of HERV-KCON during in vitro infection .............................. 126
Figure 39 Flanking nucleotides of G to A changes incurred during in vitro infection of
HERV-KCON .................................................................................................................... 127
vii

Figure 40 Comparison of in vivo and in vitro mutations ................................................ 128
Figure 41 Integration target site selection of HERV-KCON relative to other retroviruses
......................................................................................................................................... 134
Figure 42 Integration target site selection of HERV-KCON by chromosome .................. 135
Figure 43 Integration of HERV-KCON versus resident ERV2 elements ......................... 139
Figure 44 HERV-K integration into the Y chromosome ................................................ 140
Figure 45 Proviral orientation of de novo HERV-KCON vs resident HERVs ................. 141

viii

LIST OF TABLES

Table 1 HERV-K(HML-2) LTRs in the human genome .................................................. 55
Table 2 Proviral HERV-K(HML-2) in the human genome .............................................. 64
Table 3 Integration data sets used ................................................................................... 135

ix

LIST OF PUBLICATIONS

Brady T.L., Lee Y.N., Ronen K., Malani N., Berry C.C., Bieniasz P.D., Bushman, F.D. (2009)
Integration target site selection by a resurrected human endogenous retrovirus. Genes and
Development. 23(5):633-42.
Jouvenet N., Neil S.J., Zhadina M., Zang T., Kratovac Z., Lee Y.N., McNatt M., Hatziioannou T.,
Bieniasz P.D. (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by
tetherin. Journal of Virology. 83:1837-44.
Lee Y.N., Malim M.H., and Bieniasz P.D. (2008) Hypermutation of an ancient human retrovirus
by APOBEC3G. Journal of Virology. 82:8762-70.
Lee Y.N. and Bieniasz P.D. (2007) Reconstitution of an infectious human endogenous retrovirus.
PLoS Pathogens. 3:e10.

x

I. INTRODUCTION

1. Retroviridae
Retroviruses are a family of clinically significant and scientifically fascinating
viruses that infect a wide array of organisms from all vertebrate classes [reviewed in
(Goff, 2007)]. The two hallmark events in the life cycle of retroviruses are the reverse
transcription of the single stranded RNA (ssRNA) genome generating a double stranded
DNA (dsDNA) and the integration of this dsDNA into the host genome (Baltimore, 1970;
Temin and Mizutani, 1970). Because integration is irreversible and the infected cells are
usually difficult to target for elimination in the host, the infection is generally permanent.
The classification of retroviruses is based on phylogenetic analysis using the
highly conserved RT sequence (Figure 1) [reviewed in (Goff, 2007)]. Alpharetroviruses
are avian retroviruses that are often oncogenic, such as Rous sarcoma virus (RSV).
Betaretroviruses include protoptype members mouse mammary tumor virus (MMTV)
and Mason Pfizer monkey virus (MPMV), which both assemble at a perinuclear region,
then are transported to the plasma membrane for release (Chopra and Mason, 1970;
Jensen et al., 1970; Rhee and Hunter, 1990a). Gammaretroviruses has the largest number
of members and also is the only genus that infects multiple vertebrate classes (Gifford
and Tristem, 2003; Goff, 2007). The most widely studied member is the group of murine
leukemia viruses (MLV), which can be divided into subgroups based on their receptor
usage (Goff, 2007). Deltaretroviruses infect primates and cattle, and contain multiple
accessory proteins (Goff, 2007). Human T-lymphotropic virus 1 (HTLV-1), the prototype
member that was the first human retrovirus discovered, causes T cell leukemia and
lymphoma in humans (Poiesz et al., 1980; Yoshida et al., 1982). Epsilonretroviruses
1

infect fish and reptiles and have large and complex genomes up to 13kb in length, with
the walleye dermal sarcoma virus as the prototype (Martineau et al., 1992; Martineau et
al., 1990). Spumaretroviruses, as exemplified by chimpanzee foamy virus, are often
highly cytopathic in cell culture, but are not associated with any disease in host (Linial,
1999). Lentiviruses have a unique cone shaped core morphology that distinguishes them
in electron microscopy from other retroviruses (Goff, 2007). The name is derived from
the slow infection and disease progression in the infected hosts from the Latin word
lentus, which means “slow” (Desrosiers, 2007). The group can be roughly divided into
primate and nonprimate members, with the highly related human immunodeficiency
viruses (HIVs) and simian immunodeficiency viruses (SIVs) making up the primate
group.

Figure 1 Phylogenetic analysis of Retrovirus family
An unrooted neighbor-joining phylogenetic tree based on the amino acid sequence of RT protein. SnRV,
snake retrovirus. WDSV, walleye dermal sarcoma virus. PERV, porcine endogenous retrovirus. GALV,
gibbon ape leukemia virus. FeLV, feline leukemia virus. FFV, feline foam virus. BFV, bovine foamy virus.
SFV, simian foamy virus. SRV, squirrel monkey retrovirus. BLV, bovine leukemia virus. Other viruses are
discussed in the text. This figure is taken from Weiss (Weiss, 2006).
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HIV-1, the most important and well-studied member of all retroviruses, is the
causative agent of acquired immune deficiency syndrome (AIDS) for which no vaccine
or cure is known. In 1981, Centers for Disease Control and Prevention reported five cases
of Pneumocystis carinii pneumonia in young, homosexual men, a disease that normally
affects only severely immunosupressed patients (CDC, 1981). The causative agent was
identified by two separate groups in 1983 and 1984 from patients exhibiting AIDS or preAIDS symptoms (Barre-Sinoussi et al., 1983; Popovic et al., 1984). Since recognition of
the AIDS epidemic, around 25 million people have died from HIV-1 related causes,
including 2 million in 2007 (UNAIDS, 2008). Currently, 33 million people are believed
to be living with the virus, with most of these people living in sub-Saharan Africa, where
67% of all infected people reside and 75% of AIDS deaths occurred in 2007 (UNAIDS,
2008).
Retrovirus genomes range between 7kb to 13kb in length, but the basic genomic
features are common to all retroviruses (Figure 2). Two copies of the long terminal repeat
(LTR) that flank the ends of the viral genome are identical at the time of integration.
They contain important cis elements such as the promoter sequence, TATA box, and
polyA signal. The repeat nature of LTR is important in the process of reverse
transcription, and ensures that the entire viral sequence is copied to following virus
generations. Between the LTRs are the three protein coding open reading frames (ORFs),
gag, pol, and env. The gag ORF encodes the structural protein domains that target Gag to
a membrane (matrix, MA), form the virus core (capsid, CA), and encapsidate the viral
genome (nucleocapsid, NC), and is sufficient to form virus-like particles. The pol ORF
encodes the protease, responsible for cleaving the polyproteins into individual

3

Figure 2 Basic genomic layout of retroviruses
All retroviruses have the same basic genomic layout. LTR, long terminal repeats, includes three regions U3,
R, and U5. The solid line between the two LTRs represents the genomic sequence. Three main ORFs gag,
pol, and env are depicted by the open boxes between the two LTRs. No accessory proteins are depicted.

components during maturation, reverse transcriptase (RT), and integrase (IN) proteins.
However, betaretroviruses and deltaretroviruses encode protease in a separate ORF from
Pol. The env ORF encodes for the Env protein, necessary for interaction with host receptor and

virus entry. Some viruses encode additional proteins, collectively called accessory
proteins, which are usually products of different splice events.
HIV-1 life cycle, shown in Figure 3, has been studied in great detail and serves as
an example for all retroviruses. The infection begins with the interaction between the
virus Env and a host cell membrane protein or proteins that is recognized and bound by
Env, also called a receptor. Most viruses use one receptor protein, such as MMTV, which
uses transferrin receptor (Tfr-1) as its receptor (Ross et al., 2002), but primate lentiviruses
utilize CD4, and an additional coreceptor of either CCR5 or CXCR4 (Alkhatib et al.,
1996; Choe et al., 1996; Dalgleish et al., 1984; Deng et al., 1996; Doranz et al., 1996;
Feng et al., 1996; Maddon et al., 1986). For most retroviruses, the interaction between
Env and its receptor leads to the fusion of the virus membrane and the host cell plasma
membrane and the entry of the viral core into the cell cytoplasm (Marsh and Helenius,
1989; McClure et al., 1990; Stein et al., 1987). A few exceptions of this method of entry

4

Figure 3 Life cycle of HIV-1
A simplified life cycle of HIV-1 is depicted. gp120 and gp41 are the transmembrane and surface subunits
of HIV-1 Env. p24 is HIV-1 CA. The three classes of antiretroviral drugs, fusion inhibitors, RT inhibitors,
and protease inhibitors, are depicted at the location of their action. NRTI, nucleoside RT inhibitor. NNRTI,
non-nucleoside RT inhibitor. This figure is taken from Simon et al (Simon and Ho, 2003).

are MMTV, some strains of MLV, and subgroup A of avian leukosis virus (ALV), which
are thought to be dependent on pH-dependent conformational change of Env in
endosomes prior to fusion of the host and virus membranes (McClure et al., 1990;
Mothes et al., 2000; Ross et al., 2002). Recently, data suggesting an endocytosed route of
entry for HIV-1 as also been published (Miyauchi et al., 2009).
The fusion of the two membranes leads to the entry of the virus core into the
cytoplasm. The core is composed of a shell of CA, and within the shell two copies of the
viral genome and the associated virus proteins such as NC, RT, and IN. Different viruses
form different core shapes according to genera, which are distinguishable by electron
5

microscopy. The disassembly of the virus core, a process named uncoating, is not well
understood, but permits reverse transcription to begin in most retroviruses. What triggers
reverse transcription is unknown, but is likely linked to a proper disassembly of the core,
as mutations that disrupt the stability but not the formation of the core impairs reverse
transcription (Forshey et al., 2002). It has also been postulated to be the exposure to high
concentrations of dNTPs in the cytoplasm during uncoating (Goff, 2007). Foamy viruses
are an exception, where reverse transcription begins as early as assembly in the producer
cell, and virus particles contain partially or completely reverse transcribed virus genomes
(Moebes et al., 1997; Yu et al., 1999).
The reverse transcription complex (RTC) is a large ribonucleoprotein structure
composed of the two strands of ssRNA coated with NC, and also associated with RT, IN,
CA, and Vpr, an accessory protein, in HIV-1 in which reverse transcription takes place
(Bukrinsky et al., 1993; Fassati and Goff, 2001; Heinzinger et al., 1994). In MLV, the
RTC is composed minimally of the viral genome, CA, RT, and IN (Fassati and Goff,
1999). The two ssRNA are used as template for the synthesis of the final dsDNA viral
genome by RT in a series of discrete and highly ordered steps depicted in Figure 4
(Gilboa et al., 1979a; Gilboa et al., 1979b).
After reverse transcription, the dsDNA and associated proteins are called
preintegration complex (PIC), a large complex that contains elements necessary for
nuclear entry and integration. In addition to the viral dsDNA, MLV PIC is known to
contain CA, and likely also contains RT and IN proteins (Bowerman et al., 1989). HIV
PIC contains the dsDNA genome, Vpr, IN, and RT, but no longer contains CA and NC,

6

Figure 4 Reverse transcription of retroviruses
The black line represents RNA, light and dark orange lines represent minus and plus strands of DNA,
respectively. Reverse transcription is primed by 3’ end of tRNA bound to the primer binding site (PBS) to
begin the synthesis of minus-strand strong stop DNA. Once RT reaches the 5’ end of RNA, the DNA is
degraded by the RNase-H portion of RT. In first strand transfer, the minus-strand DNA anneals to the 3’
end of RNA by the repeated (R) sequence to resume minus strand DNA synthesis, along with RNaseH
digestion of the RNA in RNA:DNA hybrid sequence. A polypurine tract (PPT) in the RNA genome that is
relatively resistant to RNaseH primes the synthesis of plus strand strong stop DNA, which continues until
the PBS of the minus strand. RNaseH removes the tRNA, exposing the PBS in the plus strand that is
complementary to PBS in the minus strand. In second strand transfer, the PBS in the minus and plus strands
anneal. Each strand serves as the template for the other for completion of reverse transcription. This figure
is taken from Telesnitsky et al (Telesnitsky and Goff, 1997).
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which likely has disassociated from the complex since reverse transcription (Bukrinsky et
al., 1993; Heinzinger et al., 1994; Miller et al., 1997; Vodicka et al., 1998).
Retroviral PICs access the host genome for integration via different methods.
MLV requires mitosis for the breakdown of the nuclear membrane to access the host
genome, as they do not possess a means to cross the nuclear membrane (Lewis et al.,
1992; Lewis and Emerman, 1994). In contrast, lentiviruses can infect nondividing cells,
due to the ability of lentiviral PICs to actively cross the intact nuclear membrane in an
ATP dependent manner (Lewis et al., 1992; Lewis and Emerman, 1994; Weinberg et al.,
1991). An exception to these two methods is RSV, which can infect nonreplicating cells
at low efficacy, although it infects dividing cells much more efficiently (Hatziioannou
and Goff, 2001).
After the nuclear import of PIC, the dsDNA is integrated into the host genomic DNA via
3’ end processing, strand transfer, and gap repair (Figure 5). In 3’ end processing, the
blunt dsDNA viral genome is processed by IN whereby the two terminal nucleotides at
the 3’ strand are removed (Brown et al., 1989; Roth et al., 1989). The resulting 3’ OH
groups are used to transfer the viral DNA into the host genome via attack of the
phosphodiester bonds in the host DNA in strand transfer (Brown et al., 1989; Engelman
et al., 1991; Fujiwara and Mizuuchi, 1988). The 5’ ends are then repaired by unknown
factors (Roe et al., 1997), leaving a repeat of 4-6 nucleotides from the host DNA flanking
the integrated virus where the strand transfer occurred. As there is no mechanism to
target the integrated virus sequence and excise it from the genome, integration is
irreversible.
The integrated virus sequence, now called a provirus, contains promoter

8

Figure 5 Retrovirus integration
The orange line represents the viral cDNA, while the yellow line represents the genomic DNA. The U3, R,
and U5 regions in the LTR are represented as grey, black and white boxes. In 3’ end processing, IN
removes two nucleotides from the 3′ ends of the viral DNA, exposing 3′ hydroxyl groups. In strand transfer,
IN joins the 3′ ends of viral DNA to the genomic DNA. DNA repair enzymes fill the gaps and repairs the
break. The resulting provirus is flanked by repeated segments of the target DNA.

sequences in the U3 region of 5’ LTR to host RNA polymerase II system for
transcription. In HIV-1 and HTLV-1, accessory proteins Tat and Tax promote the
elongation of the transcript and induce higher levels of transcript, respectively (Cann et
al., 1985; Felber et al., 1985; Kao et al., 1987). Like most RNA polymerase II transcripts,
the viral transcript is capped at the 5’ end, processed, and polyadenylated at the
polyadenylation site in the 3’ LTR (Goff, 2007). The full length transcript is also spliced
to yield transcripts for Env and accessory proteins.
9

There are two means by which retroviruses export partially spliced or unspliced
transcripts from the nucleus to the cytoplasm, such as the full length genomic transcript.
Many retroviruses, such as HIV-1, HTLV-1, and MMTV, encode for an accessory
protein named Rev, Rex, and Rem, respectively, which bind to full length transcripts and
export them to the cytoplasm in a CRM-1 dependent manner (Bogerd et al., 1998; Felber
et al., 1989; Hammarskjold et al., 1989; Indik et al., 2005b; Inoue et al., 1987; Mertz et
al., 2005b; Neville et al., 1997). In contrast, unspliced MPMV transcripts contain a
constitutive export element (CTE) near the 3’ end of the genomic RNA that enable
transcript export without additional viral proteins (Bray et al., 1994). RNA with CTE are
exported in a TAP/NXF1-mediated pathway (Braun et al., 2001; Gruter et al., 1998;
Guzik et al., 2001; Katahira et al., 1999).
Viral proteins are translated from exported transcripts as polyproteins. The three
main ORFs, gag, pol, and env, encode for the structural proteins, enzymatic proteins, and
the Env protein. In betaretroviruses and deltaretroviruses, the protease protein, which is
located 5’ in the pol ORF in other viruses, is a separate ORF from the rest of pol. Pol or
prot-pol ORFs are translated as an extension of gag via translational read-through, where
the stop codon in Gag is suppressed by the ribosome, which inserts a tRNAgln at the stop
codon a fraction of the time (Yoshinaka et al., 1985), or translational frameshifting where
the ribosome slips near the end of gag ORF and continues translation in a different
reading frame (Jacks and Varmus, 1985). Hence, Gag, Gag-Prot, Gag-Prot-Pol, or GagPol polyproteins are translated depending on the virus.
The translated proteins and full length viral genome assemble to produce new
virus particles. Most retroviruses assemble at the plasma membrane via MA in the form
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of either a stretch of basic residues, named membrane-binding domain (M domain)
(Verderame et al., 1996; Zhou et al., 1994), and/or myristoylation of MA (Henderson et
al., 1983). At the plasma membrane, Gag is thought to multimerize by the effects of the
interaction domain (I domain) located at the amino terminus of NC (Campbell and Vogt,
1995; Carriere et al., 1995; Hansen and Barklis, 1995). The binding of RNA by NC is
thought to promote Gag multimerization by acting as a structural scaffold where Gag
proteins can interact (Campbell and Vogt, 1995). Betaretroviruses and spumaretroviruses
are exceptional, as the particles first assemble in a pericentriolar region in the cytoplasm
instead of the plasma membrane, then are transported to the plama membrane for release
(Rhee et al., 1990; Yu et al., 2006). The RNA genome is packaged into the particle
usually via the packaging (Ψ) sequence located in the untransted region between the 5’
LTR and gag ORF, which is either near or overlaps with sequences important for viral
RNA dimerization and splicing and binds to the Cis-His motifs in NC [reviewed in
(D'Souza and Summers, 2005)].
The final release of virus particle from the host cell is accomplished via the late
domain (L domain), which are found in various locations in the Gag protein of different
viruses [reviewed in (Bieniasz, 2006)]. PT/SAP, PPXY, and YPXL motifs have been
identified thus far as L domains, and each helps recruit a network of proteins called
endosomal sorting complexes required for transport (ESCRT) that are normally involved
in vacuolar protein sorting pathway. HIV-1 contains the PTAP motif which is recognized
by Tsg101 (Garrus et al., 2001; Martin-Serrano et al., 2001; VerPlank et al., 2001). RSV,
MPMV, HTLV-1, and MLV contain the PPPY motif which is recognized by Nedd4
family members (Blot et al., 2004; Kikonyogo et al., 2001; Martin-Serrano et al., 2005;
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Sakurai et al., 2004; Yasuda et al., 2002). Equine infectious anemia virus (EIAV)
contains the YPDL motif, which binds to Alix (Martin-Serrano et al., 2003; Strack et al.,
2003). Viruses with mutations in L domains fail to separate from the host cell membrane
remain tethered by a membraneous stalk (Gottlinger et al., 1991; Wills et al., 1994; Xiang
et al., 1996), indicating that the ESCRT complexes may help the final scission of the lipid
bilayer between the virus and the cell. After the separation of the virus particle and the
host cell, virus protease cleaves the polyproteins into the individual components, which
reassemble in the virus to form a new, mature virus particle.
The methods by which retroviruses cause diseases are diverse. Oncogenic
retroviruses were first recognized in 1911 by Peyton Rous by the discovery that transfer
of cell-free supernatant from chicken sarcoma can cause sarcoma in a new host (Rous,
1910, 1911). This discovery was followed by the discovery of viral agent in mice called
Bittner’s agent transmitted by breast milk that causes breast cancer (Bittner, 1936, 1942;
Lyons and Moore, 1962; Moore, 1963), as well as a retrovirus that caused “spontaneous
leukemia” in AKR mice (Gross, 1951). These agents, RSV, MMTV, and MLV
respectively, are the first retroviruses described and can cause cancer via different
methods. RSV and MLV are examples of transducing oncogenic retroviruses. RSV
carries the v-src gene, an avian oncogene which can transform infected cells. MLV is also
capable of transferring viral oncogenes, such as v-abl (Ableson MLV), v-ras (Harvey
MLV), and v-mos (Moloney murine sarcoma virus) (Goff et al., 1980; Shih et al., 1979;
Van Beveren et al., 1981). The discovery that viral oncogenes actually derive from the
host opened up a new field of molecular cancer research (Flint et al., 2004; Hanafusa et
al., 1977; Stehelin et al., 1976). Cellular counterparts of these genes are now known as
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proto-oncogenes, and often are involved in cell cycle or death, hence any changes to their
expression or activity may induce abnormal states, such as cancer. Non-transducing
oncogenic retroviruses do not carry oncogenic genes, but may induce cancer via
insertional mutagenesis; hence, all retroviruses are potentially non-transducing oncogenic
retroviruses. A clinical example of viral insertional mutagenesis causing cancer is the five
gene therapy patients who were treated for SCID-X, an X-linked disorder caused by a
lack of a functional γc cytokine receptor, which results in the lack of T and NK
lymphocytes (Hacein-Bey-Abina et al., 2008; Hacein-Bey-Abina et al., 2003; Howe et
al., 2008). In two separate studies, 19 of 20 patients developed functional T and NK
lymphocytes, but five developed leukemia. All five patients displayed an over-abundance
of cell clones with insertion in or near proto-oncogenes, as well as additional
chromosomal irregularities in three patients.
Non-cancer related immunodeficiency is a second means by which retroviruses
commonly cause human disease. Primate lentiviruses infect CD4+ cells, hence can infect
various immune cells such as T cells, macrophages, and dendritic cells (Dalgleish et al.,
1984; Klatzmann et al., 1984). HIV-1 infection is characterized by a slow decline of
CD4+ T cells over years, which eventually results in immunodeficiency [reviewed in
(Simon and Ho, 2003; Stevenson, 2003)]. Whether the CD4+ cells die from virus
infection or immune reaction against the infection is still unclear. Nonprimate lentiviruses
often infect macrophages or dendritic cells, and can cause immunodeficiencies (feline
immunodeficiency virus, bovine immunodeficiency virus), arthritis-like diseases (caprine
arthritis encephalitis virus, Visna Maedi virus), and anemia (EIAV).
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2. Integration site preference of retroviruses
Many of these diseases are due to the integration of the viral genome, which
accounts for the persistence of infection and insertional mutagenesis. Integrase is the viral
protein that catalyses the integration of the viral sequence into the host genome, one of
the hallmarks of retrovirus infection. An interesting and important aspect of integrase
function is how it determines where in the genome to integrate the viral genome. Studies
have shown that most retroviruses have a unique preference for the location of integration.
This preference correlates strongly with genomic markers such as transcription units or
promoter regions rather than a specific nucleotide sequence. For example, HIV-1 has a
two-fold preference to integrate into active transcription units over matched random
controls, a feature which is also independent from the target cell type used (Barr et al.,
2006; Mitchell et al., 2004; Schröder et al., 2002a). This preference may be dependent on
the association between IN protein and the host protein LEDGF/p75, which rescues IN
from proteosomal degradation in the cytoplasm, enhances DNA binding of IN, and
tethers IN to host chromatin (Busschots et al., 2005; Cherepanov et al., 2003; Llano et al.,
2004a; Llano et al., 2004b; Maertens et al., 2003). LEDGF also interacts with IN proteins
of other lentiviruses, namely HIV-2, EIAV, BIV, VMV, FIV, and EIAV, and may help
determine their preferences as well (Busschots et al., 2005; Cherepanov, 2007; Llano et
al., 2004b).
Conversely, the IN proteins of nonlentiviruses, such as RSV (alpharetrovirus),
MPMV (betaretrovirus), MLV, feline leukemia virus (FeLV, gammaretroviruses), and
HTLV-1 (deltaretrovirus) do not interact with LEDGF (Busschots et al., 2005;
Cherepanov, 2007; Llano et al., 2004b). HTLV-1 and MMTV have been shown to have
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no integration site preference (Derse et al., 2007; Faschinger et al., 2008). MLV has a
strong integration preference for promoter regions and CpG islands (Hematti et al., 2004;
Mitchell et al., 2004; Wu et al., 2003). Lastly, avian sarcoma-leukosis virus (ASLV) has a
largely random integration with minor preference for genes (Barr et al., 2005; Mitchell et
al., 2004). What determines this difference, whether it be other host proteins or intrinsic
differences in the IN proteins, is unknown.

3. Endogenous retroviruses
When retroviruses infect germ cells or germ cell progenitors, the virus can
become endogenized [reviewed in (Bannert and Kurth, 2004; Gifford and Tristem, 2003;
Lower et al., 1996)]. These viruses are called endogenous retroviruses (ERV). The
provirus will be present in the genome of all cells of the individual derived from the
infected germ cell, and be passed on to progeny in a Mendelian manner to following
generations. Both chance and the insertion’s effect on the fitness of the host can
determine the allelic frequency in the population. Hence, elements which produce large
quantities of viral proteins and progeny or elements that insert into a necessary gene will
likely reduce the fitness of the host and as an allele will be negatively selected in the host
population.
Endogenous retroviruses exist as either a provirus or a solo LTR. Over time, the
two LTR sequences in a provirus can homologously recombine, deleting all internal
sequence and leaving behind only a solo-LTR that is a composite of the two original
LTRs. How long an element remains as a provirus until its LTRs recombine is unknown,
but likely variable and stochastic. One study has shown that one nucleotide difference
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may reduce the likelihood of recombination by ten-fold (Belshaw et al., 2007). In
humans, around 85% of all human ERVs (HERVs) exist in the solo-LTR form (Lander et
al., 2001). Theoretically, exogenous retroviruses can also form solo-LTRs, but this
potential is probably of little importance in the face of the pathogenesis of the full length
virus. A preintegration site describes a state within the host population where the
integration has not occurred. Potentially, all sequence in a host is a preintegration site, but
the term is applied as a relative state to an integrated element rather than to signify the
integration potential at that location.
As discussed earlier, integration can be detrimental via insertional mutagenesis of
genes, but integration into introns can provide alternate splice sites and premature polyA
signals. While most likely harmful, these insertions can provide new transcript isoforms
(Kapitonov and Jurka, 1999; Mager et al., 1999). Also, as an LTR includes promoter and
enhancer sequences, integration near a gene can alter transcription levels or the tissue
specificity with which a given gene is expressed (Dunn et al., 2003; Landry et al., 2002;
Medstrand et al., 2001; Medstrand et al., 2002). At a genomic scale, ERVs can induce
genomic rearrangements between highly similar elements, such as ecotopic
recombination (Hughes and Coffin, 2001, 2005).
Endogenous retroviruses are present in the genomes of all vertebrates except
Agnathas, and are closely related to all genera of retroviruses except deltaretroviruses
(Herniou et al., 1998; Jern et al., 2005; Martin et al., 1997) . The naming of HERVs has
been erratic, but many are named after the primer binding site and the tRNA most likely
used to prime reverse transcription (Bannert and Kurth, 2004). Thus, HERV-K indicates
a HERV that likely uses tRNA-lysine as its RT primer.
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Most ERVs align closely with beta-, gamma-, and spumaretroviruses, which are
otherwise named as Class I, II, and III, respectively. In humans, there are around 72
HERV Class I families, such as HERV-H, HERV-W, and HERV-FRD, which intermix
with known exogenous gammaretroviruses in phylogenetic analysis (Jern et al., 2005;
Lander et al., 2001; Tristem, 2000). HERV-W and HERV-FRD include rare examples of
endogenous retroviral sequence being co-opted by the host. One locus each of HERV-W
and HERV-FRD proviruses have maintained expression and fusogenic capacity of the
Env protein in trophoblast cells in the placenta (Blaise et al., 2003; Blond et al., 2000;
Bonnaud et al., 2004; Mi et al., 2000). Named syncytin-1 and syncytin-2, the fusion
mediated by these ERV Env proteins are thought to create a layer of fused cells in the
placenta, called syncytiotrophoblasts, which is important for placentogensis and
pregnancy. Similar proteins and phenomenon have been described in mice and sheep, and
have also been shown to be necessary for a successful pregnancy in sheep (Dunlap et al.,
2006; Dupressoir et al., 2005).
An interesting nonhuman gammaretrovirus-related ERV is the koala retrovirus
(KoRV). Discovered while studying the high incidence of leukemia and lymphomas in
koalas, KoRV seems to be currently undergoing endogenization (Hanger et al., 2000;
Tarlinton et al., 2006). Both exogenous and endogenous forms of KoRV can be found,
and isolated populations do not have the endogenous form, suggesting that the
endogenization has occurred in the past 100 years after the separation of koala
populations (Tarlinton et al., 2006). How infection by this virus is related to the leukemia
and lymphoma is unclear, but plasma viral RNA levels correlate positively with disease
(Tarlinton et al., 2005).
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In humans, class II ERVs consist of ten subfamilies which align most closely with
each other in phylogenetic analysis than with any other retrovirus known, and are known
as HERV-K superfamily due to their tRNA binding site (Bannert and Kurth, 2004;
Lander et al., 2001). Betaretroviruses MMTV and Jaagsiekte sheep retrovirus (JSRV),
which infect mice and sheep respectively, exist in both endogenous and exogenous forms
and align closely with HERV-K superfamily (Gifford and Tristem, 2003). Class III has
around 20 families in the human genome, including HERV-L and HERV-S (Cordonnier
et al., 1995; Jern et al., 2005; Lander et al., 2001; Yi et al., 2004). Recently, endogenous
lentiviruses from rabbits (RELIK) and grey mouse lemurs (pSIVgml) have been
discovered, and likely form a separate class of ERVs (Gifford et al., 2008; Gilbert et al.,
2009; Katzourakis et al., 2007).
In humans, around 8% of the genome is composed of sequences of retroviral
origin, independent from retrotransposon sequences (Lander et al., 2001). All known
HERVs are defective, replete with mutations, premature stop codons, and truncations.
The retroviral insertions are found on all chromosomes, although the number does not
correlate with chromosomal size (Kim et al., 2004a; Villesen et al., 2004). Most
insertions are found outside of genes, and when in genes, are more often in the opposite
transcriptional orientation relative to the gene (van de Lagemaat et al., 2006; Villesen et
al., 2004).
As all retroviral insertions found in the human genome are defective, how the
insertions proliferate in the genome is worth considering. There are two general
mechanisms by which ERVs may proliferate. ERVs can proliferate via bone fide
extracellular particle formation and infection of a new target cell, which requires an intact
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virus sequence. Interestingly, all HERVs with a high copy number seem to have
proliferated via means additional to true replication (Gifford and Tristem, 2003).
Defective ERVs may proliferate by methods other than bone fide virus replication, such
as via exogenous infection events following complementation in trans, where functional
proteins are supplied by other endogenous or exogenous viruses. This may result in
retention of only sequences important for transcription and packaging, hence protein
ORFs should deteriorate over time. HERV-H and ERV-9 may have proliferated by this
method (Belshaw et al., 2005b). Alternatively, envelope-independent retrotransposition in
cis may occur, where an element copies itself and inserts into a new genomic locus within
the same cell, forgoing the normal extracellular phase of the retroviral life cycle. Via this
method, all ORFs except env are likely to retain a functional sequence, as Gag and Pol
will still be required for replication. HERV-K(HML-3) is a potential example of this
scenario, as its pol sequence seems to have been maintained (dN/dS = 0.15), while env
ORF has been changing more rapidly (dN/dS = 0.73) (Belshaw et al., 2005b). Defective
proviruses can also proliferate as a result of long interspersed element 1 (LINE-1) aided
retrotransposition, where the enzymes of LINE-1 provide necessary function for the viral
sequence to be reverse transcribed and integrated, akin to the proliferation of Alu
elements. In this scenario, only the sequences required for transcription and packaging
will be required, and most protein ORFs will not be maintained. Indeed, two major
groups of the HERV-W family can be traced back to either independent replication or
LINE-1 dependent replication, based on the proviral and flanking genomic sequence
(Belshaw et al., 2005b; Costas, 2002).
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Currently, there is no known replication competent HERV, but one family of
Class II HERV, HERV-K(HML-2), seems to have been replicating until recently. The
HERV-K(HML-2) family includes human specific members and elements that are
polymorphic in the human population, suggesting replication since the divergence of
humans and chimpanzees 6 million years ago and potentially more recently as well
(Barbulescu et al., 1999; Turner et al., 2001).
Although inactive, many HERVs are expressed in various tissues, and as a result
many diseases have been connected to HERV expression of RNA, protein, or virus
particles, or generation of anti-HERV antibodies [reviewed in (Blomberg et al., 2005;
Moyes et al., 2007)]. This includes various cancers (melanoma, breast cancer, germ cell
tumors), neurologic diseases (schizophrenia, bipolar disorder, multiple sclerosis),
autoimmune diseases (psoriasis, arthritis, systemic lupus erythematosus, type I diabetes),
HIV-1, and pregnancy. Notably, healthy individuals also express various HERV
products. Overall, none of the correlations with diseases establish clear evidence of
HERVs as the cause of the disease. The best correlation between HERV expression and
disease is between HERV-K(HML-2) and seminoma, where two independent studies
found that a high percentage (60% and 70%) of patients are positive for anti-Gag
antibody (Boller et al., 1997; Sauter et al., 1995). This type of correlation may be useful
for diagnostic or therapeutic vaccine purposes.

4. History of the discovery of HERV-K superfamily
Much of HERV research has focused on HERV-K(HML-2), a subfamily of the
Class II HERV-K superfamily. HERV-K(HML-2) first garnered attention due to its
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sequence similarity to MMTV, and more recently due to its young age and replication
potential.
The discovery of HERV-K superfamily was spurred by the desire to find a viral
etiology for breast cancer. By 1940s, it was already known that MMTV, at the time
known as Bittner agent or milk agent, could cause spontaneous mammary tumors in mice
regardless of genetic background, and that this agent was filterable and passed to
offspring via milk (Bittner, 1936, 1942). In an attempt to find an analogous agent in
humans, scientists looked for signs of virus in human milk and breast cancers. In 1969,
Moore et al reported finding particles morphologically similar to MMTV in human milk,
the occurrence which correlated with breast cancer (Moore et al., 1969). A few years later,
they also found that sera from some women with breast cancer could neutralize MMTV
infection in mice, and that MMTV-like virus particles were found in milk of women with
family history or women from populations with high incidence of breast cancer more
frequently than those who are not (Charney and Moore, 1971; Moore et al., 1971). These
particles showed RNA-dependent DNA polymerase activity and sensitivity to
ribonuclease (Ohno et al., 1977; Schlom et al., 1971), as well as the existence of a high
molecular weight RNA in human milk (Schlom et al., 1972), two features thought to be
unique to oncogenic RNA viruses at the time. Simultaneously, Axel et al showed that
human breast cancer cells express RNA that is homologous to MMTV RNA (Axel et al.,
1972), supporting the idea that an MMTV-like virus exists in human breast, and may be
associated with cancerous states.
Despite these signs of a retrovirus, no clear candidate virus emerged. As it was
already established that the Bittner agent could integrate into infected cells and become
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heritable (Moore, 1963), the search for the “human breast cancer virus” eventually turned
to genomic DNA. During early 1980s, two groups independently detected an MMTV-like
sequence in the human genome using probes designed based on the sequence of MMTV
gagpol (Callahan et al., 1982; May et al., 1983). This sequence had a recognizable
retroviral organization, with similarities in parts to known retroviruses based on both
DNA hybridization and sequence (Callahan et al., 1985; Deen and Sweet, 1986; May and
Westley, 1986). Studies using probes based on the reverse transcriptase region of the
Syrian hamster intracisternal A particle (IAP) also identified similar human endogenous
retroviral sequences (Ono, 1986). This study named the group of the identified
proviruses HERV-K, based on the lysine tRNA binding site sequence, the presumed
primer for reverse transcription. The same group also sequenced the HERV-K10 provirus
in its entirety, thus establishing the first prototype HERV-K (Ono et al., 1986). After
realizing that the MMTV-based probes hybridized to different clones with varying
strength, Franklin et al teased apart their collection into nine subgroups, NMWV-1 to
NMWV-9, based on hybridization differences (Franklin et al., 1988). The groups remain
largely intact today after analysis based on sequence data, but have been renamed human
MMTV like-1 (HML-1) to HML-10, in an altered order (Andersson et al., 1999).
Furthermore, studies showed that sequences similar to HERV-K is found in other
hominoids and Old World monkeys, but not New World monkeys or prosimians
(Mariani-Costantini et al., 1989), suggesting that the first germ cell integration occurred
around 35 million years ago after the divergence of New World and Old World monkeys.
In a separate line of inquiry, ultrastructural examination and electron microscopy
of cells derived from a testicular cancer revealed retrovirus-like particles budding from
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the cell, which were named human teratocarcinoma derived virus (HTDV) (Bronson et
al., 1979; Bronson et al., 1978). Transfer of supernatant from virus like particle (VLP)
producing cells to fresh cells did not result in detectable virus particles in the new cells,
suggesting either that these viruses were not infectious, or that the target cells were
nonpermissive (Lower et al., 1984). However, the supernatant contained high molecular
weight RNA and detectable reverse transcriptase activity at a sucrose density
characteristic of animal retroviruses of 1.16g/ml (Boller et al., 1983; Lower et al., 1987).
Furthermore, these viruses did not cross react with antibodies against other animal
retroviruses, and were visually and immunologically distinguishable from HTLV-1 and
HIV-1, the two human retroviruses known at the time (Lower et al., 1987). However,
excitement at discovering a new human retrovirus was soon dashed, as studies using
antibody derived against HERV-K Gag for immunoelectron microscopy and western blot
analysis of teratocarcinoma cell lines showed that HDTV and HERV-K(HML-2) are
identical viruses (Boller et al., 1993b).

5. Activity and replication potential of HERV-K(HML-2)
Since its discovery, research on HERV-K(HML-2) has focused on characterizing
the multiple proviruses in the genome, testing the activity of its individual components in
an effort to understand viral replication, and searching for a replication competent
provirus. Prior to the completion of the human genome sequencing project, screening was
manually conducted by Southern blotting analysis, Northern blotting analysis, or PCR
from cellular genomic DNA or libraries (Andersson et al., 1999; Barbulescu et al., 1999;
Barbulescu et al., 2001; Mayer et al., 1999a; Medstrand and Blomberg, 1993b;
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Medstrand and Mager, 1998; Sugimoto et al., 2001; Tonjes et al., 1999; Turner et al.,
2001; Zsiros et al., 1998). After genome sequencing, both manual genomic screens via
blots and bioinformatic approaches have been used (Belshaw et al., 2005a; Belshaw et
al., 2004; Costas, 2001; Hughes and Coffin, 2004, 2005; Romano et al., 2006).
Collectively, these studies show that components of HERV-K are still functional.
Structural proteins are capable of assembling into particles and budding from cells (Bieda
et al., 2001; Mueller-Lantzsch et al., 1993; Tonjes et al., 1999; Tonjes et al., 1997), and
protease, RT, and IN are functional in vitro (Berkhout et al., 1999; Kitamura et al., 1996;
Mueller-Lantzsch et al., 1993; Schommer et al., 1996). However, as most of the clones
tested were derived from PCR reactions that did not distinguish between the proviruses,
the identity of the proviruses to which the functional components belong is unknown.
And while not all HERV-K env ORFs encode an active protein, one Env that can
pseudotype SIV particles and permit infection has been identified (Dewannieux et al.,
2005).
More work has been conducted on an accessory protein, Rec/K-Rev. Retroviruses
often use overlapping ORFs or multiple splice products to enable expression of multiple
protein products. The splice sites, while useful for generating new transcripts, creates
another problem, namely nuclear retention of full length or partially spliced viral
transcripts. Some retroviruses, such as HIV-1, HTLV-1, and MMTV, have solved this
problem by encoding a nuclear-cytoplasm shuttling protein, which specifically binds full
length and partially spliced viral transcripts and exports them to the cytoplasm, named
Rev, Rex, and Rem, respectively (Chang and Sharp, 1989; Emerman and Malim, 1998;
Hidaka et al., 1988; Indik et al., 2005a; Mertz et al., 2005a).
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In HERV-K, northern blot analysis of polyA+ RNA from the GH teratocarcinoma
cell line using an U5 region specific probe showed the expected transcripts of GagPol and
Env, as well as smaller transcripts around 1.8-1.5 kb (Lower et al., 1993). Sequencing
these transcripts showed a doubly spliced mRNA encoding a protein whose amino acid
sequence revealed an arginine-rich motif reminiscent of HIV-1 Rev and HTLV-1 Rex
proteins. This protein, named Rec or K-Rev, has been shown to be expressed in
teratocarcinoma cell lines such as GH and Tera-2, and localizes to the nucleolus (Lower
et al., 1995). Like its HIV-1 counterpart Rev, Rec/K-Rev contains a leucine-rich nuclear
export signal (NES) and an arginine-rich nuclear localization signal (NLS), and can
export unspliced or partially spliced viral transcripts via a CRM-1 dependent manner
(Boese et al., 2001; Boese et al., 2000; Magin et al., 2000; Magin et al., 1999; Yang et al.,
1999). The Rec response element (RcRE), an RNA element that Rec/K-Rev recognizes
on the full length and partially spliced transcripts, has been mapped to the U3 region of
the 3’ LTR, which is likely folds into a complex structure (Magin-Lachmann et al., 2001;
Magin et al., 1999; Yang et al., 2000; Yang et al., 1999).
HERV-K also encodes for a dUTPase, a ubiquitously expressed protein that
catalyzes the conversion of dUTP to dUMP and PPi. This protein, encoded by
herpesviruses (EBV, VZV, and HSV-1), poxviruses (Orf virus and vaccinia virus) and
retroviruses (Baldo and McClure, 1999), is thought to reduce the fatal incorporation of
dUTP into the viral genome during replication. The acquisition of dUTPase by viruses is
believed to have occurred as a result of horizontal transfer of the dUTPase gene from a
host (Baldo and McClure, 1999). In retroviruses, three groups contain the dUTPase gene,
namely betaretroviruses, non-primate lentiviruses, and an ancient mammalian ERV-L
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family (Cordonnier et al., 1995). These three groups encode dUTPase in different
locations in their genomes, suggesting that the acquisition of dUTPase may have
occurred independently three times in retroviral evolution.
Like MMTV and MPMV, HERV-K families encode for a dUTPase protein
(Harris et al., 1997a; Mayer and Meese, 2003). A consensus dUTPase, derived from an
alignment of PCR derived HERV-K dUTPase sequences from human cell lines, is
functional in vitro (Harris et al., 1997a; Harris et al., 1999). HERV-K dUTPase is
expressed in some human cell lines, but the proviral origin and its functional capability or
effect on host is unknown (Harris et al., 2000).
Beyond individual proteins, scientists were also interested in discovering new
HERV-K proviruses, with the hopes of finding a replication competent provirus. In
screens prior to the human genome sequencing, multiple full length proviruses were
identified (Barbulescu et al., 1999; Barbulescu et al., 2001; Mayer et al., 1999a;
Sugimoto et al., 2001). The most exciting of these finds are the human specific and the
polymorphic proviruses, the youngest and the most likely to be active (Barbulescu et al.,
1999; Belshaw et al., 2005a; Herrera et al., 2006; Hughes and Coffin, 2004; Macfarlane
and Simmonds, 2004; Turner et al., 2001).
There are multiple signs in the human specific proviruses that hint at their young
age. First, the human specificity indicates that the proviruses likely integrated after the
divergence of humans and chimpanzees, estimated to have occurred around six million
years ago (Bannert and Kurth, 2004; Barbulescu et al., 1999). The polymorphic insertions
may be even younger (Barbulescu et al., 1999; Turner et al., 2001), is based on the idea
that fixation time for neutral mutations in the human population with an effective
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population size of 10,000 and generation time of 20 years will be around 800,000 years
(Graur and Li, 2000; Hughes and Coffin, 2004). Hence, any unfixed neutral insertion is
likely to have inserted less than 800,000 years ago. Furthermore, insertions that have
identical LTR sequences are thought to be less than approximately 200,000 years old.
The two LTRs of a provirus, identical at the time of integration due to the nature of
reverse transcription, will accumulate mutations independently from each other over
time, hence the number of differences between the two LTRs may serve as a molecular
clock for the insertion (Johnson and Coffin, 1999). Based on calculations of the
divergence between insertions in both humans and chimpanzees and the time since that
divergence, one change between the two LTRs is expected to occur per 200,000 to
450,000 years (Johnson and Coffin, 1999; Turner et al., 2001). Thus, identical LTRs in a
provirus is an indication that the insertion may have occurred as recently as 200,000 or
fewer years ago. One provirus, K113, incited particular excitement, as it exhibited all the
characteristics just described, in addition to its complete set of open reading frames that
exhibited no obvious mutations or truncations (Turner et al., 2001).
Bioinformatic search is a more thorough method to identify HERV-K(HML-2)
elements in the human genome. One study identified 553 HERV-K(HML-2) insertions,
of which 113 are human specific (Belshaw et al., 2005a). Most identified elements,
including all the human specific ones, likely inserted independently (Belshaw et al.,
2004; Romano et al., 2006). Two characteristics of these insertions suggest that HERVK(HML-2) was replication competent until recent times. First, the independently inserted
elements show a purifying selection on all ORFs, suggesting that the protein sequence
and likely its function has been preserved (Belshaw et al., 2005c; Belshaw et al., 2004;
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Costas, 2001). This is true for Env ORF as well, suggesting that retrotransposition in cis
(retrotransposition within the same cell) is unlikely to be a major method of proliferation.
Secondly, stop codons do not seem to be inherited from one provirus to another, which is
likely to occur if the viruses replicated via retrotransposition in trans.
The low activity of most HERVs is not surprising, as high levels of viral protein
expression or continuous replication is likely harmful to the host. One way by which
hosts may defend themselves against constant genomic assault is via antiviral host
proteins called restriction factors.

6. Restriction factors
Various SIVs and HIVs are highly similar to each other in sequence and behavior,
but also exhibit species-specific characteristics that may govern interspecies transmission
and adaptation in a new host. One determinant of the transmission or the lack thereof
between closely related species may be restriction factors, host proteins that are
expressed in many types of cells, including non-immune cells. Three major classes of
restriction factors described and studied here are the Fv-1 and TRIM5 group of proteins,
the APOBEC family of proteins, and tetherin.
Fv-1, which confers resistance to the Friend strain of MLV in various strains of
mice in a dominant and heritable by single locus manner (Lilly, 1967) [reviewed in
(Bieniasz, 2004a; Goff, 2004)], is a Gag like protein similar to that of the MuERV-L
endogenous retrovirus in mice (Benit et al., 1997; Best et al., 1996; Qi et al., 1998). Two
major alleles of the locus were found in different strains of mice which dictated their
susceptibility to different strains of MLV: cells from NIH3T3 mice carrying only the
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Fv1n allele are infectable by N-tropic MLV but block B-tropic MLV, while cells with
only the Fv1b allele, found in BALB/c mice, show the opposite susceptibility phenotype
(Gardner et al., 1980; Goff, 2004). Mice with both alleles block infection from both
strains of viruses, showing that resistance is dominant (Odaka et al., 1978). The
restriction occurs at a step after reverse transcription, but before the nuclear transport of
the virus preintegration complex and the target of Fv-1 on the virus maps to amino acid
110 of MLV CA (DesGroseillers and Jolicoeur, 1983; Kozak and Chakraborti, 1996;
Rommelaere et al., 1979). Furthermore, Fv-1’s restriction activity saturates at high
quantities of incoming virus, suggesting that a limiting factor is being used up.
Although intriguing in itself, the restriction phenotype of Fv-1 is also important
because a similar block in retrovirus infection occurs in primates (Besnier et al., 2003;
Cowan et al., 2002; Towers et al., 2003). The factor in human cells that restrict N-tropic
MLV was termed Ref-1 (restriction factor 1), and a similar factor in various nonprimate
cells that restrict HIV-1 and other retroviruses was termed Lv-1 (lentivirus susceptibility
factor 1).
Lv-1 was identified from rhesus macaque cells as TRIM5α (tripartite motif 5α)
(Stremlau et al., 2004). Subsequent studies showed that Ref-1 is the human homolog of
Lv-1, and characterized the susceptibility of numerous retroviruses to each protein
(Hatziioannou et al., 2004; Keckesova et al., 2004; Perron et al., 2004; Yap et al., 2004).
TRIM5 protein is a member of the TRIM family, whose characteristic tripartite motifs
include an N terminal RING domain, a B-box domain, and a coiled-coil domain, with an
additional C terminal domain in many members [reviewed in (Johnson and Sawyer,
2009b)].
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TRIM5α, the longest splice variant of the trim5 gene, contains a C-terminal
B30.2/SPRY domain, which is the most variable portion of the protein between species
and determines restriction specificity (Nakayama et al., 2005; Perez-Caballero et al.,
2005; Sawyer et al., 2005a; Sebastian and Luban, 2005; Stremlau et al., 2005; Yap et al.,
2005). The functions of RING and B box domains in TRIM5α remain unclear but both
are important for the protein’s restriction activity (Diaz-Griffero et al., 2006; Javanbakht
et al., 2005; Perez-Caballero et al., 2005; Stremlau et al., 2004). The coiled-coil domain
is important for multimerization, which is necessary for restriction (Mische et al., 2005;
Perez-Caballero et al., 2005). The mechanism of TRIM5α action is still unclear, but may
involve the disruption of disassembly of the viral core (Anderson et al., 2006; Perron et
al., 2007; Sebastian and Luban, 2005; Shi and Aiken, 2006; Stremlau et al., 2006; Wu et
al., 2006). Furthermore, TRIM5α has been shown to function as a RING-type finger E3
ubiquitin ligase (Yamauchi et al., 2008), suggesting a potential role independent from
retroviral infection related to protein degradation.
In a twist to the story, TRIM-Cyp, a TRIM5 protein with a retrotransposed CypA,
was described in owl monkeys that is also capable of restricting HIV-1 (Nisole et al.,
2004a; Sayah et al., 2004a). Astoundingly, an independent retrotransposition event
resulting in similar TRIM-Cyp protein have been found in macaque species as well
(Macaca nemestrina, Macaca fascicularis, and Macaca mulatta) (Brennan et al., 2008;
Liao et al., 2007; Newman et al., 2008; Virgen et al., 2008; Wilson et al., 2008).
The second family of restriction factors is the APOBEC (apolipoprotein B mRNA
editing enzyme, catalytic polypeptide-like) family of cytidine deaminases. Prior to their
identification as an antiretroviral factor, signatures of the activity of APOBEC3 proteins
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had already been detected in the HIV-1 grown in ex vivo cultures and peripheral blood
mononuclear cells (PBMCs) of HIV-1+ patients as mutations of Gs to As in the context of
either GG or GA dinucleotides (Borman et al., 1995; Janini et al., 2001; Vartanian et al.,
1991). These changes were thought to be a result of misincorporation by RT, which is
highly error prone (Preston et al., 1988; Roberts et al., 1988).
The actual cause of these changes was identified in a search for the host target of
HIV-1 accessory protein Vif. It was already established that Vif was necessary for the
production of replication competent HIV-1 particles from cells such as CEM cells, but
not in others such as CEM-SS and 293T cells (Gabuzda et al., 1992; von Schwedler et al.,
1993). A complementary DNA subtraction strategy was used to selectively amplify
cDNA unique to the nonpermissive cell population (CEM) from a related, permissive cell
population (CEM-SS) (Sheehy et al., 2002). These cDNAs were used as probes in
Northern blotting analysis to identify APOBEC (A3G) as the factor in nonpermissive
cells responsible for producing noninfectious particles from Vif-deficient HIV-1 (Sheehy
et al., 2002). In the absence of Vif, A3G is packaged into virus particles during assembly
in the producer cell and inactivates the virus for the next round of infections (Bogerd and
Cullen, 2008; Khan et al., 2007; Khan et al., 2005; Sheehy et al., 2002; Zennou et al.,
2004).
The initial studies of APOBEC proteins showed that the cytidine deaminase
activity, which resulted in a “hypermutation” of the viral genome, was important for its
restriction activity (Bishop et al., 2004b; Harris et al., 2003; Mangeat et al., 2003; Zhang
et al., 2003). A3G deaminates Cs to Us on the ssDNA, negative strand intermediate of
reverse transcription, which is read by RT as Ts and thus transcribed as As in the positive
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strand (Iwatani et al., 2006; Yu et al., 2004c). This results in the G to A change ultimately
detected on the positive strand of the viral DNA sequence. Other APOBEC3 family
members were also shown to have cytidine deaminase and antiviral activity (Bishop et
al., 2004a; Dang et al., 2008; Dang et al., 2006; Harris and Liddament, 2004b; OhAinle et
al., 2006; Yu et al., 2004a; Zennou and Bieniasz, 2006). Furthermore, other viruses and
repeat elements, including hepatitis B virus (HBV), HPV, LINE-1, Alu elements, HTLV1, foamy viruses, adeno-associated virus (AAV), MLV, and murine endogenous
retroelements, were also shown to be susceptible to antiviral effects of APOBEC family
of proteins (Bogerd et al., 2006a; Chen et al., 2006; Chiu and Greene, 2006; Delebecque
et al., 2006; Esnault et al., 2006; Muckenfuss et al., 2006; Niewiadomska et al., 2007;
Sasada et al., 2005; Stenglein and Harris, 2006; Turelli et al., 2004a; Vartanian et al.,
2008b).
Ensuing studies using mutant APOBEC proteins that lack cytidine deaminase
activity showed that hypermutation may not be the sole component of restriction (Bishop
et al., 2006; Newman et al., 2005; Opi et al., 2006; Shindo et al., 2003). Blocks in reverse
transcription and integration have been proposed as additional mechanisms, with the
caveat that the studies were conducted using APOBEC overexpression systems (Guo et
al., 2006; Holmes et al., 2007; Mbisa et al., 2007; Yang et al., 2007). However, when
A3G is titrated to natural levels, the catalytic activity seems to be the main determinant of
A3G’s antiviral activity (Browne et al., 2009; Miyagi et al., 2007).
Unfortunately, human APOBEC proteins cannot restrict HIV-1. HIV-1 Vif
prevents the encapsidation of human A3G (hAG) and A3F (hA3F) into the virus particles
by recruiting the cullin-RING ubiquitin ligase complex which leads to the

32

polyubiquitination and degradation of A3G and A3F (Kao et al., 2003; Liu et al., 2005a;
Mehle et al., 2004; Sheehy et al., 2003; Yu et al., 2003; Yu et al., 2004e).
Studies of Vpu, another HIV-1 accessory protein, led to the discovery of tetherin.
Vpu was known to enhance budding of a variety of retroviruses, suggesting that it likely
acts on a host factor rather than directly on the virus particles (Gottlinger et al., 1993;
Klimkait et al., 1990; Strebel et al., 1989; Strebel et al., 1988; Terwilliger et al., 1989). Its
effect is cell-type specific: Vpu defective particles assemble and bud normally in simian
cells such as African green monkey COS-1 cells but are blocked in others, and
accumulate at the plasma membrane as fully assembled and mature particles (Sakai et al.,
1995). Heterokaryons of permissive and nonpermissive cells result in a block, suggesting
that the factor is present in the nonpermissive cells and is dominant (Varthakavi et al.,
2003). Furthermore, IFN treatment enhances the block of Vpu defective HIV-1 release,
suggesting that the host factor responsible for the block is upregulated by IFN (Neil et al.,
2007).
Comparative microarray assay of permissive and non-permissive cell lines, as
well as IFNα treated and untreated permissive cells pinpointed the factor responsible for
blocking HIV-1 particle release in the absence of Vpu as tetherin (Neil et al., 2008a; Van
Damme et al., 2008b). Tetherin, also known as CD317, Bst-2, and HM1.24, is a
membrane protein with unknown function, but is highly expressed in B cells and multiple
myeloma-derived cells (Goto et al., 1994; Kupzig et al., 2003). Its extracellular domain
contains a coiled coil domain and three cysteines, while the C-terminus is anchored to the
membrane via a GPI-anchor and the N-terminus via a transmembrane domain (Kupzig et
al., 2003). Prior to its association with HIV-1, tetherin was thought to participate in
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vesicular trafficking due to its localization at both the plasma membrane and intracellular
compartments and its ability to be internalized (Kupzig et al., 2003). The mechanism of
tetherin’s activity on virus particles and the converse mechanism of Vpu on tetherin is
currently under investigation.
There are a few characteristics of the restriction factors described above that
further support their antiviral nature. The most prominent characteristic is positive
selection, detected by a high dN/dS ratio (nonsynonymous changes to synonymous
changes). This ratio quantifies the nucleotide changes that result in amino acid change
relative to nucleotide changes that do not, and reflect the need for and pattern of
evolution of the host in the face of evolving or new pathogens, particularly their evasion
of the host immune defense. TRIM5α, six of seven APOBEC3 family members, and
tetherin all exhibit this sign of positive selection (Conticello et al., 2005; Liu et al.,
2005b; McNatt et al., 2009a; Rhodes et al., 2005; Sawyer et al., 2004; Sawyer et al.,
2005a). Another sign of adaptation is the expansion of the locus, whereby duplicate
copies of the same gene can each adapt in different ways to different pressures, and
thereby specialize in function. For example, the APOBEC3 protein family is composed of
seven highly related members that are capable of targeting different pathogens, as noted
earlier [reviewed in (Harris and Liddament, 2004a)]. In humans, the TRIM5 locus
includes three other family members TRIM6, TRIM34, and TRIM22, the latter protein
also having evolved under under positive selection; in cows, TRIM5 locus has expanded
to five potential coding genes (Sawyer et al., 2007). Furthemore, these proteins are
upregulated by IFN, suggesting that they may be a part of a concerted effort by the host
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to combat pathogens (Asaoka et al., 2005; Neil et al., 2007; Sakuma et al., 2007; Tanaka
et al., 2006).
The constant adaptation of restriction factors is suggestive of an ongoing battle
between host and old and new pathogens. The identity of these pathogens is unknown, as
current state of restriction factors is likely a result of selective pressure from multiple
pathogens. Isolating the influence of a single pathogen is difficult, and also does not help
identify the pathogen. Furthermore, many of these battles likely occurred millions of
years ago, potentially against ancestors of modern pathogens, or against pathogens that
have been successfully controlled by the host and may no longer exist.
The only ancient pathogens whose genomic information is available are those
which have integrated their genome into that of the host, such as endogenous retroviruses
and other repeat elements. Endogenous retroviruses are fossils of ancient infections, and
their sequence provides a snapshop of the pathogen from millions of years ago.
Furthermore, as constant genomic companions to the host, any virus activity such as the
expression of viral proteins or virus replication may provide continuous interaction
between the virus and the host. Thus, ERVs likely exerted a constant selective pressure
on the host, and may have played a large role in shaping how hosts defend themselves
against current retroviruses.
A major problem of working with ERVs is the deteriorated state of the sequence,
which over years in the host genome has accumulated numerous mutations and
truncations that shrouds the original sequence at the time of infection. In this body of
work, this problem is circumvented by deducing a consensus sequence from the youngest
set of HERV proviruses. Named HERV-KCON, the function of its individual components
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and the replication potential of this virus is tested, and its life cycle is characterized.
Lastly, HERV-KCON’s interaction with current anti-retroviral host proteins is accessed,
and evidence of the same interaction occurring in vivo is presented.

36

II. MATERIALS AND METHODS

1. Cloning of endogenous HERV-K proviruses
BAC plasmid containing HERV-K113 provirus (BAC RP11-398B1) was
prepared according to instructions from the manufacturer (Invitrogen). K113 was PCR
amplified using the purified BAC DNA as template into two fragments using primers
targeting the flanking genomic sequence and SacI restriction site (4415) in pol ORF. For
clarification, all the restriction sites in HERV-K113 and HERV-KCON (discussed in
Results) used for construction of HERV-K plasmids are noted in Figure 6. The primers
targeting the flanking genomic sequence were designed based on the NCBI Nucleotide
entries AF387847 and AF387849. The 3’ half of K113 was first cloned into pXF3 using
SfiI and NheI restriction sites in the multiple cloning site (MCS) of pXF3 (K113-3’ For
SfiI: TCAACCCATGGGGCCGAGGCGGCCTGGG, K113-3’ Rev NheI: CATGTTT
CCTG CTAGCCCACAAACACATGCAGACG). The 5’ half of K113 was amplified
(K113-5’ For SfiI: TCATTCTAGGCCGAGGCGGCCTTGCATGGGGAGATTCAGAA
CC, K113 Rev1: TCTTATCAGATGCTATTGCCAGTCC) and cloned into pXF3
containing the 3’ half of K113 into SacI (4415) and SfiI restriction sites (pXF3 MCS) to
construct pXF3/K113 (Figure 6). pXF\3 is a low-copy plasmid for expression in
mammalian cells.
CMVP was cloned into the 5’ LTR U3 region up to the TATA box by overlap
PCR to construct pXF3/CMVP K113 using ClaI (pXF3 MCS) and SalI (1037) restriction
sites (Figure 6). BAC plasmid DNA containing the K108 provirus was prepared
according to instructions from the manufacturer from BAC 33P21 (Invitrogen). K108
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sequence from SacII (6488) to the end was amplified from purified DNA (HERVK SacII
For: GCACCTCCGCGGAGACGGAGACATCGCAATCG, K108 Flanking 3': GACCA
GCCTGACCAAGATGGTGAAACCTGTAGGGGTG), and inserted into SacII (6488)
and NheI (pXF3 MCS) restriction sites of either pXF3/K113 or pXF3/CMVP K113 to
construct pXF3/K113 K108 and pXF3/CMVP K113 K108 (Figure 6).

Sal I (1037)

Sac I (4416)
EcoRV (1800)

Xho I (1013)

DraIII (5756)

Age I (3975)

SpeI (3260)

Sac II (6488)
XbaI (6640)
KpnI (6851)

LTR

SwaI (8265)

LTR
Gag

Env
Prot
Pol

Figure 6 Location of restriction sites in HERV-K(HML-2)

The restriction sites used for constructing HERV-K113 and HERV-KCON plasmids are listed by name and
location in the genome. The locations are identical for K113 and HERV-KCON.

2. Derivation and synthesis of HERV-KCON
The complete HERV-K113 proviral sequence was used to search human genome
sequence using National Center for Biotechnology Information nucleotide-to-nucleotide
BLAST. Multiple entries of the same HERV-K proviruses were identified by inspection
of flanking genomic sequence and only the most recently sequenced entries were used for
the alignment. The first ten hits were aligned using AlignX program (Vector NTI
Advance 10.0.1, Invitrogen, http://www.invitrogen.com) to derive a consensus sequence
that was termed HERV-KCON. Namely, the ten hits were K101, K102, K104, K107, K108,
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K109, K113, K115, 11q22, and 12q13. Information about these proviruses is listed on
Table 2.
The complete HERV-KCON proviral sequence was synthesized using overlapping
oligonucleotides of approximately 60 bases spanning the entire genome. Oligonucleotides
were assigned to 13 groups corresponding to 13 HERV-KCON fragments of approximately
700 nucleotides and assembled using sequential PCRs. 1μl of each 100μM
oligonucleotide was mixed with other oligonucleotides of each group to make an equal
molar mix. In the first round PCR, 1μl of the mix was used in the reaction and 15 cycles
of synthesis were executed using Pfu DNA polymerase (94 °C for 10 s, 45 °C for 20 s,
72 °C for 30 s), which fills the gaps between the oligonucleotide overlaps. Thereafter, 2µl
of the reaction product was subjected to amplification using the 5′ and 3′ oligonucleotides
in each fragment group (94 °C for 20 s, 45 °C for 20 s, 72 °C for 3 min; 15 cycles).
Fragments from regions of the HERV-K genome lacking convenient restriction sites were
assembled into longer fragments of up to 1.5 kb via overlap extension PCR. A derivative
of the low-copy-number plasmid vector, pXF3, was cloned by inserting a synthetic
oligonucleotide encoding the restriction sites ClaI (pXF3 MCS), XhoI (1013), EcoRV
(1800), SpeI (3260), AgeI (3975), SacI (4416), DraIII (5756), XbaI (6640), and NheI
(pXF3 MCS) that corresponded to convenient restriction sites in the HERV-KCON
genome (Figure 6). These sites were used to sequentially insert the synthesized DNA
fragments, thereby generating the final pXF3/HERV-KCON proviral plasmid. The entire
HERV-KCON was sequenced.
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3. HERV-KCON–derived expression plasmids
Various versions of HERV-KCON were synthesized as packageable viral genome
for experiments by replacing the U3 region of 5’ LTR with cytomegalovirus (CMV)
promoter/enhancer sequence to enhance transcription and inserting a selectable marker
into the Env open reading frame to detect infection (Figure 21). CHKCG was created
from the pXF3/HERV-KCON proviral plasmid by first replacing HERV-K U3 sequences 5′
to the TATA box of the 5’ LTR with CMV promoter/enhancer sequences using
overlapping PCR and ClaI (pXF3 MCS) and EcoRV (1800) restriction sites to generate
pXF3/CMVP HERV-KCON (Figure 6). In parallel, an EGFP cDNA (Clontech) was
inserted into pCR3.1 (Invitrogen), followed by PCR amplification and insertion of the
CMVP-EGFP into KpnI (6851) site of pXF3/CMVP HERV-KCON to create CHKCG.
Similarly, a Puro cDNA was digested from pMSCV Puro (Clontech) with HinDIII and
XbaI and inserted into pCR3.1. Thereafter, a CMVP-Puro cassette was PCR amplified
and cloned into the KpnI (6851) restriction site of pXF3/CMVP-HERV-KCON to construct
CHKCP.
CCGBX, a derivative of CHKCG, was constructed by inserting a CMVP-EGFP
cassette into XbaI (6640) and SwaI (8265) restriction sites of CHKCG, resulting in a
vector genome that is slightly smaller than CHKCG and gives higher infectious titers.
CCGBX-P was derived from CCGBX by inserting a 53-bp HIV-1-derived sequence
(GATCTGAGCCTGGGAGCTCTCTGGCTTGTGACTCTGGTAACTAGAGATCCCT
C) into the 5' end of the 3' long terminal repeat (LTR) to allow specific amplification of
de novo HERV-KCON sequences upon infection of human cells. The insertion was made
using overlap extension PCR and SwaI (8265) and NheI (pXF3 MCS) restriction sites in
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the HERV-KCON vector sequence. CCBXS is a modified CCGBX with a blasticidin
resistance gene in place of EGFP for clone selection. Reverse transcriptase mutant
versions of all Pol containing plasmids were constructed by mutating the conserved
YIDD (amino acids 195-198) RT domain into AIAA, then inserting the amplified
fragment with nucleotide changes into pol ORF using SacII (6488) and DraIII (5756)
restriction sites.
HERV-K protein expression plasmids pCRVI/Gag, pCRVI/Gag-PR, and
pCRVI/Gag-PR-Pol were generated by insertion of the respective ORFs from
pXF3/HERV-KCON into the NotI restriction site of pCRVI, an HIV-1 based expression
plasmid that also expresses HIV-1 accessory proteins Tat, Rev, and Vpu (Figure 7).
Similarly, a PCR-amplified HERV-KCON Env-encoding fragment was inserted using
EcoRI and NotI restriction sites, generating pCRVI/Env. A mutant version of
pCRVI/Gag-PR, pCRVI/Gag-PR(mut), was generated by substituting the conserved
putative active site residues DTG (amino acids 33-35) to AAA. The two Rec exons were
PCR amplified from BAC RP11-33P21 (Invitrogen) containing the HERV-K108
sequence, which encodes a Rec protein that is identical to the consensus sequence, joined
using overlapping PCR, and inserted into the EcoRI and XhoI sites of pCR3.1 to generate
pCR3.1/Rec. pCR3.1 is a commercially available plasmid (Invitrogen) designed to
transiently express a cloned sequence at high levels in mammalian cells and includes the
human cytomegalovirus virus promoter and the BGH polyA signal. pCRVI/Gag-GFP
was cloned by first deleting an NcoI restriction site (1251) near the start of gag ORF by
site-directed mutagenesis. This Gag sequence was cloned into pCAGGS-HA via NcoI
and EcoRI sites, then the EGFP sequence inserted into the EcoRI site, and screened for
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correct EGFP orientation. Like pCR3.1, pCAGGS is a plasmid designed to transiently
express cloned inserts at high levels in mammalian cells, and includes the enhancer from
human cytomegalovirus immediate early promoter, the chicken β-actin/rabbit β-globin
hybrid promoter, and the rabbit β-globin polyadenylation signal. Gag-GFP was then
cloned into the NotI restriction site in pCRVI.

Figure 7 Map of pCRVI
pCRVI is a high copy plasmid for transient expression in mammalian cells derived by combining sequences
of HIV-1 and pCR3.1 (Invitrogen). Inserts cloned into the MCS are expressed at high levels by the CMV
promoter enhancer sequences and the expression of HIV-1 accessory protein, Tat. Tat activation region, the
viral sequence Tat recognizes to promote transcript elongation is located in the RU5 region. The transcripts
are exported efficienty by Rec and Rec response element (RRE) by CRM-1 dependent RNA export
pathway. Exon1 and exon2 encode for Tat and Rev in different open reading frames. Splice donor and
acceptor sites are marked by yellow and red dots, respectively.

pCR3.1/K113 LTR GFP, a plasmid that expresses GFP under the control of
HERV-K113 LTR, was constructed by a three-way ligation with K113 LTR from
pXF3/K113 described earlier (SpeI and EcoRI sites), EGFP from pEGFP-N1 (EcoRI and
NotI sites, Invitrogen), and pCR3.1 (NotI and SpeI sites). pEGFP-N1 is a commercially
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available plasmid designed to express the cloned insert in fusion with EGFP transiently at
high levels in mammalian cells (Invitrogen). The EGFP contains two amino acid changes
from GFP sequence (F64L and S65T) for higher expression and brighter fluorescence
(Invitrogen). This cloning strategy eliminates the CMVP from pCR3.1.

4. Other expression plasmids
CSGW, a packageable HIV-1 vector plasmid expressing enhanced green
fluorescent protein (EGFP), and HIV-1NL4-3 GagPol expression plasmids have been
described elsewhere (Bainbridge et al., 2001; Cowan et al., 2002). Plasmids expressing
various human APOBEC3 proteins, namely hA3A, hA3B, hA3C, hA3F, and hA3G, have
been described previously (Bishop et al., 2004a). Plasmids expressing additional human
APOBEC3 proteins (hA3DE and hA3H) were constructed using the same pCMV4-HA
vector and HindIII and XbaI restriction sites.

5. Cell lines
293T, MDTF (mouse), NIH3T3 (mouse), Pindak (squirrel monkey), TE671
(human), HeLa, CRFK (cat), and HT1080 (human) cells were maintained in Dulbecco's
modified Eagle's medium (DMEM), CHO745 (Chinese hamster) cells and TRIM5expressing derivatives in Ham's F-12 medium, and CEM (human) cells in RPMI medium,
all supplemented with 10% fetal calf serum and gentamicin.
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6. Transfection
To generate virus-like particles, 293T cells were seeded on 10-cm plates at 6 ×
106 cells per plate or in six-well plates at 1 × 106 cells per well. The following day, the
cells were transfected using 4 µg of polyethylenimine (PEI) per µg of DNA.
To generate VSVG pseudotyped HERV-KCON particles, 293T cells in six-well
plates were transfected with 1.3 μg of HERV-KCON packageable genome plasmid, 1 μg of
pCRVI/Gag-PR-Pol, 0.5 μg of pCR3.1/Rec, and 0.2 μg of VSVG. Alternatively, 293T
cells in 10-cm dishes were transfected with 6.5 μg of HERV-KCON packageable genome
plasmid, 4 μg of pCRVI/Gag-PR-Pol, 3 μg of pCR3.1/Rec, and 1.5 μg of VSVG. To
generate infectious HIV-1 virions, 293T cells were transfected in six-well plates with
0.75 µg of CSGW, 0.75 µg HIV-1 Gag-Pol, and 0.2 µg VSVG. To generate HIV-1
(HERV-KCON) pseudotypes, 293T cells in 10-cm plates were transfected with 6 μg of
HIV-1-GagPol, 6 μg of CSGW, and either 3 μg of pCRVI/HERV-KCON Env or empty
pCRVI as a control. Additional plasmids or empty control vectors were transfected when
necessary and as noted for each experiment. Medium was changed 5 or 12 hours after
transfection with fresh medium containing 5µM sodium butyrate, and virus-containing
supernatants were collected 48 hours after transfection. No Vif protein was expressed
during the generation of virions for APOBEC experiments in Figures 38, 39, and 40.

7. Infection
For infection, cells were seeded on 24-well plates the previous day (293T and
TE671 cells at 5 x 104 cells per well, CHO745 cells at 4 x 104 cells per well, HT1080
cells at 3 x 104 cells per well, Pindak, CRFK, NIH3T3, and MDTF cells at 2 x 104 cells
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per well). Filtered supernatant from transfected cells (0.2 µm) was layered onto cells with
fresh medium supplemented with 5 µg of polybrene/ml. For experiments in Chapter 4,
cells were also spinoculated at 2,000 rpm for 2 hours at room temperature. Two days after
infection, the infected cells were quantified either by counting foci microscopically, by
fluorescence-activated cell sorter analysis for GFP+ cells, or by selecting cells for drug
resistance depending on the packageable genome plasmid used for particle production.
For drug selection, cells were expanded 24 hours post infection, and placed under
blasticidin (0.25 μg/ml) or puromycin (2.5 μg/ml) for approximately ten to fourteen days.

8. Reverse Transcription Assay
Reverse transcriptase activity in 293T culture supernatants was measured using a
commercially available Lenti RT Activity Kit (Cavidi, http://www.cavidi.se) in which
BrdUTP is incorporated into a plate-bound oligo(dT)/poly(rA) substrate. Thereafter, solid
phase polymerized BrdU is detected using an anti–BrdU–alkaline phosphatase conjugate
and a colorimetric substrate. Activity is standardized using a recombinant HIV-1 RT
standard. The Lenti RT Activity Kit was used, as HERV-K(HML-2) RT had been shown
to preferentially use Mg2+ over Mn2+ as the divalent cation like HIV-1 (Berkhout et al.,
1999).

9. Generation of anti-HERV-K CA antibody
To generate an anti-CA polyclonal antiserum, the N-terminal cleavage site of CA
was first determined by Edman sequencing of the putative CA protein isolated from
purified HERV-KCON virion particles. 293T cells were transfected with pCRVI/Gag-PR,
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and the supernatant was replaced 12 hours post transfection with fresh medium
containing 5µM of sodium butyrate. After an additional 48 hours, the virus particles were
purified through a 30% sucrose gradient, and the proteins separated in a protein gel by
SDS-PAGE. The proteins were stained using amido black stain, and two bands at 30kDa
and approximately 15kDa were cut from the gel for Edman sequencing. The bands were
sent to University of Texas Medican Branch (UTMB) at Galveston Texas Protein
Chemistry Core for Edman sequencing
(http://www.utmb.edu/brf/cores/ProteinChemistry/index.html).
The exact location of cleavage is depicted in Figure 9. As CA is estimated to be
around 30 kDa, the position of the C-terminal CA cleavage site was estimated based on
the determined position of the CA N terminus. The deduced CA-encoding sequence was
cloned into pGEX-6P-1 (GE Healthcare Life Sciences) to express a glutathione Stransferase (GST)-tagged CA protein that was purified using glutathione-agarose beads.
The GST tag was eliminated by PreScission protease cleavage as per the manufacturer's
instructions (GE Healthcare Life Sciences). The purified recombinant CA protein was
used to generate the antiserum (Covance).

10. HERV-K protein analysis
The 293T cells were transfected with HERV-K plasmids as described above.
Supernatant was collected two days post-transfection, filtered (0.2 μm), and
ultracentrifuged through a 20% sucrose layer at 100,000g for 90 min at 4 °C to pellet
virus-like particles (VLPs). Transfected cells were lysed via sonication in SDS-PAGE
loading buffer and separated on 10% SDS-PAGE gels (Bio-Rad, http://www.biorad.com).
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Proteins were transferred onto nitrocellulose membrane and probed with a commercially
purchased anti–HERV-K Gag antibody (Austral Biologicals,
http://www.australbiologicals.com), or the generated anti-HERV-K CA polyclonal
antiserum. Alternatively, VLPs were separated on 4% to 20% gradient or 10% SDSPAGE gel (Bio-Rad) and silver stained using a kit, as per the manufacturer's instructions
(Sigma-Aldrich, http://www.sigmaaldrich.com).

11. Analysis of de novo integrated HERV-KCON proviral DNA
CHO745 cells were infected with CHKCP-carrying HERV-KCON(VSVG) virus
stock and transduced cells selected in 2.5 μg/ml puromycin for approximately 10 days.
From the puromycin-resistant population comprising several hundred colonies, four
single cell clones were derived by limiting dilution and expanded in culture for
approximately 2 weeks. Total DNA was extracted from each clone using the Qiagen
DNeasy Blood and Tissue Extraction kit as per manufacturer’s instructions
(http://www.qiagen.com). The extracted DNA was used as template for PCR analysis
using HERV-KCON gag-specific primers Gag-S (nucleotides 1236 to 1262) and Gag-AS
(nucleotides 1991 to 1946). Additionally, host DNA sequences flanking the integrated
CHKCP proviral DNA were cloned using the GenomeWalker kit (Clontech) according to
the manufacturer's instructions and PCR primers directed to the HERV-KCON LTRs.
Specifically, LTR-AS (GCA AGA GAG ATC AGA TTG TTA CTG TGT CTG) and
LTR-S (TAC GAG AAA CAC CCA CAG GTG TGT AGG) oligonucleotides were used
to clone sequences flanking the 5′ and 3′ LTRs, respectively. Additional PCR primers,
targeting flanking hamster DNA sequences identified via the GenomeWalker approach,
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were used to authenticate the presence of preintegration sites in uninfected CHO745 cells
and integrated provirus in three CHKCP transduced cell clones. In the example (clone No.
1) shown in Figure 27D, the primers Ham-S (GCT ACC CTG AAG ATT TGA GCC
AGT GTG C) and Ham-AS (TCT TGC AAG TTG TCC TGT GGC ATG G) were used.
For all PCR reactions, 30 cycles of amplification were completed using 200 ng of cellular
DNA, with no DNA, uninfected CHO cell DNA, or human DNA templates analyzed as
negative and positive controls, as appropriate.

12. HERV- K sequence analysis
Full-length HERV-K(HML-2) sequences in the human genome were identified
using a TBLASTX search (www.ensembl.org/Multi/blastview) of the human genome
with the HERV-KCON Gag sequence as the query sequence. Sixteen unique (by
chromosomal location) human-specific full-length HERV-K(HML-2) proviruses were
identified by cross-referencing with insertions identified by Belshaw et al. and Romano et
al. (Belshaw et al., 2005a; Romano et al., 2006). All identified insertions were included in
subgroup N, as defined by Romano et al. (Romano et al., 2006). Specifically, the
proviruses included K101, K102, K104, K106, K107, K108, K109, K113, K115, 11q22,
12q14, 19q12, 1p31 (K4), 3q27 (K50b), 3q21 (KI), and 21q21 (K60). All GenBank
accession numbers for these sequences are found in the reports by Barbulescu et al. and
Romano et al. In addition, the K60 sequence was deduced from GenBank entry
AL109763 (Barbulescu et al., 1999; Romano et al., 2006). The proviruses were aligned to
HERV-KCON using AlignX (Invitrogen) for comparison. Figures 34 and 38, below, depict
G-to-A differences between the provirus and HERV-KCON and were derived using the
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HYPERMUT program
(http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html). The p values
that accompany the sequence analyses were calculated by a chi-square test of
independence to determine whether the frequency at which each nucleotide occurred at
each position flanking each mutation was significantly different relative to its expected
frequency based on nucleotide composition.

13. HERV-K hypermutation assay
Infectious HERV-KCON particles were generated as described above using
CCGBX-P in place of CCGBX. Prior to infection, supernatant was supplemented with 10
mM MgCl2 and treated with DNase I (0.1 U per µl; Roche) for 1 h at 37°C to eliminate
residual transfected DNA. Fresh 293T cells were infected as described above. Ten hours
postinfection, total DNA was collected using the DNeasy blood and tissue kit (Qiagen).
Partial EGFP (Clontech) and HERV-K sequence of 762 nucleotides were amplified using
oligos designed to target EGFP (CGC ACC ATC TTC TTC AAG GAC GAC G) and the
inserted HIV-1 sequence (GAG GGA TCT CTA GTT ACC AGA GTC ACA AGC C)
using Phusion polymerase (Invitrogen) (98°C for 10 s, 55°C for 10 s, and 72°C for 15 s;
30 cycles). Amplified DNA was purified using a gel extraction kit (Qiagen) and cloned
into pCR-Blunt II-TOPO according to the manufacturer's instructions (Invitrogen). To
confirm the complete elimination of transfected DNA, amplification of plasmid sequence
using primers targeting the plasmid backbone sequence and the untranslated region of
HERV-K using similar PCR conditions was attempted. Also, to confirm that the
amplified sequences were derived from de novo reverse-transcribed DNA, HERV-K
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particles containing a mutationally inactivated reverse transcriptase were subjected to the
same infection procedure and PCR analysis. Twelve clones were sequenced for each
APOBEC3 protein studied, as well as the empty vector control, and compared to the
original CCGBX-P sequence for evidence of hypermutation.

14. Aphidicolin induced cell arrest and infection
HT1080 cells were seeded in 24-well plate at 5 x 104 cells per well and treated
with 2 µg/ml of aphidicolin 24 hours prior to infection to arrest at G1/S phase. The same
concentration of aphidicolin was maintained during infection. 48 hours post-infection, the
cells were fixed with 4% PFA, permeabilized in 0.1% Triton/1X PBS, and stained with
propidium iodide (1 µg/ml), and checked for cell cycle arrest and infection by FACS.

15. Infection and recovery of integration sites
For infection, 293T and HT1080 cells were seeded at 2.5 × 105 and 1.5 × 105 cells
per well, respectively, in six-well plates the previous day. Cells were spinoculated with
the DNase-treated HERV-KCON virus at 2000 rpm for 2 h at room temperature. Total
DNA was collected 48 h post-infection.
Recovery of integration sites was performed as described (Wang et al., 2007).
Two micrograms of genomic DNA were digested overnight with MseI or ApoI, ligated to
linkers overnight at 16°C, and digested a second time with PstI and DpnI. Nested PCR
was then carried out under stringent conditions using LTR primers complementary to
HERV U3 sequences. Oligonucleotides used in this study are listed in Supplemental
Table 1. DNA barcodes were included in the second-round PCR primers in order to track
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sample origin (Hoffmann et al., 2007). Amplification products were gel-purified and
sequenced by massively parallel pyrophosphate sequencing. Only sequences that
uniquely aligned to the human genome by BLAT (hg18, version 36.1, >98% match score)
and began within 3 bp of the LTR end were used in downstream analyses. Integration
sites sequences have been deposited in GenBank under the accession numbers FI497131–
FI498695.
Of the 25,102 sequences analyzed, 6873 showed a high-quality match to the
HERV-KCON vector using BLAT. Sequences were classified as 2-LTR circle if there was
a match to the U5 LTR end in the expected orientation, while allowing indels of 100 bp.
One-thousand-fifty-eight were an internal fragment derived from the internal U3 LTR
and flanking sequences. A total of 3784 sequences showed the viral DNA end abutting
internal HERV-KCON sequences and were classified as autointegration products. Another
14 sequence reads had complex structures and were not included in the above categories.
Analysis of other retroviruses and genomic HERVs integration site data sets
published previously (Table 3) were analyzed using the bioinformatics pipeline
mentioned above. Discrepancies in data set sizes likely result from differences in qualitycontrol thresholds compared with the original publications. The ERV2 data set was
generated using RepeatMasker and the human genome (hg18, version 36.1). For the
HML2(85) data set, the HERV-KCON LTR sequence was used as a query to search for
sequences 85% or higher in nucleotide similarity and longer than 600 bp using the
Ensembl BLASTN (http://www.ensembl.org/Multi/blastview). The remaining sequences
were organized by chromosomal location, and LTRs <9000 bp apart were manually
determined as either solo-LTRs or LTRs of the same provirus based on the LTR flanking
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sequence and identification of target site duplication sequence. Duplicate hits due to
genome duplications or belonging to the same provirus were condensed into a single
entry.

16. Analysis of integration site distributions
Analyses were carried out as described (Berry et al., 2006; Marshall et al., 2007).
Analyses of gene expression used data from 293T cells, with expression measured using
the Affymetrix HU133 plus 2.0 gene chip array. Expression values were ranked and
divided into eight bins according to rank. Consensus sequence analysis at the point of
integration was performed using WebLogo (http://weblogo.Berkeley.edu/logo.cgi), and
the primary sequence features found to match those expected for HERV-K integration
(data not shown).
CD4+ T cells were used to generate ChIP-Seq data (Barski et al., 2007), differing
from the cell types studied here. However, genome-wide surveys of modification
densities in different cell types from the ENCODE project show that a substantial fraction
of epigenetic marks are common to most cell types analyzed probably because a large
fraction of transcription is from “housekeeping genes.” For example, for HIV data sets,
there is no stronger correlation with epigenetic marks measured in T cells than for
integration site data sets from T cells than from other cell types (C.C. Berry, T.L. Brady,
F.D. Bushman, and K. Ronen, unpublished.). Furthermore, differences due to
experimental error were generally greater than differences due to cell type (ENCODE
Project Consortium, 2004). Thus the data from Barski et al represent a useful
approximation to the cell types studied here.
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III. RESULTS

Chapter 1. Endogenous HERV-K proviruses
1.1 Introduction to human endogenous retroviruses
Retrovirus-like LTR elements, also known as human endogenous retroviruses
(HERV), make up more than 8% of the human genome (Lander et al., 2001). There are
three main groups of human endogenous retroviruses: class I, II, and III, which are
similar to gammaretroviruses, betaretroviruses, and spumaretroviruses, respectively
(Bannert and Kurth, 2004). Regardless of genus affiliation, all HERVs known to date are
heavily mutated with insertions, deletions, premature stop codons, and truncations, and
are unlikely to be replication competent.
The class II HERVs are also known as the HERV-K superfamily, a designation
based on the tRNA-lys binding site on the viral sequence, the interaction of which is
believed to prime reverse transcription (Ono, 1986). The superfamily is subdivided into
ten families from HML-1 to HML-10 based on LTR and RT sequence (Andersson et al.,
1999; Medstrand and Mager, 1998). Each family is composed of insertions that are
around 80% or more similar to each other in RT sequence (Andersson et al., 1999;
Medstrand and Blomberg, 1993a). Of the ten subfamilies, HERV-K(HML-2) family has
been a source of particular interest, as it is believed to be the youngest of the HERV-K
superfamily, and most likely to include replication competent members.
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1.2 HERV-K(HML-2)
Many insertions of HERV-K(HML-2) family are human-specific, indicating that
they inserted after the human-chimpanzee divergence approximately six million years
ago; some are polymorphic within human population indicating an even more recent
insertion time (Belshaw et al., 2005a; Hughes and Coffin, 2004; Turner et al., 2001).
Table 1 list the HERV-K(HML-2) LTRs that were found by Ensembl nucleotide to
nucleotide BLAST using HERV-KCON LTR (HERV-KCON discussed later), organized by
chromosome location. Only hits that were 600 bps or longer and 85% or higher in
sequence similarity to HERV-KCON LTR were included. The 600 bps limit was selected
to eliminate SVA elements, a repeat element which include partial Env and 3’ LTR
sequences from HERV-K(HML-2) of around 490 bps in length and greatly outnumbers
HERV-K elements (Wang et al., 2005). The 85% sequence similarity cut off was based
on sequence similarity within HML-2 group and sequence divergence between HML-2
and HML-1, the subfamily closest in sequence to HML-2 (Medstrand and Blomberg,
1993a). 402 insertions were found. Including K113 and K103, which were discovered in
a BAC screen and is not present in the NCBI human genome sequencing project sample,
a total of 404 insertions are listed in Table 1 (Turner et al., 2001).
The number of insertions were compared to chromosome size (Lander et al.,
2001). If HERV-K integrates randomly, the insertions should be found evenly across the
chromosomes despite the differences in size, hence the number of insertions in a given
chromosome should correlate proportionately with its size. Figure 8 displays the ratio of
proportion of HERV-K insertions in each chromosome of total insertions to
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Table 1 HERV-K(HML-2) LTRs in the human genome (pages 55-61)
HERV-KCON LTR sequence was used as query in the Ensembl BLASTN search tool (http://www.ensembl.org/Multi/blastview) to identify HERV-K(HML-2)
LTRs. Hits that were less than 600 bps were eliminated in final list. All LTRs are 85% or more identical to HERV-KCON LTR, and organized by chromosome.
Both solo-LTRs and LTRs associated with proviruses are listed. The LTRs in proviral context are only listed once, and the provirus identified. LTRs that were
less than the distance of a full length HERV-K(HML-2) of 9472 bps were manually checked for proviral sequence or flanking five to six nucleotide repeats to
confirm status.

Start

End Length

Chromosome 1
1
968
1
858
252
965
123
965
1
965
1
965
123
965
1
668
5
668
1
965
4
965
1
965
220
965
1
968
5
965
123
968
3
737
1
965
1
968
1
851
123
968
1
968

969
859
717
845
972
966
845
676
670
970
964
975
757
970
965
847
740
967
968
854
849
968

Chromosomal location
Statistics
Start
End
E-val

1335050
1505586
10409558
15578104
25786928
29537184
29558546
33301704
36727459
40810285
45766362
46558555
46568022
52244505
65378071
66663086
70698933
73367572
75615359
78221263
89305134
93514927

1336016
1506443
10410267
15578945
25787892
29538146
29559386
33302369
36728118
40811250
45767324
46559519
46568771
52245471
65379030
66663931
70699668
73368536
75621731
78222109
89305980
93515894

0
0
0
0
0
0
0
2E-245
2E-279
0
0
0
0
0
0
0
0
0
0
0
0
0

Notes
% ID

Start

96.8
96.3
92.9
96.0
92.1
96.1
95.9
88.3
90.3
93.5
96.4
92.3
91.2
97.9
93.8
98.1
91.1
93.8
99.0
96.7
96.4
99.1

1
14
1
1
254
1
1
1
14
1
1
1
1
1
1
1
1
1
1
1
1
1
1

K4

End Length
965
737
965
725
849
725
639
737
965
725
725
725
965
968
968
965
965
729
965
737
961
639
965

970
732
974
732
602
731
647
744
956
731
732
732
967
968
968
970
965
738
968
745
967
649
972

Chromosomal location
Statistics
Start
End
E-val
108861590
111704102
114402293
143314771
144213168
144779880
145044648
145178373
145672607
146076983
146723221
146832410
153835955
153863081
154415638
154417876
158004210
158888553
158927199
159185475
159253249
163328444
205875083

108862554
111704821
114403262
143315496
144213765
144780605
145045283
145179105
145673553
146077708
146723946
146833135
153836920
153872260
154416605
154418833
158005174
158889277
158936427
159186205
159254211
163329078
205876042

0
9E-305
0
0
0
0
1E-246
0
0
0
0
0
0
0
0
0
0
5E-303
0
1E-300
0
4E-204
0

Notes
% ID
92.9
88.9
92.2
90.4
91.0
91.0
88.4
90.1
92.5
91.0
90.7
90.6
96.1
99.3
99.3
92.9
95.9
89.3
95.0
88.7
95.0
86.1
90.3

K102

K18

Start

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

Start
1
123
1
1
1
157
5
304
1
1
125
123
1
123
1
1
300
14
14
1
1
123
1
1
1

1
968
1
965
1
670
123
965
Chromosome 2
14
737
1
968
1
968
1
965
1
968
1
965
293
965
1
965
14
737
1
737
1
965
1
965
123
965
254
965
1
965
123
968
1
598
307
965
115
965
1
965
123
968
123
968
292
965
4
965

968
966
673
844

222594156
226122667
244312610
245245711

222595123
226123632
244313279
245246553

0
0
0
0

99.0
95.5
94.2
96.7

730
968
968
972
968
972
676
967
729
744
972
972
848
717
973
847
602
661
858
967
848
846
679
968

26826246
27536350
30689842
32354158
37305965
39401803
55360205
86341933
98112994
100667760
112436894
113408302
130436011
193114916
201711970
207609916
208772524
215376160
223763553
228936605
231416598
232149853
232996251
234741451

26826970
27537317
30690809
32355122
37306932
39402769
55360871
86342898
98113717
100668495
112437857
113409266
130436854
193115627
201712932
207610762
208773125
215376818
223764402
228937569
231417441
232150698
232996916
234742413

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9E-296
0
0
0
0
0
0
0

91.0
99.3
98.9
93.0
99.0
94.1
91.9
95.2
91.8
89.7
93.0
93.2
95.6
91.6
92.2
99.1
95.0
96.1
91.1
96.8
97.2
97.9
89.8
92.2

Chromosome 3
1
737
1
968
1
668
1
965
293
965

746
968
675
966
680

12690614
14107686
14289349
23561161
39434797

12691346
14108653
14290011
23562120
39435469

2E-290
0
7E-278
0
0

89.5
99.3
90.4
95.6
91.5

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

968
968
968
716
616
965
965
965
965
965
965
968
639
786
786
732
965
736
737
968
968
965
965
965
968

968
848
969
721
621
810
973
663
970
969
850
846
649
664
786
738
672
730
730
969
968
845
966
967
968

47276028
50532441
53986581
75525034
75777169
101474031
101537863
101867678
102901581
102905370
113765620
114225814
119741740
127092106
130842811
131258822
135717474
146909964
147722750
177106032
186763030
188087360
188093703
190451857
197138793

47276995
50533283
53987548
75525743
75777782
101474838
101538821
101868338
102902546
102906335
113766460
114234858
119742376
127101103
130843595
131259548
135718133
146910682
147723473
177106999
186772209
188088203
188094666
190452821
197139760

0
0
0
7E-284
0
0
0
0
0
0
0
0
0
0
0
9E-274
0
0
3E-302
0
0
0
0
0
0

99.1
97.5
97.4
89.9
88.9
94.6
91.9
95.6
95.6olo LTRs
95.9
90.9
99.3
K106
87.5
97.9
KI
97.3
89.6
91.1
89.2
90.7
97.1
98.6
K50B
96.6
96.8
94.4
99.4

Chromosome 4
1
968
4
734
1
732
63
732
51
767
294
965
1
769
1
968
1
965

968
740
738
676
718
676
773
969
971

135521
191826
3978297
9342737
9738282
15687679
47982337
63489191
66907073

136488
192551
3979022
9343403
9738990
15688350
47983105
63490158
66908036

0
3E-287
8E-283
2E-285
0
0
0
0
0

99.1
88.5
89.3
88.9
91.9
93.6
89.9
97.7
93.1

Start
1
123
1
1
123
1
1
4
1
1
1
1

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

Start
1
1

968
965
968
965
968
668
968
965
965
965
725
725

968
845
968
967
846
675
968
966
970
973
730
730

73213805
118323838
120483137
120536969
157445364
161117393
161799388
166046119
166130985
166136290
175540755
175558486

73214772
118324681
120484102
120537932
157446209
161118053
161800355
166047082
166131949
166143515
175541480
175559210

0
0
0
0
0
8E-282
0
0
0
0
2E-285
2E-266

99.6
96.5
99.2
96.2
99.1
88.9
99.3
96.2
93.0
92.3
91.2
90.1

Chromosome 5
1
968
1
965
1
968
1
965
123
968
1
968
304
965
1
968
123
968
1
737
1
965
123
968
1
613
14
640
123
968
1
786
1
636
14
737
1
968
123
968
5
618
1
968

971
968
969
967
848
971
664
969
846
746
967
846
619
632
847
788
646
733
968
846
620
968

1649092
4978041
8990854
18614320
30522517
35212244
43616583
44766346
54902779
55488581
58795369
74937414
92818429
105623100
116184848
119558459
149302586
149813747
156017295
169356457
178157687
178873570

1650059
4979006
8991820
18615285
30531624
35213212
43617245
44767313
54903624
55489314
58796334
74938259
92819040
105623722
116185693
119559245
149303220
149814464
156026474
169357302
178158298
178874537

0
0
0
0
0
0
0
0
0
1E-275
0
0
2E-294
1E-285
0
0
4E-217
0
0
0
5E-230
0

97.4
96.1
98.0
96.2
97.8
97.6
93.7
98.1
98.8
89.1
95.9
99.7
90.2
90.7
98.1
98.5
85.9
88.7
99.2
98.1
90.2
98.0

K5

K104

K107

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

965
737

966
744

180186875
180626704

180187835
180627433

0
0

95.6
91.7

Chromosome 6
1
965
1
737
1
965
1
737
1
965
1
965
123
968
1
965
1
668
1
668
123
968
1
679
123
968
1
968
1
968
2
968
1
872
254
965
1
965
1
968
294
965
1
737
1
965
123
968

969
740
973
745
968
970
847
968
669
674
847
683
846
968
968
969
873
720
971
969
673
743
967
851

2853896
24508490
26107438
26864459
27850221
32853826
33885715
34795218
44404059
52734587
52895551
74571757
78483381
79625224
89148026
93939805
99983968
121294551
126138689
135021941
151818041
158093470
160135762
169488305

2854860
24509226
26108401
26865189
27851186
32854790
33886560
34796183
44404724
52735250
52896397
74572435
78492688
79626191
89148993
93940769
99984839
121295255
126139654
135022908
151818712
158094201
160136717
169489152

0
0
0
3E-265
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

94.4
91.9
91.6
88.9
96.4
95.0
97.8
96.2
96.0
88.7
98.9
94.3
99.4
99.1
99.1
97.7
96.5
88.2
93.7
98.5
97.5
89.2
94.4
96.2

Chromosome 7
1
965
1
968
1
732
115
917
1
968
1
968

967
968
741
814
968
968

2395571
4588583
6908153
7007983
16203872
23046000

2396533
4606557
6908879
7008786
16204839
23046967

0
0
7E-282
7E-304
0
0

94.4
99.3
88.7
89.8
99.6
99.2

K109

K108

Start
1
1
14
115
123
1
1
1
123
1
1
1
1
1
1

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

Start
123
1

668
965
737
818
965
737
965
968
965
643
968
968
968
965
968

677
968
733
707
846
745
967
969
846
652
968
968
968
972
968

23763659
27747807
47995810
54710547
64340835
65721614
100579858
104175605
112768812
118527860
123207927
124648460
125595450
138802691
157722244

23764323
27748765
47996523
54711250
64341677
65722348
100580822
104176571
112769654
118528500
123208894
124649427
125596417
138803656
157723211

1E-226
0
3E-302
0
0
3E-278
0
0
0
2E-262
0
0
0
0
0

88.3
94.7
89.2
91.9
96.2
88.6
96.0
98.4
96.7
89.3
99.1
99.3
98.4
93.4
99.5

Chromosome 8
1
968
1
968
1
968
1
737
1
965
1
968
280
968
1
968
123
968
1
737
1
968
123
968
1
732
110
962
14
733
1
968
1
736
1
965
1
968

968
968
968
744
968
970
690
968
848
745
968
847
738
860
726
968
746
967
970

7342807
18695739
37170044
39627707
42769997
43713839
48206821
55106794
58274716
59747085
91765436
91766405
113853579
120998825
138496009
140541331
143907261
144440838
144986147

7352155
18696706
37171011
39628434
42770963
43714806
48207509
55107761
58275563
59747817
91766403
91767250
113854311
120999675
138496728
140542298
143907988
144441796
144987115

0
0
0
8E-274
0
0
0
0
0
5E-302
0
0
0
0
2E-296
0
6E-237
0
0

99.3
99.3
99.9
89.5
95.7
96.9
98.0
99.6
97.1
90.7
98.6
98.5
90.9
90.8
90.5
98.6
88.2
95.8
97.5

K115

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

965
965

845
966

145003872
145992083

145004708
145993047

0
0

95.7
96.8

Chromosome 9
1
737
1
968
366
965
1
968
1
668
123
968
1
968
2
965
123
968
1
737
14
737
1
968
123
968
123
965
4
965
1
668

748
970
603
968
677
846
968
966
846
744
733
968
846
846
964
680

11884757
17435359
26705151
31622877
33505170
67767163
71567873
74891946
110396828
112628352
113677413
123231205
133222041
135812837
135947382
136746896

11885489
17436326
26705751
31623844
33505834
67768008
71568840
74892910
110397673
112629081
113678133
123232172
133222884
135813681
135948344
136747562

9E-260
0
0
0
3E-264
0
0
0
0
2E-256
3E-272
0
0
0
0
0

88.0
97.4
93.0
98.6
89.2
98.7
98.8
96.0
98.6
88.2
89.4
99.2
99.1
97.0
97.2
87.7

Chromosome 10
1
965
1
968
1
968
1
968
1
968
1
965
1
968
268
908
123
754
1
707
1
965
1
965

969
968
968
969
971
968
969
645
633
709
972
968

6906150
27222405
27182398
41846062
43152657
66838997
69955435
99166645
101570798
104141192
104204125
132316211

6915609
27223372
27183366
41847027
43153624
66839960
69956399
99167278
101571430
104141899
104205082
132317170

0
0
0
0
0
0
0
0
0
0
0
0

93.0
99.2
99.0
98.3
97.5
94.2
97.6
92.9
96.8
96.9
91.1
94.1

K33
K103

Start

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

Chromosome 11
1
968
14
639
123
968
1
958
5
737
1
968
1
965
14
737
123
965
1
965
1
968
123
968
1
737
123
968
1
968
1
737
1
968
1
737
1
965
264
965

968
635
846
963
742
969
968
732
847
967
968
846
741
847
968
743
968
747
967
706

10369432
18878249
24424330
54955047
55581713
61179061
61718708
61850657
62382569
63052022
63054362
67127401
67281936
67392011
71553066
95962343
101071004
104640788
118096937
118415195

10370399
18878870
24425174
54956001
55582438
61180024
61719673
61851377
62383410
63052986
63055329
67128246
67282660
67392856
71554033
95963072
101080469
104641519
118106093
118415894

0
9E-242
0
0
4E-277
0
0
3E-290
0
0
0
0
7E-280
0
0
3E-282
0
1E-265
0
0

98.6
87.2
98.6
92.2
89.1
96.3
96.3
89.6
96.3
96.8
98.6
99.3
89.3
98.4
99.0
89.6
99.4
88.6
96.3
91.5

Chromosome 12
2
965
1
668
1
968
1
965
1
968
1
737
1
968
1
968
5
732
1
968
1
968
1
964
1
968

973
675
968
968
969
745
970
968
734
968
969
964
968

4700661
5516444
6865285
8505795
9644328
10615370
29976254
32143712
36418393
50134338
54013482
55080416
57007509

4701626
5517111
6866246
8506759
9645295
10616102
29977221
32144679
36419120
50135305
54014450
55081376
57016965

0
8E-289
0
0
0
2E-272
0
0
2E-282
0
0
0
0

93.2
91.0
97.0
94.9
98.5
89.8
98.5
99.1
88.8
99.2
98.8
98.6
99.3

Start
1
1
1
1
1
1
123
14
275

End Length
668
737
670
965
965
968
965
732
965

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

673
742
676
967
968
968
845
726
692

57223515
71689007
84387145
91992310
104396470
109492226
117028286
121801603
122543380

57224172
71689742
84387812
91993273
104397435
109493193
117029128
121802322
122544070

6E-268
5E-296
2E-285
0
0
0
0
0
0

89.8
89.9
90.8
96.3
96.3
99.2
96.9
91.1
95.8

Chromosome 13
1
968
1
737
1
965
1
965
1
965
1
664

969
741
967
973
973
679

19072358
22286024
49071159
53738946
69087014
94718276

19073325
22286759
49072124
53739902
69087975
94718939

0
1E-297
0
0
0
8E-225

97.7
91.5
96.6
89.9
91.7
87.6

Chromosome 14
1
965
1
965
1
965
1
965
1
968
1
737
1
965
123
965
1
965

972
969
967
967
968
745
970
846
971

19622586
19806922
22263737
37657055
64515059
77171609
77197497
77330773
99847884

19623552
19807886
22264701
37658020
64516026
77172341
77198461
77331616
99848848

0
0
0
0
0
3E-277
0
0
0

92.1
93.5
95.6
95.7
98.8
88.6
94.2
96.2
91.8

Chromosome 15
1
716
1
968
1
965
3
965
1
968
1
968

721
970
967
964
968
970

56913073
63305933
63813045
73950253
86884787
100217703

56913787
63306900
63814010
73951216
86885754
100218670

0
0
0
0
0
0

91.1
97.6
96.0
95.6
99.0
97.9

11q22
K37

K41

Start

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

Chromosome 16
1
964
1
968
4
965
14
618
123
968
123
965
1
965
1
968
1
957

964
968
967
610
848
844
967
968
957

5744394
8168764
14637508
21140961
23518420
34090800
35047430
46455871
73390803

5745357
8169731
14638461
21141561
23519265
34091640
35048394
46456838
73391759

0
0
0
1E-252
0
0
0
0
0

99.6
99.0
92.8
90.7
98.1
97.8
95.5
99.3
99.3

Chromosome 17
1
968
1
965
2
737
1
968
1
965
123
965
1
965
1
968
1
965
115
965
123
968
1
965
1
965

969
969
746
968
969
844
970
969
969
859
847
967
968

4918699
19348866
25914572
26051185
31491551
38787962
41716760
49633934
60356602
62753427
64111728
76139606
78295700

4919665
19349827
25915305
26052152
31492519
38788804
41717724
49634901
60357560
62754279
64112573
76140571
78296662

0
0
7E-272
0
0
0
0
0
0
0
0
0
0

98.0
94.9
89.0
99.0
96.4
95.1
93.6
98.0
92.7
91.5
97.8
96.3
95.4

Chromosome 18
1
968
1
968
1
965
1
668
1
737
1
736
1
737
14
732
1
965

968
969
967
674
745
744
747
728
967

1990815
4907278
22035800
27644462
37017830
62895237
63923695
64760725
64861072

1991782
4908246
22036764
27645126
37018561
62895969
63924425
64761441
64862037

0
0
0
4E-253
1E-265
7E-295
3E-268
1E-285
0

98.2
98.0
95.8
89.6
89.0
90.2
88.5
89.8
96.0

Start

End Length

Chromosome 19
130
965
127
769
1
680
14
668
1
737
1
961
1
968
246
965
83
769
76
968
1
965
1
965
1
668
1
737
123
786
1
965
1
639
14
885
1
885
1
968
137
965
110
965
1
968
1
965
1
668
1
965
1
965
1
618
38
965
5
737
1
737
1
962
1
965
1
959
3
731

838
648
680
663
742
964
968
722
688
893
970
967
678
741
664
968
645
876
886
968
836
860
969
965
674
967
967
624
931
742
744
965
968
964
748

Chromosomal location
Statistics
Start
End
E-val

337801
8285858
12203926
20054160
20440977
21542584
21633376
22258423
22549664
32820338
33313377
33872062
40102922
41416343
41429889
42188901
42298271
42712628
42812769
43048657
43813622
45156981
49789258
54084705
57100757
57103260
57238197
57534186
57616024
57680607
57753762
57892811
59033692
60153473
63026807

338634
8286501
12204605
20054811
20441705
21543546
21633376
22259142
22556398
32821230
33314342
33873027
40103586
41417074
41430552
42189859
42298906
42713500
42813653
43049624
43814444
45157833
49790225
54085664
57101423
57104222
57239162
57534797
57616952
57681333
57754488
57893771
59034655
60154429
63027532

0
0
0
1E-291
0
0
0
0
0
0
0
0
3E-255
0
0
0
5E-301
0
0
0
0
0
0
0
1E-275
0
0
2E-295
0
7E-261
5E-262
0
0
0
2E-180

Notes
% ID

96.1
90.7
96.2
89.0
89.2
94.4
99.0
96.7
92.6
98.8
93.3
95.9
88.9
91.5
99.0
94.9
88.8
93.6
97.6
99.7
91.8
90.7
98.4
95.9
91.1
95.7
96.9
87.2
94.5
88.1
88.2
93.9
93.7
92.3
84.1

K113
K51

Start

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

Chromosome 20
1
767
1
668
123
947
1
733
14
965
1
965
1
968
1
968

771
678
827
742
960
972
969
968

7884847
23623299
23789256
23911278
25162477
25169882
33313343
40032950

7885613
23623964
23790081
23912007
25163429
25170848
33314310
40033917

0
1E-224
0
4E-253
0
0
0
0

92.2
87.8
95.8
89.0
92.6
93.2
97.4
99.1

Chromosome 21
1
965
1
821
1
961
1
965
1
966
1
965
123
968
115
965

970
825
967
970
967
965
847
855

14114072
14575284
17988412
18226910
18862868
41714669
43440309
44527174

14115037
14576104
17989372
18227874
18863833
41715633
43441154
44528018

0
0
0
0
0
0
0
0

92.8
90.3
92.5
92.7
97.8
95.5
98.4
90.5

Start

End Length

Chromosomal location
Statistics
Start
End
E-val

Notes
% ID

Chromosome 22
1
968
1
737
1
737
1
965
123
965

968
745
745
967
846

17306187
21322053
22208249
22579271
22936863

17315361
21322789
22208982
22580233
22937703

0
1E-279
3E-273
0
0

98.9
89.5
89.7
93.7
96.0

Chromosome X
83
737
1
668
282
965
1
639

661
678
693
647

57378544
89354986
122641474
133992041

57379199
89355649
122642160
133992677

0
5E-243
0
3E-231

89.9
88.5
89.8
88.1

Chromosome Y
1
968
1
965
1
968
1
670
1
965
1
968
1
968
1
968

969
969
970
681
967
968
968
968

6676930
13084687
13725131
16394742
20320758
23448574
25082323
25697883

6677896
13085651
13726097
16395407
20321721
23449541
25083290
25698850

0
0
0
1E-202
0
0
0
0

97.0
92.7
96.5
86.9
93.8
99.7
99.7
99.6

K101

proportion of each chromosome length of total chromosome length. A ratio of 1 should
indicate that the number of insertions reflect the size of the chromosome. Unexpectedly,
chromosome 19 has far more insertions than expected by size while chromosomes 13, 15,
and X have far less. Other chromosomes have modest or no differences relative to
expected according to chromosome size. Aside from chromosomal size, other factors,
such as the selection of insertions based on their effect on host fitness and the fixation of
insertions at the population level may also determine HERV accumulation after infection.
A more detailed study is needed to determine the true integration preference and forces
influencing the fixation of HERV-K(HML-2) in primate genome. How chromosomal
characteristic affects HERV-K integration preference will be addressed in Chapter 4.

4.0
% HERV-K / %Chomosome

3.5
3.0
2.5
2.0
1.5
1.0
0.5

Chr 1
Chr 2
Chr 3
Chr 4
Chr 5
Chr 6
Chr 7
Chr 8
Chr 9
Chr 10
Chr 11
Chr 12
Chr 13
Chr 14
Chr 15
Chr 16
Chr 17
Chr 18
Chr 19
Chr 20
Chr 21
Chr 22
Chr X
Chr Y

0.0

Figure 8 Chromosomal distribution of HERV-K(HML-2) LTRs.
The chromosomal distribution of HERV-K(HML-2) LTRs is represented as the ratio between the
proportion of HERV-K insertions per chromosome of total insertions and proportion of each chromosome
length of total genome length. A ratio of 1 should indicate that the number of insertions reflect the size of
the chromosome. The chromosome size is taken from Lander et al, and the number of insertions from Table
1 (Lander et al., 2001).
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Although LTRs are the most abundant forms of HERV, there are also numerous
full length and truncated proviruses. Table 2 lists the insertions that include proviral
sequence in addition to LTR, including both full-length and truncated insertions. The
amino acid sequence of HERV-KCON Gag (discussed later) was used as query to search
for HERV-K insertions with coding sequence via TBLASTN search tool. Only hits that
were 85% or higher in sequence similarity to HERV-KCON were included based on
reasons described above. This search yielded forty one hits, of which twenty three are full
length, arbitrarily defined as 90% or greater in total sequence length relative to the full
length HERV-K (9472 bp) (Ono et al., 1986). Of these, seventeen proviruses are found in
human but not chimpanzee reference genome, although the sequence and location of
K103 is unknown (Barbulescu et al., 1999). Three proviruses, K4, K106, and K113, have
identical LTRs, suggesting insertion events 200,000 years ago or less (Belshaw et al.,
2005a; Johnson and Coffin, 1999).
A few insertions had non-matching flanking nucleotide repeats, suggesting that
the insertion contains sequences derived from more than one provirus. Other groups have
suggested that such insertions likely reflect homologous recombination or gene
conversion of the genomic locus with a solo-LTR, which outnumber full-length elements
by ten-fold or more, rather than a recombination of two full length elements at internal
ORF sequences (Belshaw et al., 2004; Hughes and Coffin, 2001; Johnson and Coffin,
1999). Inspection of other primate genomes may be able to resolve this issue depending
on the length of host genomic sequence included in the recombination or gene conversion.
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Table 2 Proviral HERV-K(HML-2) in the human genome (pages 64-65)
Amino acid sequence of HERV-KCON Gag was used as query to search for HERV-K(HML-2) insertions with internal sequence in the Ensemble TBLASTN
search tool (http://www.ensembl.org/Multi/blastview). Only sequences 85% or higher in similarity were included. One flanking short repeat sequence is included
when the two ends are identical, two ends are included when they do not match or cannot be clearly determined. The numbering of each insertion is according to
the HERV-KCON sequence. The proviruses described by Hughes et al have been cross-referenced (Hughes and Coffin, 2001). The names of insertions are from
previous publications (Barbulescu et al., 1999; Hughes and Coffin, 2004; Romano et al., 2006; Sugimoto et al., 2001; Turner et al., 2001). FL, full length; HS,
human specific; ID LTRs, identical LTRs.

Location
1p31.1
1q22
1q23.3
1q32.2
2q21.1
3p25.3
3q12.3
3q13.2
3q21.2
3q24
3q27.2
4q32.3
5p13.3
5p11
5q33.3
6p22.1
6q14.1
7p22.1
7q22.2
7q34
8p23.1

Flanking
ATGGAA
GGGATG
TGAGAC
GCATTC
AGAACT
CTTGGT/GAAAGT
GAGGT
GGCTGG
GGCCC
Unknown
GGTACA
CTTTCT/TTTTAT
CAGAAC
CTCCC
ACTGC
CCTGGG
ATATGC
GGTTTC
Unknown
Unknown
CCTTT

Name
K4
K102, K50A
K110, K18
None
None
K11
KII
K106, K68
KI
None
K50B
K5
K104, K50d
K8
K107, K10
HERV-K20
K109
K108, C7
None
None
K115

Contig
AC093156
AL353807
AL121985
AL137789
AC079776
AC018809
AC084198
AC078785
AC092903
AC069410
AC099661
AC106872
AC025757
AC126750
AC016577
AL121932
AL590785
AC072054
AC079796
AC004979
AC134684

Features
State
HS, ID LTRs 1-3505, 6313-6502, 6795-end
HS
FL. By ensembl blast, only one provirus found.
FL
5929-end
6094-end
Missing 3684-5940
FL
HS, ID LTRs FL
HS
FL
961-4887
HS
FL
Missing 3686-5992.
HS
FL. K104 and 50a are the same element.
FL, with insertion
HS
FL
196-end, has internal solo LTR with flanking seq GATCCC.
HS
FL
HS
FL
969-4887
937-4886
HS
FL

Location
8q24.3
10p12
10p14
10q24.2
11q12.3
11q22.1
11q23.3
12p11.1
12q14.1
12q24.11
16p11.2
19p13.3
19p12
19p12
19q12
19q13.12
19q13.42
20q11.22
21q21.1
22q11.21

Flanking
Unknown
ATGGGG
TCATTC
CAGGTG
TGGATT/ATCATT
TTGTG
AGCCT
CTGCTC/unclear
TTGGTA
AGTATT/Unknown
CTGAGG
Unknown/CAGGTC
Unknown/TGTAAT
CTCTAT
AGGTAT
Unknown
Unknown/GGCTGA
Unknown, unclear
GCCAGG/Unknown
ACCCAG

Name
None
K103
K33
None
None
11q22, K36
K37
K50e
12q14, K41
None
None
None
K51
K113
None
None
None
None
K60
K101

Contig
Features
AC087354
AF164611
HS
AL392086
AL392107
AP003064
AP000776
HS
AP002954
AC144535
AC025420
HS
AC002350
AC135776
AC010641
AC011467
AY037928
HS, ID LTRs
AC112702
HS
AD000090
AC010467
AL031668
AL109763, AF2HS
AC007326
HS

State
947-2246
FL
FL
940-end, missing chunk of Env
Two parts, start-6966, 6955-end.
FL
FL
FL, 88% identical to HERV-Kcon
FL
1-1484
6795-end
6922-end
83-end, missing 3685-5940
FL
947-end, but flanking sites both there.
3329-3922, 5328-8625
4788-5713, insertion of 1011bps, 5709-end.
4604-6161, insertion of 1916bps, 6610-end
Start - 8761
FL

1.3 HERV-K113 LTR
Of the twenty three full length HERV-K(HML-2) proviruses (Table 1), HERVK113 is believed to be the most likely candidate to be replication competent (Turner et al.,
2001). This idea is based on three major points: its polymorphic state, the identical
sequence of its LTRs, and its complete open reading frames (Burmeister et al., 2004). As
described in the Introduction, an element that is polymorphic in the human population is
thought be less than 800,000 years old based on Kimura’s neutral theory (Graur and Li,
2000). The identical nature of K113’s LTRs decrease its estimated age to around 200,000,
based roughly on substitution rate between humans and chimpanzees (Johnson and
Coffin, 1999). Lastly, K113 is the only provirus described to date with the complete open
reading frames that lack obvious mutations such as premature stop codons, mutations that
inactivate essential motifs, or large truncations of sequence. Hence, replication potential
of K113 was examined. The LTRs were chosen as the first subject of inquiry.
Transcriptional tropism of a virus depends on the expression level of the
necessary host factors the LTR interacts with to induce transcription. HERV-K(HML2)’s expression tropism in teratocarcinomas was discovered in the late 1970s, when virus
particles were detected in cells derived from teratocarcinomas by EM (Boller et al.,
1993b; Bronson et al., 1978; Lower et al., 1981). To become endogenized, all ERVs must
infect germ cells or progenitors, but the actual target cell of any ERV is unknown.
Teratocarcinomas, as malignant cancer of germ cells derived from the testes, are closely
related to potential natural target cells for ERV, and transcriptional activity in these cells
may reflect the natural situation of HERV-K infection and endogenization. Work by
Ruda et al have shown that HERV-K LTR is as active as SV40 promoter in
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teratocarcinoma cell line, Tera-1, which is tenfold or more active relative to other cell
lines (Ruda et al., 2004). Also, Ruprecht et al showed that numerous HERV-K(HML-2)
transcripts are expressed in Tera-1 cell line, especially HERV-K101, and packaged
preferentially into particles over other RNA (Ruprecht et al., 2008). Thus, it is well
established that the HERV-K LTR can induce transcription and is active in
teratocarcinoma-derived cells.
To test whether K113 LTR is functional, 293T cells were transfected with
pCR3.1/K113 LTR GFP and HTLV-1 Env. 12 hours post transfection, 293T cells were
fused to either fresh 293T or NCCIT cells, which are teratocarcinoma cells known to
express HERV-K proteins at high levels which assemble into particles (Bieda et al.,
2001). As expected, 293T cells expressed an increased quantity of GFP when fused to
NCCIT cells, but not 293T cells (Figure 9). This data indicates that K113 LTR is
functional, and transcription from it and the resulting virus replication is cell type
dependent. This also suggests that factor or factors responsible for the increased
expression from K113 LTR is dominant and expressed in NCCIT cells, but not 293T
cells.

1.4 HERV-K113 and YY2
Retrovirus long terminal repeats contain regulatory elements that control the
transcription of the viral genome, which in turn controls the replication of the virus. The
LTR is divided into three main regions U3 (unique 3’), R (repeat), and U5 (unique 5’),
which are defined by the start (U3-R) and end (R-U5) of transcription. R region is
especially important for reverse transcription, ensuring that all necessary virus sequence
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Figure 9 The activity of HERV-K(HML-2) LTR inducing factor or factors in NCCIT cells
293T cells were transfected with pCR3.1/K113 LTR-GFP and HTLV-1 Env, which uses GLUT-1 glucose
transporter as a receptor to enable fusion of membranes expressing the two proteins. 12-hours post
transfection, the cells were incubated with untransfected 293T cells or NCCIT teratocarcinoma cells, and
grown for an additional 24 hours. 293T cells fused to 293T cells do not show an increase in GFP levels
detectable by eye, while those fused to NCCIT cells are noticeably brighter. The pictures shown are
representative of three experiments.

The TATA box is located towards the end of U3 at the 5’ LTR. The 3’ LTR also contains
the same functional promoter sequences, but only the 5’ LTR is used for the proviral
transcription. The remaining U3 region likely contains regulatory sequences to aid
transcription, such as binding sites for transcription factors. The HERV-K LTR is nearly
ten-fold more active in teratocarcinoma derived cell line than non-teratocarcinoma
derived human cell lines, but the determinants of this tropism is unknown (Casau et al.,
1999; Ruda et al., 2004). A putative glucocorticoid responsive element sequence
(nucleotides 75-88) has been found in the HERV-K LTR but remains functionally
untested (Ono, 1986; Ono et al., 1986). Another partially overlapping fragment of around
20 nucleotides (nucleotides 62 to 83) was found to be important for transcription
enhancement in teratocarcinoma derived cells via several DNA-binding complexes by
two independent groups (Akopov et al., 1998; Knossl et al., 1999). One complex was
found to include the transcription factor YYI, but this complex was not responsible for
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the teratocarcinoma cell line specificity of HERV-K transcription, as it was found also in
non-teratocarcinoma cell lines HeLa and HepG2 as well (Knossl et al., 1999). Another
complex, which was specific to teratocarcinoma cell lines tested and binds to the same
sequence region, remains unidentified.
Since the study of YY1 and its effects on HERV-K LTR, a second family member
has been discovered. YY2 is the result of a YY1 mRNA retrotransposition event that
occurred around 60 to 100 million years ago, as it is found only in placental mammals
(Kim et al., 2007). YY2 shares 56.2% sequence similarity to YY1 in amino acid
sequence, and 86.4% similarity in the DNA binding zinc finger region (Nguyen et al.,
2004). It has also been shown to have the same DNA binding motif as YY1, and can bind
and modulate sequences that YY1 binds and regulates (Kim et al., 2007; Nguyen et al.,
2004). Thus, YY2 is a valid alternative regulatory factor to YY1, and a candidate for the
teratocarcinoma cell line -specific factor for enhancing HERV-K transcription.
To test this idea, 293T cells were transfected with plasmids expressing GFP under
the control of either HIV-1 or HERV-K113 LTR and pCR3.1/Flag-YY2 or control
plasmid pCR3.1. As shown in Figure 10, expression of GFP increased modestly in both
LTRs when coexpressed with YY2: 1.5-fold in HIV-1 LTR and less than 3-fold in K113
LTR relative to controls not expressing YY2. Similar results were obtained with
untagged YY2 and HERV-K LTR, suggesting that the flag tag did not interfere with
protein activity. Although GFP expression did increase when YY2 was overexpressed,
the three fold increase does not account for the tenfold or higher increase detected in
other teratocarcinoma cell lines (Casau et al., 1999; Ruda et al., 2004). This data suggests
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Figure 10 The modest transcription enhancing activity of YY2
1.5 µg of pCR3.1/HIV-1 LTR-GFP or pCR3.1/K113 LTR-GFP plasmids were transfected into 293T cells
in a 6-well format with 1.5 µg of FLAG-YY2 or pCR3.1. Two days post transfection, the percent of GFP+
cells was accessed by FACS.

that YY2 is unlikely to be the only or the main upregulator of HERV-K expression in
teratocarcinomas.

1.5 Replication capacity of K113 and K108
Thus far, with its active but tissue specific LTR, K113 still remains as the most
likely candidate fo r replication competent HERV. Hence, K113 was cloned to test its
replication potential. The constructed proviral plasmids are depicted in Figure 11. As
K113 LTR was shown to be inactive in 293T cells, a derivative where the 5’ LTR’s U3
region was replaced with a cytomegalovirus promoter sequence to enhance transcription
was also constructed. However, one study showed that K113 Env could not induce
infection of retroviral VLPs despite K108 Env being able to do so, suggesting that K113
Env, while full length, is functionally defective (Dewannieux et al., 2005). Despite its
functional Env, HERV-K108 has a premature stop codon in the Gag ORF, a frameshift in
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protease, as well as a mutation of a highly conserved YIDD motif in reverse transcriptase
into CIDD (Mayer et al., 1999b; Reus et al., 2001). This mutation is believed to render
the full length virus replication incompetent, making K108 an unlikely candidate for
replication.
Although K113 and K108 may be individually nonfunctional, it was possible that
a hybrid between the two proviruses may be replication competent. To test this
hypothesis, K113 K108 hybrid construct was cloned by replacing the K113 Env and 3’
LTR sequence with that of K108 (Figure 11). A CMVP containing K113 K108 hybrid
was constructed as well.
The plasmids were transfected into 293T cells; two days post-transfection the
cells were lysed and the VLPs in the supernatant spun through 20% sucrose gradient to
purify and concentrate and the particles. Western blotting analysis of the cell lysate and
VLPs using the commercially available antibody (Austral Biologicals) showed no
expression of HERV-K Gag or VLPs (data not shown), indicating that both K113 and
K113K108 hybrid proviruses may not express viral proteins at a detectable level
regardless of the promoter used.
The HERV-K genome has an unusual nucleotide composition in that it is
relatively A-rich (Zsíros et al., 1999). For example, K113 is composed of 32% A, 26% T,
21% G, and 21%C. This feature, which is characteristic of lentiviruses such as HIV-1, is
partly responsible for the nuclear retention of HIV-1 mRNAs and contributes to the
requirement for Rev in mediating export of incompletely spliced HIV-1 transcripts.
Indeed, HERV-K encodes a functional ortholog of the Rev protein, termed K-Rev
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Figure 11 K113 and K108 derived proviral constructs
K113 construct and its derivatives CMVP-K113, K113 K108, and CMVP K113 K108 are depicted. LTRs
and ORFs are depicted as boxes. The 5’ LTR U3 region is replaced with the CMVP up to the TATA box,
represented by the yellow box. The green and blue boxes represent K113 and K108 sequences, respectively.
K108 sequences are inserted into the SacII restriction site in Env ORF, which is 37 nucleotides from the
ATG of Env and is identical in amino acid sequence between the two proviruses.

or Rec, which mediates nuclear export of HERV-K RNA (Boese et al., 2000; Magin et al.,
2000; Magin et al., 1999; Yang et al., 2000; Yang et al., 1999). Therefore, because of the
likely requirement for a Rev-like post-transcriptional activator for efficient HERV-K
mRNA export, K108 Rec was cloned to test its effect on K113 and K113-K108
replication. K108 Rec differs only in amino acid 52 (Ser to Thr) from a functionally
tested Rec (Magin et al., 1999; Yang et al., 1999). Thus, K108 Rec was co-transfected
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with viral genomic plasmids to enhance nuclear export of viral transcripts. No VLPs were
detected in the supernatant via western blotting analysis (data not shown).
Thus far, infection capability of HERV-K(HML-2) was tested by enhancing
transcription by insertion of CMVP, replacing a defective Env with a functional Env, and
increasing transcript nuclear export by co-expression of Rec. The expression and function
of viral proteins were also tested independently from rest of the virus via cloning the
ORFs into a different expression plasmid. Gag, Gag-protease (PR), and Gag-PR-Pol of
HERV-K113 were cloned into HIV-1 based expression vector pCRVI, which eliminates
potential expression problems of K113 due to expression of HIV-1 accessory proteins
that aid in transcription, and nuclear export of transcript (Figure 7). Hence, any sequence
cloned into this plasmid should be expressed at high levels. Despite these optimal
conditions, the transfection of pCRVI based HERV-K plasmids resulted in poorly
expressed proteins that were inefficiently released as VLPs, like the whole genomic
plasmids (data not shown).
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Chapter 2. Derivation of HERV-KCON and the single-cycle infection system

2.1 Derivation of HERV-KCON
Despite the aid for transcription from CMVP and transcript export from Rec, and
the cloning of the ORFs into high-expression plasmids, K113 and K113-K108 failed to
produce detectable quantities of VLPs. Reasons may be numerous, but as there are no
obvious mutations in K113, it is difficult to locate the source or sources of the problem.
To bypass this difficulty, a consensus HERV-K sequence was derived. This idea was
based on the assumption that any inherent replication defects encoded within HERVK(HML-2) proviruses present in contemporary human DNA are either unique to each
provirus or shared only by a minority of recently integrated proviruses. If this assumption
is correct, then each individual defect should be selected out from a sequence
representing the consensus of a collection of proviruses, even if each individual provirus
that contributes to the consensus is defective.
To derive the consensus sequence, HERV-K113 was used to search for similar
full-length HERV-K proviruses in the human genome via nucleotide to nucleotide
BLAST. Only human-specific and non-redundant insertions were selected. The top ten
matches were chosen for alignment, which are K101, K102, K104, K107, K108, K109,
K113, K115, and proviruses K11q22 and K12q14, named after their genomic location
(Table 2). All of these proviruses are human specific, indicating integration into the
germ-line within the last 6 million years (Barbulescu et al., 1999; Belshaw et al., 2005a;
Hughes and Coffin, 2004; Turner et al., 2001). Moreover, several show insertional
polymorphism in humans, with intact preintegration sites present in a fraction of the
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Figure 12 Undisrupted open reading frames in HERV-K proviruses
Diagram of HERV-K(HML-2) provirus. ORFs are depicted as boxes. Proviruses used in the design of
HERV-KCON that contain intact versions of Gag, protease, Pol, and Env are listed under each ORF. *K108
encodes a full-length Pol ORF, but a presumed essential YIDD motif is mutated.

human population (K108, K109, K113, K115, K11q22, K12q14), suggesting an even
more recent replication for these proviruses. While all insertions except HERV-K113
encoded an obvious defect in at least one ORF, all proviruses also had an undisrupted
ORF for at least one of the putative HERV-K proteins (Figure 12).

2.2 HERV-KCON sequence
The nucleotide encoded by the majority of the ten proviruses was deduced for
each of the 9,472 nucleotide positions to derive the consensus sequence using the AlignX
program. This sequence was named HERV-KCON. Thereafter, using a set of synthetic,
approximately 60 base oligonucleotides spanning the entire HERV-KCON sequence and a
PCR-based strategy to progressively link them together, a plasmid containing the entire
HERV-KCON proviral genome was constructed. As expected, the HERV-KCON sequence
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was positioned close to the root of a phylogenetic tree constructed using HERV-KCON
itself and each of the ten proviruses used to derive it (Figure 13).
HERV-KCON is 9472 nucleotides long, with intact major protein open reading
frames (Figure 14). The long terminal repeats are 968 bps, with a consensus TATA box
and poly-A signal. All identifiable motifs important for retroviral protein function can be

Figure 13 Phylogenetic analysis of HERV-K proviruses and HERV-KCON
HERV-KCON and the ten proviruses used to deduce it were phylogenetically analyzed. The tree was
constructed using Kimura 2-parameter algorithm in the Treemaker program after gap-stripping the
sequence alignment (http://www.hiv.lanl.gov/content/hivdb/CONTAM/Treemker/TreeMaker.html).
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found on HERV-KCON sequence. The MA protein contains the consensus myristoylation
signal at the start (MGXXXS/T). A PTAP motif, often found in late assembly domains
and important for the final scission of the particle membrane from the host membrane, is
found in Gag as well, although its function has not been tested. The CA protein contains
the major homology region (QXXXEXXXXAromaticXXR) that is present in all
retroviruses, and the NC protein contains two CCHC-type zinc binding motifs,
presumably for binding the viral RNA for packaging. The dUTPase is the sole protein
with possible functional defect in HERV-KCON: of the five highly conserved motifs, two
motifs contain an amino acid change each (motif 3 GVVDSDYKG to SVVDSDYKG and
motif 5 KRIGGFGSTD to KRIGGLGSTD) (Harris et al., 1997b). Of the sixteen humanspecific proviruses whose sequence is available, three proviruses each encode for a G in
motif 3 (19q12, K50B, and K60) and a F in motif 5 (K50B, K104, and 3q21). Thirteen
proviruses encode for the potentially inactivating amino acid, suggesting that the correct
HERV-K consensus sequence was derived. Whether Con dUTPase retains its enzymatic
activity and whether its activity is still necessary for replication is unknown. Protease, RT,
and IN each retain the correct, highly conserved DTG, YIDD, and DD(35)E motifs,
respectively. Incidentally, HERV-KCON Rec is identical to K108 Rec in amino acid
sequence, and contains the arginine rich motif at N terminus (nuclear localization signal)
and a leucine rich stretch at the C terminal (nuclear export signal).
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Figure 14 Sequence of HERV-KCON (pages 78-88)
The nucleic sequence of HERV-KCON and the amino acid sequence of the open reading frames are shown. The start and end of both LTRs are marked above the
nucleic sequence by arrows. The TATA box (TATAAAA) and polyA signal (AATAAA) are underlined. The presumed primer binding site is bolded. Gag, Pro,
Pol, Env, and Rec ORFs are shown in red, green, blue, purple, and orange. The C terminus cleavage sites in Gag of p15 and CA (discussed later) are shown in
pink. The myristoylation signal of MA, PTAP motif, MHR of CA, Cis-His boxes of NC, DTG motif of Prot, YIDD motif of RT, and DD(35)E motif of IN are
highlighted. The DD(35)E motif of IN was estimated based on alignments with other retrovirus IN proteins.
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TGTGGGGAAAAGCAAGAGAGATCAGATTGTTACTGTGTCTGTGTAGAAAGAAGTAGACATAGGAGACTCCATTTTGTTAT

80

81

GTACTAAGAAAAATTCTTCTGCCTTGAGATTCTGTTAATCTATGACCTTACCCCCAACCCCGTGCTCTCTGAAACGTGTG

160
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CTGTGTCAACTCAGAGTTGAATGGATTAAGGGCGGTGCAGGATGTGCTTTGTTAAACAGATGCTTGAAGGCAGCATGCTC
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CTTAAGAGTCATCACCACTCCCTAATCTCAAGTACCCAGGGACACAAAAACTGCGGAAGGCCGCAGGGACCTCTGCCTAG

320
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GAAAGCCAGGTATTGTCCAAGGTTTCTCCCCATGTGATAGTCTGAAATATGGCCTCGTGGGAAGGGAAAGACCTGACCGT

400

401

CCCCCAGCCCGACACCCGTAAAGGGTCTGTGCTGAGGAGGATTAGTAAAAGAGGAAGGAATGCCTCTTGCAGTTGAGACA

480
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AGAGGAAGGCATCTGTCTCCTGCCTGTCCCTGGGCAATGGAATGTCTCGGTATAAAACCCGATTGTATGCTCCATCTACT
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GAGATAGGGAAAAACCGCCTTAGGGCTGGAGGTGGGACCTGCGGGCAGCAATACTGCTTTGTAAAGCACTGAGATGTTTA
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TGTGTATGCATATCTAAAAGCACAGCACTTAATCCTTTACATTGTCTATGATGCAAAGACCTTTGTTCACGTGTTTGTCT

720
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GCTGACCCTCTCCCCACAATTGTCTTGTGACCCTGACACATCCCCCTCTTTGAGAAACACCCACAGATGATCAATAAATA

800
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CTAAGGGAACTCAGAGGCTGGCGGGATCCTCCATATGCTGAACGCTGGTTCCCCGGGTCCCCTTATTTCTTTCTCTATAC

880

881

TTTGTCTCTGTGTCTTTTTCTTTTCCAAATCTCTCGTCCCACCTTACGAGAAACACCCACAGGTGTGTAGGGGCAACCCA
←
CCCCTACATCTGGTGCCCAACGTGGAGGCTTTTCTCTAGGGTGAAGGTACGCTCGAGCGTGGTCATTGAGGACAAGTCGA

960

961
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M G Q
CGAGAGATCCCGAGTACGTCTACAGTCAGCCTTACGGTAAGCTTGTGCGCTCGGAAGAAGCTAGGGTGATAATGGGGCAA

1120

1121

T K S K I K S K Y A S Y L S F I K I L L K R G G V K V
ACTAAAAGTAAAATTAAAAGTAAATATGCCTCTTATCTCAGCTTTATTAAAATTCTTTTAAAAAGAGGGGGAGTTAAAGT

1200

1201

S T K N L I K L F Q I I E Q F C P W F P E Q G T L D
ATCTACAAAAAATCTAATCAAGCTATTTCAAATAATAGAACAATTTTGCCCATGGTTTCCAGAACAAGGAACTTTAGATC

1280

1281

L K D W K R I G K E L K Q A G R K G N I I P L T V W N
TAAAAGATTGGAAAAGAATTGGTAAGGAACTAAAACAAGCAGGTAGGAAGGGTAATATCATTCCACTTACAGTATGGAAT

1360

1361

D W A I I K A A L E P F Q T E E D S V S V S D A P G S
GATTGGGCCATTATTAAAGCAGCTTTAGAACCATTTCAAACAGAAGAAGATAGCGTTTCAGTTTCTGATGCCCCTGGAAG

1440

1441

C I I D C N E N T R K K S Q K E T E G L H C E Y V A
CTGTATAATAGATTGTAATGAAAACACAAGGAAAAAATCCCAGAAAGAAACGGAAGGTTTACATTGCGAATATGTAGCAG

1520

1521

E P V M A Q S T Q N V D Y N Q L Q E V I Y P E T L K L
AGCCGGTAATGGCTCAGTCAACGCAAAATGTTGACTATAATCAATTACAGGAGGTGATATATCCTGAAACGTTAAAATTA

1600

1601

E G K G P E L V G P S E S K P R G T S P L P A G Q V P
GAAGGAAAAGGTCCAGAATTAGTGGGGCCATCAGAGTCTAAACCACGAGGCACAAGTCCTCTTCCAGCAGGTCAGGTGCC

1680

1681

V T L Q P Q K Q V K E N K T Q P P V A Y Q Y W P P A
CGTAACATTACAACCTCAAAAGCAGGTTAAAGAAAATAAGACCCAACCGCCAGTAGCCTATCAATACTGGCCTCCGGCTG

1760

1761

E L Q Y R P P P E S Q Y G Y P G M P P A P Q G R A P Y
AACTTCAGTATCGGCCACCCCCAGAAAGTCAGTATGGATATCCAGGAATGCCCCCAGCACCACAGGGCAGGGCGCCATAC

1840

1841

P Q P P T R R L N P T A P P S R Q G S E L H E I I D K
CCTCAGCCGCCCACTAGGAGACTTAATCCTACGGCACCACCTAGTAGACAGGGTAGTGAATTACATGAAATTATTGATAA
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S R K E G D T E A W Q F P V T L E P M P P G E G A Q
ATCAAGAAAGGAAGGAGATACTGAGGCATGGCAATTCCCAGTAACGTTAGAACCGATGCCACCTGGAGAAGGAGCCCAAG

2000

2001

E G E P P T V E A R Y K S F S I K M L K D M K E G V K
AGGGAGAGCCTCCCACAGTTGAGGCCAGATACAAGTCTTTTTCGATAAAAATGCTAAAAGATATGAAAGAGGGAGTAAAA

2080

2081

Q Y G P N S P Y M R T L L D S I A H G H R L I P Y D W
CAGTATGGACCCAACTCCCCTTATATGAGGACATTATTAGATTCCATTGCTCATGGACATAGACTCATTCCTTATGATTG
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2161

E I L A K S S L S P S Q F L Q F K T W W I D G V Q E
GGAGATTCTGGCAAAATCGTCTCTCTCACCCTCTCAATTTTTACAATTTAAGACTTGGTGGATTGATGGGGTACAAGAAC

2240

2241

Q V R R N R A A N P P V N I D A D Q L L G I G Q N W S
AGGTCCGAAGAAATAGGGCTGCCAATCCTCCAGTTAACATAGATGCAGATCAACTATTAGGAATAGGTCAAAATTGGAGT
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2321

T I S Q Q A L M Q N E A I E Q V R A I C L R A W E K I
ACTATTAGTCAACAAGCATTAATGCAAAATGAGGCCATTGAGCAAGTTAGAGCTATCTGCCTTAGAGCCTGGGAAAAAAT
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Q D P G S T C P S F N T V R Q G S K E P Y P D F V A
CCAAGACCCAGGAAGTACCTGCCCCTCATTTAATACAGTAAGACAAGGTTCAAAAGAGCCCTATCCTGATTTTGTGGCAA

2480

2481

R L Q D V A Q K S I A D E K A R K V I V E L M A Y E N
GGCTCCAAGATGTTGCTCAAAAGTCAATTGCCGATGAAAAAGCCCGTAAGGTCATAGTGGAGTTGATGGCATATGAAAAC

2560

2561

A N P E C Q S A I K P L K G K V P A G S D V I S E Y V
GCCAATCCTGAGTGTCAATCAGCCATTAAGCCATTAAAAGGAAAGGTTCCTGCAGGATCAGATGTAATCTCAGAATATGT

2640

2641

K A C D G I G G A M H K A M L M A Q A I T G V V L G
AAAAGCCTGTGATGGAATCGGAGGAGCTATGCATAAAGCTATGCTTATGGCTCAAGCAATAACAGGAGTTGTTTTAGGAG

2720

2721

G Q V R T F G G K C Y N C G Q I G H L K K N C P V L N
GACAAGTTAGAACATTTGGAGGAAAATGTTATAATTGTGGTCAAATTGGTCACTTAAAAAAGAATTGCCCAGTCTTAAAC

2800
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K Q N I T I Q A T T T G R E P P D L C P R C K K G K H
AAACAGAATATAACTATTCAAGCAACTACAACAGGTAGAGAGCCACCTGACTTATGTCCAAGATGTAAAAAAGGAAAACA
W
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N G Q P L S G N E Q R G Q P Q
K W A T I V G K R A K G P A S G
TTGGGCTAGTCAATGTCGTTCTAAATTTGATAAAAATGGGCAACCATTGTCGGGAAACGAGCAAAGGGGCCAGCCTCAGG
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K

2960

A
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P Q Q T G A F P I Q P F V P Q G F Q G Q Q P P L S Q
P T T N W G I P N S A I C S S G F S G T T T P T V P
CCCCACAACAAACTGGGGCATTCCCAATTCAGCCATTTGTTCCTCAGGGTTTTCAGGGACAACAACCCCCACTGTCCCAA

3040

3041

V F Q G I S Q L P Q Y N N C P P P Q A A V Q Q *
S V S G N K P V T T I Q Q L S P A T S G S A A V D L C
GTGTTTCAGGGAATAAGCCAGTTACCACAATACAACAATTGTCCCCCGCCACAAGCGGCAGTGCAGCAGTAGATTTATGT

3120

3121

T I Q A V S L L P G E P P Q K I P T G V Y G P L P E G
ACTATACAAGCAGTCTCTCTGCTTCCAGGGGAGCCCCCACAAAAAATCCCCACAGGGGTATATGGCCCCCTGCCTGAGGG

3200

3201

T V G L I L G R S S L N L K G V Q I H T S V V D S D
GACTGTAGGACTAATCTTGGGAAGATCAAGTCTAAATCTAAAAGGAGTTCAAATTCATACTAGTGTGGTTGATTCAGACT

3280

3281

Y K G E I Q L V I S S S I P W S A S P G D R I A Q L L
ATAAAGGCGAAATTCAATTGGTTATTAGCTCTTCAATTCCTTGGAGTGCCAGTCCAGGAGACAGGATTGCTCAATTATTA

3360

3361

L L P Y I K G G N S E I K R I G G L G S T D P T G K A
CTCCTGCCATATATTAAGGGTGGAAATAGTGAAATAAAAAGAATAGGAGGGCTTGGAAGCACTGATCCAACAGGAAAGGC

3440

3441

A Y W A S Q V S E N R P V C K A I I Q G K Q F E G L
TGCATATTGGGCAAGTCAGGTCTCAGAGAACAGACCTGTGTGTAAGGCCATTATTCAAGGAAAACAGTTTGAAGGGTTGG

3520

3521

V D T G A D V S I I A L N Q W P K N W P K Q K A V T G
TAGACACTGGAGCAGATGTCTCTATCATTGCTTTAAATCAGTGGCCAAAAAATTGGCCTAAACAAAAGGCTGTTACAGGA

3600
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3601

L V G I G T A S E V Y Q S T E I L H C L G P D N Q E S
CTTGTCGGCATAGGCACAGCCTCAGAAGTGTATCAAAGTACGGAGATTTTACATTGCTTAGGGCCAGATAATCAAGAAAG

3680

3681

T V Q P M I T S I P L N L W G R D L L Q Q W G A E I
TACTGTTCAGCCAATGATTACTTCAATTCCTCTTAATCTGTGGGGTCGAGATTTATTACAACAATGGGGTGCGGAAATCA

3760

3841

T M P A P L Y S P T S Q K I M T K M G Y I P G K G L G
CCATGCCCGCTCCATTATATAGCCCCACGAGTCAAAAAATCATGACCAAGATGGGATATATACCAGGAAAGGGACTAGGG
N K S R K R R N R V S F L G
K N E D G I K V P V E A K I N Q E R E G I G Y P F *
AAAAATGAAGATGGCATTAAAGTTCCAGTTGAGGCTAAAATAAATCAAGAAAGAGAAGGAATAGGGTATCCTTTTTAGGG

3921

A A T V E P P K P I P L T W K T E K P V W V N Q W P L
GCGGCCACTGTAGAGCCTCCTAAACCCATACCATTAACTTGGAAAACAGAAAAACCGGTGTGGGTAAATCAGTGGCCGCT

4000

4001

P K Q K L E A L H L L A N E Q L E K G H I E P S F S
ACCAAAACAAAAACTGGAGGCTTTACATTTATTAGCAAATGAACAGTTAGAAAAGGGTCATATTGAGCCTTCGTTCTCAC

4080

4081

P W N S P V F V I Q K K S G K W R M L T D L R A V N A
CTTGGAATTCTCCTGTGTTTGTAATTCAGAAGAAATCAGGCAAATGGCGTATGTTAACTGACTTAAGGGCTGTAAACGCC

4160

4161

V I Q P M G P L Q P G L P S P A M I P K D W P L I I I
GTAATTCAACCCATGGGGCCTCTCCAACCCGGGTTGCCCTCTCCGGCCATGATCCCAAAAGATTGGCCTTTAATTATAAT

4240

4241

D L K D C F F T I P L A E Q D C E K F A F T I P A I
TGATCTAAAGGATTGCTTTTTTACCATCCCTCTGGCAGAGCAGGATTGCGAAAAATTTGCCTTTACTATACCAGCCATAA

4320

4321

N N K E P A T R F Q W K V L P Q G M L N S P T I C Q T
ATAATAAAGAACCAGCCACCAGGTTTCAGTGGAAAGTGTTACCTCAGGGAATGCTTAATAGTCCAACTATTTGTCAGACT

4400

4401

F V G R A L Q P V R E K F S D C Y I I H Y I D D I L C
TTTGTAGGTCGAGCTCTTCAACCAGTTAGAGAAAAGTTTTCAGACTGTTATATTATTCATTATATTGATGATATTTTATG

4480

3761

3840

3920
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4481

A A E T K D K L I D C Y T F L Q A E V A N A G L A I
TGCTGCAGAAACGAAAGATAAATTAATTGACTGTTATACATTTCTGCAAGCAGAGGTTGCCAATGCTGGACTGGCAATAG

4560

4561

A S D K I Q T S T P F H Y L G M Q I E N R K I K P Q K
CATCTGATAAGATCCAAACCTCTACTCCTTTTCATTATTTAGGGATGCAGATAGAAAATAGAAAAATTAAGCCACAAAAA

4640

4641

I E I R K D T L K T L N D F Q K L L G D I N W I R P T
ATAGAAATAAGAAAAGACACATTAAAAACACTAAATGATTTTCAAAAATTACTAGGAGATATTAATTGGATTCGGCCAAC

4720

4721

L G I P T Y A M S N L F S I L R G D S D L N S K R M
TCTAGGCATTCCTACTTATGCCATGTCAAATTTGTTCTCTATCTTAAGAGGAGACTCAGACTTAAATAGTAAAAGAATGT

4800

4801

L T P E A T K E I K L V E E K I Q S A Q I N R I D P L
TAACCCCAGAGGCAACAAAAGAAATTAAATTAGTGGAAGAAAAAATTCAGTCAGCGCAAATAAATAGAATAGATCCCTTA

4880

4881

A P L Q L L I F A T A H S P T G I I I Q N T D L V E W
GCCCCACTCCAACTTTTGATTTTTGCCACTGCACATTCTCCAACAGGCATCATTATTCAAAATACTGATCTTGTGGAGTG

4960

4961

S F L P H S T V K T F T L Y L D Q I A T L I G Q T R
GTCATTCCTTCCTCACAGTACAGTTAAGACTTTTACATTGTACTTGGATCAAATAGCTACATTAATCGGTCAGACAAGAT

5040

5041

L R I I K L C G N D P D K I V V P L T K E Q V R Q A F
TACGAATAATAAAATTATGTGGAAATGACCCAGACAAAATAGTTGTCCCTTTAACCAAGGAACAAGTTAGACAAGCCTTT

5120

5121

I N S G A W Q I G L A N F V G I I D N H Y P K T K I F
ATCAATTCTGGTGCATGGCAGATTGGTCTTGCTAATTTTGTGGGAATTATTGATAATCATTACCCAAAAACAAAGATCTT

5200

5201

Q F L K L T T W I L P K I T R R E P L E N A L T V F
CCAGTTCTTAAAATTGACTACTTGGATTCTACCTAAAATTACCAGACGTGAACCTTTAGAAAATGCTCTAACAGTATTTA

5280

5281

T D G S S N G K A A Y T G P K E R V I K T P Y Q S A Q
CTGATGGTTCCAGCAATGGAAAAGCAGCTTACACAGGGCCGAAAGAACGAGTAATCAAAACTCCATATCAATCGGCTCAA

5360
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5361

R A E L V A V I T V L Q D F D Q P I N I I S D S A Y V
AGAGCAGAGTTGGTTGCAGTCATTACAGTGTTACAAGATTTTGACCAACCTATCAATATTATATCAGATTCTGCATATGT

5440

5441

V Q A T R D V E T A L I K Y S M D D Q L N Q L F N L
AGTACAGGCTACAAGGGATGTTGAGACAGCTCTAATTAAATATAGCATGGATGATCAGTTAAACCAGCTATTCAATTTAT

5520

5521

L Q Q T V R K R N F P F Y I T H I R A H T N L P G P L
TACAACAAACTGTAAGAAAAAGAAATTTCCCATTTTATATTACTCATATTCGAGCACACACTAATTTACCAGGGCCTTTG

5600

5601

T K A N E Q A D L L V S S A L I K A Q E L H A L T H V
ACTAAAGCAAATGAACAAGCTGACTTACTGGTATCATCTGCACTCATAAAAGCACAAGAACTTCATGCTTTGACTCATGT

5680

5681

N A A G L K N K F D V T W K Q A K D I V Q H C T Q C
AAATGCAGCAGGATTAAAAAACAAATTTGATGTCACATGGAAACAGGCAAAAGATATTGTACAACATTGCACCCAGTGTC

5760

5761

Q V L H L P T Q E A G V N P R G L C P N A L W Q M D V
AAGTCTTACACCTGCCCACTCAAGAGGCAGGAGTTAATCCCAGAGGTCTGTGTCCTAATGCATTATGGCAAATGGATGTC

5840

5841

T H V P S F G R L S Y V H V T V D T Y S H F I W A T C
ACGCATGTACCTTCATTTGGAAGATTATCATATGTTCATGTAACAGTTGATACTTATTCACATTTCATATGGGCAACTTG

5920

5921

Q T G E S T S H V K K H L L S C F A V M G V P E K I
CCAAACAGGAGAAAGTACTTCCCATGTTAAAAAACATTTATTGTCTTGTTTTGCTGTAATGGGAGTTCCAGAAAAAATCA

6000

6001

K T D N G P G Y C S K A F Q K F L S Q W K I S H T T G
AAACTGACAATGGACCAGGATATTGTAGTAAAGCTTTCCAAAAATTCTTAAGTCAGTGGAAAATTTCACATACAACAGGA

6080

6081

I P Y N S Q G Q A I V E R T N R T L K T Q L V K Q K E
ATTCCTTATAATTCCCAAGGACAGGCCATAGTTGAAAGAACTAATAGAACACTCAAAACTCAATTAGTTAAACAAAAAGA

6160

6161

G G D S K E C T T P Q M Q L N L A L Y T L N F L N I
AGGGGGAGACAGTAAGGAGTGTACCACTCCTCAGATGCAACTTAATCTAGCACTCTATACTTTAAATTTTTTAAACATTT

6240
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6241

Y R N Q T T T S A E Q H L T G K K N S P H E G K L I W
ATAGAAATCAGACTACTACTTCTGCAGAACAACATCTTACTGGTAAAAAGAACAGCCCACATGAAGGAAAACTAATTTGG

6320

6321

W K D N K N K T W E I G K V I T W G R G F A C V S P G
TGGAAAGATAATAAAAATAAGACATGGGAAATAGGGAAGGTGATAACGTGGGGGAGAGGTTTTGCTTGTGTTTCACCAGG

6400

6481

M N P S E M Q R K A
N E P I G D A K K S
M N P S E M Q R K A
AGAAAATCAGCTTCCTGTTTGGATACCCACTAGACATTTGAAGTTCTACAATGAACCCATCGGAGATGCAAAGAAAAGCA
P P R R R R H R N R A P L T H K M N K M V T S E E Q M
T S A E T E T P Q S S T V D S Q D E Q N G D V R R T D
P P R R R R H R N R A P L T H K M N K M V T S E E Q M
CCTCCGCGGAGACGGAGACACCGCAATCGAGCACCGTTGACTCACAAGATGAACAAAATGGTGACGTCAGAAGAACAGAT

6561

K L P S T K K A E P P T W A Q L K K L T Q L A T K Y
E V A I H Q E G R A A D L G T T K E A D A V S Y K I S
K L P S T K K A E P P T W A Q L K K L T Q L A T K Y
GAAGTTGCCATCCACCAAGAAGGCAGAGCCGCCGACTTGGGCACAACTAAAGAAGCTGACGCAGTTAGCTACAAAATATC

E

6401

N

Q

L
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6480

6560

6640

L

6641

E N T K V T Q T P E S M L L A A L M I V S M V
R E H K G D T N P R E Y A A C S L D D C I N G G K S
L E N T K V T Q T P E S M L L A A L M I V S M V V S L
TAGAGAACACAAAGGTGACACAAACCCCAGAGAGTATGCTGCTTGCAGCCTTGATGATTGTATCAATGGTGGTAAGTCTC

6720

6721

P Y A C R S S C S *
P M P A G A A A A N Y T Y W A Y V P F P P L I R A V T
CCTATGCCTGCAGGAGCAGCTGCAGCTAACTATACCTACTGGGCCTATGTGCCTTTCCCGCCCTTAATTCGGGCAGTCAC

6800

6801

W M D N P I E V Y V N D S V W V P G P I D D R C P A
ATGGATGGATAATCCTATAGAAGTATATGTTAATGATAGTGTATGGGTACCTGGCCCCATAGATGATCGCTGCCCTGCCA

6880
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6881

K P E E E G M M I N I S I G Y R Y P P I C L G R A P G
AACCTGAGGAAGAAGGGATGATGATAAATATTTCCATTGGGTATCGTTATCCTCCTATTTGCCTAGGGAGAGCACCAGGA

6960

6961

C L M P A V Q N W L V E V P T V S P I S R F T Y H M V
TGTTTAATGCCTGCAGTCCAAAATTGGTTGGTAGAAGTACCTACTGTCAGTCCCATCAGTAGATTCACTTATCACATGGT

7040

7041

S G M S L R P R V N Y L Q D F S Y Q R S L K F R P K
AAGCGGGATGTCACTCAGGCCACGGGTAAATTATTTACAAGACTTTTCTTATCAAAGATCATTAAAATTTAGACCTAAAG

7120

7121

G K P C P K E I P K E S K N T E V L V W E E C V A N S
GGAAACCTTGCCCCAAGGAAATTCCCAAAGAATCAAAAAATACAGAAGTTTTAGTTTGGGAAGAATGTGTGGCCAATAGT

7200

7201

A V I L Q N N E F G T I I D W A P R G Q F Y H N C S G
GCGGTGATATTACAAAACAATGAATTTGGAACTATTATAGATTGGGCACCTCGAGGTCAATTCTACCACAATTGCTCAGG

7280

7281

Q T Q S C P S A Q V S P A V D S D L T E S L D K H K
ACAAACTCAGTCGTGTCCAAGTGCACAAGTGAGTCCAGCTGTTGATAGCGACTTAACAGAAAGTTTAGACAAACATAAGC

7360

7361

H K K L Q S F Y P W E W G E K G I S T P R P K I V S P
ATAAAAAATTGCAGTCTTTCTACCCTTGGGAATGGGGAGAAAAAGGAATCTCTACCCCAAGACCAAAAATAGTAAGTCCT

7440

7441

V S G P E H P E L W R L T V A S H H I R I W S G N Q T
GTTTCTGGTCCTGAACATCCAGAATTATGGAGGCTTACTGTGGCCTCACACCACATTAGAATTTGGTCTGGAAATCAAAC

7520

7521

L E T R D R K P F Y T V D L N S S L T V P L Q S C V
TTTAGAAACAAGAGATCGTAAGCCATTTTATACTGTCGACCTAAATTCCAGTCTAACAGTTCCTTTACAAAGTTGCGTAA

7600

7601

K P P Y M L V V G N I V I K P D S Q T I T C E N C R L
AGCCCCCTTATATGCTAGTTGTAGGAAATATAGTTATTAAACCAGACTCCCAGACTATAACCTGTGAAAATTGTAGATTG

7680

7681

L T C I D S T F N W Q H R I L L V R A R E G V W I P V
CTTACTTGCATTGATTCAACTTTTAATTGGCAACACCGTATTCTGCTGGTGAGAGCAAGAGAGGGCGTGTGGATCCCTGT

7760
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7761

S M D R P W E A S P S V H I L T E V L K G V L N R S
GTCCATGGACCGACCGTGGGAGGCCTCACCATCCGTCCATATTTTGACTGAAGTATTAAAAGGTGTTTTAAATAGATCCA

7840

7841

K R F I F T L I A V I M G L I A V T A T A A V A G V A
AAAGATTCATTTTTACTTTAATTGCAGTGATTATGGGATTAATTGCAGTCACAGCTACGGCTGCTGTAGCAGGAGTTGCA

7920

7921

L H S S V Q S V N F V N D W Q K N S T R L W N S Q S S
TTGCACTCTTCTGTTCAGTCAGTAAACTTTGTTAATGATTGGCAAAAAAATTCTACAAGATTGTGGAATTCACAATCTAG

8000

8001

I D Q K L A N Q I N D L R Q T V I W M G D R L M S L
TATTGATCAAAAATTGGCAAATCAAATTAATGATCTTAGACAAACTGTCATTTGGATGGGAGACAGACTCATGAGCTTAG

8080

8081

E H R F Q L Q C D W N T S D F C I T P Q I Y N E S E H
AACATCGTTTCCAGTTACAATGTGACTGGAATACGTCAGATTTTTGTATTACACCCCAAATTTATAATGAGTCTGAGCAT

8160

8161

H W D M V R R H L Q G R E D N L T L D I S K L K E Q I
CACTGGGACATGGTTAGACGCCATCTACAGGGAAGAGAAGATAATCTCACTTTAGACATTTCCAAATTAAAAGAACAAAT

8240

8241

F E A S K A H L N L V P G T E A I A G V A D G L A N
TTTCGAAGCATCAAAAGCCCATTTAAATTTGGTGCCAGGAACTGAGGCAATTGCAGGAGTTGCTGATGGCCTCGCAAATC

8320

8321

L N P V T W V K T I G S T T I I N L I L I L V C L F C
TTAACCCTGTCACTTGGGTTAAGACCATTGGAAGTACTACGATTATAAATCTCATATTAATCCTTGTGTGCCTGTTTTGT

8400

8481

S A G V P N S S E E T A T I E N G P *
L L L V C R C T Q Q L R R D S D H R E R A M M T M A V
CTGTTGTTAGTCTGCAGGTGTACCCAACAGCTCCGAAGAGACAGCGACCATCGAGAACGGGCCATGATGACGATGGCGGT
→
L S K R K G G N V G K S K R D Q I V T V S V *
TTTGTCGAAAAGAAAAGGGGGAAATGTGGGGAAAAGCAAGAGAGATCAGATTGTTACTGTGTCTGTGTAGAAAGAAGTAG

8561

ACATAGGAGACTCCATTTTGTTATGTACTAAGAAAAATTCTTCTGCCTTGAGATTCTGTTAATCTATGACCTTACCCCCA

8401

8480

8560
8640
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8641

ACCCCGTGCTCTCTGAAACGTGTGCTGTGTCAACTCAGAGTTGAATGGATTAAGGGCGGTGCAGGATGTGCTTTGTTAAA

8720

8721

CAGATGCTTGAAGGCAGCATGCTCCTTAAGAGTCATCACCACTCCCTAATCTCAAGTACCCAGGGACACAAAAACTGCGG

8800

8801

AAGGCCGCAGGGACCTCTGCCTAGGAAAGCCAGGTATTGTCCAAGGTTTCTCCCCATGTGATAGTCTGAAATATGGCCTC

8880

8881

GTGGGAAGGGAAAGACCTGACCGTCCCCCAGCCCGACACCCGTAAAGGGTCTGTGCTGAGGAGGATTAGTAAAAGAGGAA

8960

8961

GGAATGCCTCTTGCAGTTGAGACAAGAGGAAGGCATCTGTCTCCTGCCTGTCCCTGGGCAATGGAATGTCTCGGTATAAA

9040

9041

ACCCGATTGTATGCTCCATCTACTGAGATAGGGAAAAACCGCCTTAGGGCTGGAGGTGGGACCTGCGGGCAGCAATACTG

9120

9121

CTTTGTAAAGCACTGAGATGTTTATGTGTATGCATATCTAAAAGCACAGCACTTAATCCTTTACATTGTCTATGATGCAA

9200

9201

AGACCTTTGTTCACGTGTTTGTCTGCTGACCCTCTCCCCACAATTGTCTTGTGACCCTGACACATCCCCCTCTTTGAGAA

9280

9281

ACACCCACAGATGATCAATAAATACTAAGGGAACTCAGAGGCTGGCGGGATCCTCCATATGCTGAACGCTGGTTCCCCGG

9360

9361

GTCCCCTTATTTCTTTCTCTATACTTTGTCTCTGTGTCTTTTTCTTTTCCAAATCTCTCGTCCCACCTTACGAGAAACAC
←
CCACAGGTGTGTAGGGGCAACCCACCCCTACA 9472

9440

9393

2.3 HERV-KCON proteins
To determine whether HERV-KCON proteins were capable of assembling into
retrovirus-like particles, pCRVI based plasmids expressing the consensus Gag, Gag-PR
and Gag-PR-Pol ORFs were constructed. Transfection of the plasmids resulted in the
expression of a protein of approximately 70 to 80 kDa, detected by Western blotting
using a commercially available antibody raised against HERV-K Gag (Covance) (Figure
15A). This approximated to the expected size (74 kDa) of intact HERV-K Gag. A
concurrent analysis of proteins pelleted from culture supernatant through 20% sucrose
revealed that Gag expression alone could efficiently generate extracellular particles
(Figure 15A). In addition to the 74-kDa Gag precursor, a protein of approximately 40
kDa that reacted with the HERV-K Gag antibody was detected in lysates of cells
transfected with Gag-PR and Gag-PR-Pol expression plasmids. While the precise identity
of the 40-kDa protein is unknown, it likely represents a proteolytically processed form of
Gag, which suggests that the HERV-KCON protease is active.
Analysis of extracellular particles by SDS-PAGE and silver staining revealed that
HERV-KCON Gag expression alone produced a protein band around 74 kDa as expected
for the full length Gag (Figure 15B and C). Particles generated by Gag-PR contained a
dominant protein of 30 kDa, which based on previous studies likely represents HERVKCON capsid (CA) (Bieda et al., 2001; Boller et al., 1993a; Mueller-Lantzsch et al., 1993).
A smaller protein or proteins of 20 kDa were also observed in Gag-PR particles, which
presumably represent other mature Gag processed products such as MA or NC proteins
(Figure 15B). Additionally, a protein of 40 kDa that likely corresponded to the 40-kDa
band detected by Western blotting was also observed on
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Figure 15 Expression of HERV-K proteins and release of virus-like particles
293T cells were transfected with HERV-K protein expression vectors, pCRVI/Gag, pCRVI/Gag-PR,
pCRVI/Gag-PR-Pol, or pCRVI/Gag-PR(mut), and harvested two days after transfection. A. Western blot
analysis of HERV-K protein expression in cell lysates (left) or virus-like particle expression in the cell
supernatant (center and right) using a commercially available anti-HERV-K Gag antibody. The expected
size of full length Gag polyprotein is 74kDa. Decreasing quantities of virion lysate (0.1, 0.05, and 0.025µl
for Gag, center panel, or 0.4, 0.2, and 0.1µl for Gag-PR and Gag-PR-Pol, right panel) were loaded to
estimate relative levels of VLP production. B. Silver stain analysis of a 4% to 20% gradient SDS-PAGE gel
loaded with VLPs harvested from 293T cells transfected with HERV-K protein expression plasmids or
empty plasmid control. An asterisk marks a nonspecific 66kDa protein band, most likely BSA. C. Silver
stain analysis of VLPs harvested from 293T cells transfected with HERV-K protein expression plasmids
including pCRVI/Gag-PR(mut) which has an active site mutation (DTG to AAA) in protease. An asterisk
marks a nonspecific 66kDa band.
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silver-stained gels. However, the 40-kDa protein was a minor species in Gag-PR particles,
and it is therefore likely that this protein represents a partly processed intermediate.
HERV-K Gag-PR-Pol expression also yielded particles containing the same apparently
processed Gag proteins as those generated by Gag-PR but at slightly lower levels (Figure
15B). The 30-kDa putative CA protein on silver stained gels was abolished when three
predicted active site residues (Asp-Thr-Gly) in the HERV-KCON protease ORF were
mutated to Ala-Ala-Ala (Figure 15C). Additionally, a higher molecular-weight protein,
possibly representing the Gag-PR precursor, was observed in particles harvested from
cells expressing the mutant Gag-PR protein (Figure 15C). These data are consistent with
proper translation of the proteins, assembly and budding of particles, and cleavage of
polyprotein by protease.
Although their low abundance relative to contaminating extraneous cellular
proteins and the lack of available antibodies precluded unambiguous identification of Pol

Figure 16 RT activity of HERV-KCON VLPs
Reverse transcriptase activity was assayed in culture supernatants of 293T cells transfected with empty
pCRV1 (vector) or vectors expressing HERV-KCON Gag, Gag-PR, or Gag-PR-Pol proteins using
commercially available RT assay (Cavidi). Enzymatic activity was determined relative to a recombinant
HIV-1 reverse transcriptase standard and is representative of three experiments. Supernatants from 293T
cells transfected with an HIV-1–based proviral plasmid are included for comparison.
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proteins in SDS-PAGE analyses of HERV-KCON VLPs, supernatants of 293T cell
cultures transfected with the HERV-KCON Gag-PR-Pol expression plasmid contained
quite high levels of reverse transcriptase activity, as detected by an ELISA-based assay
designed for the detection of HIV-1 reverse transcriptase (Figure 16). No reverse
transcriptase activity was detected in control cultures transfected with HERV-KCON Gag
or Gag-PR expression plasmids.
To determine the location of protease cleavage sites in Gag, the N terminus of two
bands (p30 and p15) detected in the silver stain analysis of HERV-KCON VLPs in the
presence of protease were identified by Edman sequencing. The result shows that the p30
band, predicted to be the CA protein, begins at the 283rd amino acid of Gag (PVTLE).
The smaller band showed a cleavage site at the 149th amino acid of Gag (YNQLQ). This
data implies that the MA protein is 148 amino acids in length and estimated to weigh
16.7 kDa, and may correspond to the smallest band detected in silver stain of VLPs
between 20 and 15 kDa (Figure 15B). The protein that resides between MA and CA
(amino acids 149-282) is estimated to be 15 kDa, and includes a late domain PTAP motif.
The location of p15 between MA and CA is to the same as that of p24 in MPMV, which
also contains late domains (PPPY and PTAP motifs) that have been shown to be
important for MPMV particle release (Gottwein et al., 2003), indicating a similar role for
p15 in HERV-K. Based on the molecular weights of MA, p15, and CA, the molecular
weight of NC is estimated from the total molecular weight of Gag to be around 12 kDa,
but there is no direct evidence of this estimation.
The molecular weight of CA is estimated from previous studies to be around 30
kDa (Bieda et al., 2001; Boller et al., 1993b). Despite not knowing the exact cleavage site
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between CA and NC, knowing the N-terminus of CA allows for a rough calculation of
the position of the C-terminus based on the molecular weight of CA. Based on this
estimation, CA was expressed and purified for the generation of anti-CA polyclonal
antiserum in rabbits (Covance). CA (amino acids 289 to 532, the C terminus
conservatively estimated) was cloned into bacterial expression vector as a glutathione Stransferase (GST) tagged protein, which was purified using glutathione-agarose beads.
The GST tag was cleaved, and the purified recombinant CA protein used to generate the
antiserum (Figure 17). The western blotting analysis using HERV-KCON Gag transfected
293T cell lysate show both a full length 74 kDa band and a smaller 30 kDa band (Figure
18), confirming that the p30 protein is CA. The proteins recognized by this polyclonal
antibody is different from the commercially available anti-HERV-K Gag antibody, which
recognizes the full length 74 kDa band and a band around 40 kDa that is a minor band in
silver stain of VLPs (Figure 15A).

Figure 17 In vitro purification of HERVKCON CA
The deduced HERV-KCON CA sequence was
cloned into pGEX-6P-1 (GE Healthcare Life
Sciences) to express a glutathione Stransferase (GST)-tagged CA protein that
was purified using glutathione-agarose beads.
The GST tag was eliminated by PreScission
protease cleavage as per the manufacturer's
instructions (GE Healthcare Life Sciences).
The purified CA protein was separated in
SDS-PAGE gel, and stained with Coomassie
dye for visualization. Expected sizes of CA
and GST are 30kDa and 26kDa, respectively,
and are noted by the arrows. The minor band
between CA and GST (middle arrow) is
believed to be a minor degradation or
cleavage product of CA. The concentration
of CA was measured by Bradford assay to be
7.35 µg/µl.
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Figure 18 Efficacy of polyclonal HERV-KCON CA antibody
Cell lysates separated by SDS-PAGE on PVDF membrane was probed with
polyclonal HERV-KCON CA antibody at 1:5000. The first lane contains the 293T
cell lysate transfected with pCRVI/Con Gag-PR-Pol, and the second lane
contains untransfected 293T cell lysate. The expected sizes of full length Gag and
CA are 74kDa, and 30kDa. Gag-PR and Gag-PR-Pol are not visible.

The localization of Gag for virus particle assembly and
budding was also examined. Co-expression of HERV-KCON Gag
and Gag–green fluorescent protein (GFP) fusion proteins in 293T
cells revealed that HERV-KCON Gag localized predominantly to the plasma membrane,
where numerous fluorescent puncta were observed (Figure 19). Moreover, electron
microscopic examination of 293T cells expressing HERV-KCON Gag-PR revealed the
presence of cell-associated retrovirus-like particles and structures that appeared to
represent assembly intermediates (Figure 20). Most particles appeared to be between 100
to 150 nm in diameter, apparently spherical immature virions, with a minority assembled
as aberrant particles that appeared as two or more connected, partly assembled, virions.
While no unambiguously mature virions associated with the surface of Gag-PR

Figure 19 Plasma membrane
localization of HERV-KCON Gag
Two representative 293T cells
transfected with HERV-KCON Gag and
Gag-GFP expression plasmids. Cells
were fixed 18 hours post-transfection,
and nuclei were stained with DAPI (blue)
prior to visualization by deconvolution
microscopy. Top, images acquired at the
mid-section of the cell to show
localization of Gag-GFP proteins;
bottom, focused on the bottom of the
cell to show accumulated VLPs at the
cell-coverslip interface.
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Figure 20 Electron microscopy of HERV-KCON VLPs
Gallery of images of 293T cells transfected with a Gag-PR expressing plasmid. Black scale bars in the
upper and middle panels represent 500 nm, while scale bars in the lower two panels represent 100 nm.

expressing cells were observed, it is possible that full maturation, which was clearly
indicated by the biochemical analysis of extracellular VLPs (Figure 15 and 18), occurred
only after the completion of particle release from cells. Completely or incompletely
assembled particles appeared exclusively at the plasma membrane with a morphology
resembling partly assembled alpharetroviruses or gammaretroviruses. Even though
betaretroviruses represent HERV-Ks closest exogenous retrovirus relatives, no
cytoplasmic, nonenveloped particles, typically observed in betaretroviruses, were found.
95

2.4 Establishment of single-cycle infection system
After confirming that the viral proteins can assemble into VLPs and that protease
and RT are functional, a single-cycle infection system was established using these
components along with a viral genome that should be packaged into VLPs, reverse
transcribed, and integrated to complete the cycle. Frequently, a marker is inserted into the
genomic sequence to allow for detection of a successful infection. Therefore various
versions of the HERV-KCON genome were constructed with CMVP-GFP or CMVP-drug
resistance genes inserted into the Env ORF via KpnI restriction site (Figure 21). This
strategy disrupts the Env ORF, but infectious pseudotyped particles could, in principle,
be generated by the co-expression of vesicular stomatitis virus glycoprotein (VSVG).
VSVG is known to have a wide tropism, and thus helpful in single-cycle infection
systems as any cell can be used as target cells to study other steps of virus infection. The
HERV-KCON which contains the CMVP in the 5’ LTR and the CMVP-marker in the Env
ORF is named CMVP-HERV-KCON-CMVP marker (CHKCG for GFP and CHKCP for
puromycin-resistance gene).
As the insertion of the marker lengthens the total packaged sequence (additional
1464 bps for CMVP-GFP), the modified genome may not be packaged into the virus
particle as effectively. To address this issue, versions of the genome where the sequence
has been shorted to reflect the actual length of HERV-K (9472 bps) were constructed.
Deletions of the viral sequence around Gag, PR and Pol ORFs (Bgl II to Bgl II, a deletion
of 3918 bps which includes most of Gag to the 3’ half of Pol; Hpa I to Hpa I, a deletion
of 2526 bps which includes the 3’ half of Gag to 5’ third of Pol; Age I to Dra III, a
deletion of 1782 bps which includes the 5’ two thirds of Pol) did not result in infection
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Figure 21 Diagram of HERV-KCON derived packageable genome constructs
The packageable genomes derived from HERV-KCON with the various features are depicted. CMVPHERV-KCON contains a CMVP in the 5’ LTR U3 region, and is shown for length comparisons. CHKCG
and CHKCP contain CMVP-GFP and CMVP-puromycin resistance gene inserted into the SwaI restriction
site of Env ORF. CCGBX is shortened in the Pol and Env ORFs (6643-7784) to reduce the length of the
construct to 9287 bps for efficient packaging. CCGBX-P includes a 53 bp HIV-1 sequence in the 3’ LTR,
as depicted by the red bar.

(data not shown). These deletions all include the elimination of Age I to Hpa I fragment
of 827 bps located in the Pol ORF encoding for RT, which is near the center of the viral
genome. In HIV-1, a sequence located around that position called the central polypurine
tract (cPPT) is important for maximum efficiency of reverse transcription and is highly
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conserved (Goff, 2007). MMTV and MPMV, the closely related betaretroviruses, are not
known to contain a cPPT; none was found in HERV-K as well. Hence, why these
deletions resulted in the lack of transfer of the marker is unknown.
The final shortened genome that gave the highest virus titer retains the CMVP in
the 5’ LTR, but the CMVP-marker is cloned into the Kpn I and Swa I restriction sites of
Env ORF, eliminating 1414 bps of Env sequence. An additional truncation from the Xba
I to KpnI restriction site in the Env ORF eliminates an additional 211 bps. This final
construct was named CCGBX, reflecting the GFP as the marker (Figure 21). The length
of CCGBX is 9287 bps, 185 bps shorter than HERV-KCON. Other markers are named
accordingly; for example, CCBBX encodes for the blasticidin resistance gene. For each
experiment, the genome used is noted in the figure legend for clarity.
To determine whether particles containing the HERV-KCON genome, Gag, PR,
and Pol proteins were capable of infectious transfer of the HERV-KCON genome to target
cells, the plasmids were transfected into 293T cells for VLP production (Figure 22). As
expected, transfection of the Env-defective CHKCG construct resulted in GFP expression
in transfected 293T cells, but inoculation of target cells with 0.2-µm filtered supernatant
harvested from these cells did not result in infectious transfer of the reporter gene.
However, when VSVG was expressed in trans, GFP expression was observed in rare foci
of target cells inoculated with filtered supernatant from CHKCG-transfected cells.
Moreover, when Rec was expressed in trans with CHKCG and VSVG, infectious particle
yield was in excess of 102 infectious units/ml. Similarly, when the HERV-KCON Gag-PRPol expression plasmid was provided in trans for the combined expression of CHKCG,
VSV-G, HERV-K Gag-Pol, and Rec, the highest infectious titers were
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Figure 22 Generation of single cycle infectious HERV-KCON VLPs
Infectious titers of HERV-KCON VSV-G pseudotyped virions generated following transfection with the
indicated plasmid mixtures using 293T target cells. GFP-positive foci were enumerated visually and
expressed as infectious units per milliliter of virion-containing supernatant. CHKCG was used as the
packageable genome.

detected (up to 103 IU/ml, Figure 22). Thus, this combination of plasmids (or an
improved packageable HERV-K genome as noted) was used to generate infectious
HERV-KCON VSV-G pseudotyped particles in subsequent studies, which generated titers
approaching 104 IU/ml. While this infectious titer is low compared to that generated by
many exogenous retroviruses (e.g., murine leukemia virus [MLV] and HIV-1), the yield
of infectious HERV-K particles was of the same order as or greater than that obtained
with similarly constructed human T-cell lymphotropic virus-1 (HTLV-1) based vector
systems ((Derse et al., 2001) and unpublished data).
HERV-KCON particles with mutations in the reverse transcriptase protein were
also tested as controls. VLPs were generated using CCBXS RTX (HERV-KCON with a
blasticidin resistance gene and RT mutation) and either WT or RTX Con Gag-PR-Pol.
RTX plasmids were synthesized by mutating the highly conserved YIDD RT motif to
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Figure 23 Lack of infection by RT mutant HERV-KCON VLPs
CCBXS was used as the packageable genome for production of VLPs. 293T cells were used as target cells
for infection. 12 hours post-infection, infected cells were selected via addition of blasticidin (0.5 µg/ml) in
cell culture media for two weeks. The resistant colonies were quantified by eye, and infectious units were
calculated based on eye count.

AIAA. In RTX VLPs, no blasticidin resistant colonies were observed after selection of
infected cells, while numerous colonies were observed after infection with the WT VLPs
(Figure 23).
HERV-K108, a provirus which exists as multiple alleles, contains a YIDD to
CIDD mutation in its RT, and therefore assumed to encode an inactive protein (Mayer et
al., 1999b; Reus et al., 2001). However, when the CIDD mutation was tested in the
context of HERV-KCON for activity in an exogenous RT assay, CIDD RT was in fact
consistently slightly more active than YIDD RT (Figure 24). As K108 RT differs from
HERV-KCON in three additional amino acids, the activity of CIDD HERV-K RT does not
confirm that K108 RT is active.
Additionally, 293T cells were inoculated with VSVG pseudotyped HERV-KCON
particles containing the CHKCG genome in the presence of azidothymidine (AZT), a
100

120

Infectious units /ml

100
80
60
40
20
0
CIDD

YIDD

pCRVI

Figure 24 Infection of HERV-KCON VLPs with RT mutation
CHKCG was used as the packageable genome for VLP production with either HERV-KCON Gag-Prot-Pol
with WT RT (YIDD motif), or mutant RT (CIDD motif). Two days post transfection, supernatant was used
to infect fresh 293T cells. GFP+ cells were quantified by FACS two days post infection.

reverse transcriptase inhibitor. AZT is a thymidine analog chain terminator and is known
to inhibit reverse transcriptases from a wide variety of retroviruses (Rosenblum et al.,
2001). As can be seen in Figure 25, application of AZT to target cells inhibited HERVK–mediated reporter gene transduction by approximately 30-fold, suggesting that the
reporter gene transfer by HERV-KCON was dependent on reverse transcription.
In some cases, low levels of reporter gene expression mediated by retroviral gene
transfer can be mediated by reverse-transcribed but nonintegrated retroviral DNA, which
can exist as linear or circular forms in target cells (Saenz et al., 2004; Wu and Marsh,
2001; Yanez-Munoz et al., 2006). However, these retroviral DNA forms are diluted
during cell division and eventually lost. Stable retrovirus-mediated gene transfer that is
transferred to both daughter cells requires that retroviral DNA be integrated into the
target cell genome. While the formation of clear multicellular foci of GFP positive cells
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Figure 25 AZT sensitivity of HERV-KCON infection
Infectious titers of CHKCG containing VSVG pseudotyped HERV-KCON using
293T target cells in the presence or absence of 50 µM AZT was accessed.
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genomes that carry resistance markers. Therefore, VSVG
pseudotyped HERV-KCON particles carrying CHKCP, packageable
genome with a puromycin resistance gene, were used to infect new

target cells (Figure 26). Puromycin-resistant colonies formed following exposure of 293T
target cells to these virions and antibiotic selection for two weeks post infection,
suggesting that true integration had occurred. Indeed, the infectious titers of puromycin
resistance transducing particles were similar to that of GFP-transducing particles.
To further demonstrate that HERV-KCON genomes were capable of integration,
hamster CHO745 cells were infected with HERV-KCON particles carrying the CHKCP

Figure 26 Transduction by HERV-KCON Gag-PR-Pol and genomes
Puromycin-resistant colonies of 293T cells infected with either VSVG pseudotyped (left) or Env defective
(right) virions carrying the CHKCP genome. Infected 293T cells were selected in 0.5 µg/ml puromycin for
2 weeks and then fixed and stained to reveal colonies of viable cells. Data are representative of at least
three experiments.

102

genome and four single cell clones were derived from the resulting puromycin-resistant
cell population by limiting dilution. Cellular genomic DNA was extracted following
expansion of the clones for two weeks in culture and analyzed for the presence of
integrated HERV-K DNA using a PCR-based strategy (Figure 27). Hamster CHO745
cells were used for these experiments because they were found to be as sensitive as
human cells to HERV-KCON infection (see below), but unlike human cells, they lack
endogenous HERV-K proviruses that would complicate detection and analysis of de novo
HERV-K integration events. As can be seen in Figure 27B, PCR analysis using HERV-K
gag specific PCR primers revealed that each of the CHKCP-transduced clones, but not
parental CHO745 cells, carried HERV-K DNA. Next, sequences flanking the integrated
proviruses were identified using a PCR-based strategy (GenomeWalker kit; Clontech,
http://www.clontech.com) and in each case revealed the presence of a six nucleotide
duplicated sequence immediately flanking the provirus (Figure 27C). For three CHKCPtransduced CHO745 cell clones, PCR primers were designed that targeted hamster DNA
sequences flanking the integrated HERV-KCON provirus (Figure 27A), and these were
used to authenticate the presence of the intact preintegration site in uninfected hamster
cells (e.g., Figure 27D). Moreover, PCRs using combinations of the hamster DNAspecific and HERV-K–specific PCR primers were used to authenticate the presence
HERV-K provirus/hamster cellular DNA junctions in three of the CHKCG-transduced
clones (e.g., Figure 27D). Overall, these experiments demonstrate that HERV-K genomes
can be replicated via exogenous infection in a reverse transcriptase–dependent manner,
resulting in stable and authentic integration into the target cell genome.
Next, it was determined whether VSVG pseudotyped HERV-KCON particles could
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Figure 27 Identification and confirmation of HERV-KCON integration sites
A. Experimental strategy for detection of HERV-KCON proviruses in CHO745 cells using PCR primers
targeted to HERV-KCON Gag and LTR sequences, or flanking hamster DNA sequences. B. PCR
amplification of HERV-KCON gag DNA using Gag-S and Gag-AS primers in four expanded clones of
puromycin-resistant CHO745 cells transduced with CHKCP-containing HERV-KCON particles. C.
Nucleotide sequences at the 59 and 39 ends of integrated CHKCP proviral DNA, revealing six nucleotide
duplicated sequences at the CHKCP integration sites. D. Verification of the presence and absence of an
integrated provirus and the empty preintegration site in CHKCP-transduced and naive
CHO745 cells using combinations of HERV-K and hamster DNA targeted PCR primers (see [B] for primer
design strategy). DNA templates and PCR primer pairs used are indicated above each lane, and the
expected PCR product size is given below each lane. A representative analysis of a single CHKCGcarrying CHO745 cell clone is shown; similar results were obtained with two additional clones. Uninfected
CHO745 cells and human 293T cells serve as controls.
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transduce reporter genes into cells other than 293T and CHO745. As can be seen in
Figure 28A, several target cells of human, squirrel monkey, feline, and rodent origin
could be infected by HERV-KCON. However, it was noticeable that murine NIH3T3 cells
and squirrel monkey Pindak cells were somewhat less sensitive to HERV-KCON,
compared to the human and feline cells. The human cells were each quite similar in their
sensitivity even though 293T cells display little or no TRIM5α-dependent resistance to
retroviruses such as EIAV or N-tropic MLV, while TE671 and HT1080 exhibit strong
TRIM5α-dependent resistance to N-tropic MLV and EIAV. This finding suggested that
HERV-KCON may not be sensitive to human TRIM5α.
Additionally, to test whether the HERV-KCON envelope sequence was functional,
it was inserted into the HIV-1–based expression vector pCRV1 and expressed along with
HIV-1 Gag-PR-Pol proteins and the packageable GFP-expressing HIV-1 vector CSGW.

Figure 28 Tropism of HERVKCON
A. Human, squirrel monkey,
feline, hamster, or murine cells
were infected with VSVG
pseudotyped HERV-KCON particles.
Two days postinfection, GFP+ foci
were quantified microscopically,
and titers are expressed as number
of infectious units (i.u.) per
milliliter of virus containing
supernatant applied. B. Human,
squirrel monkey, feline, or murine
cells were infected with HERVKCON Env pseudotyped HIV-1
particles as in A. Two days
postinfection, GFP-positive foci
were quantified. All data are
representative of at least three
experiments.
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This transfection mixture should generate HIV-1 particles, putatively pseudotyped
with the HERV-KCON envelope protein. Notably, these particles were capable of infecting
293T cells, with titers of around 3 x 102 IU/ml (Figure 28B), while particles generated in
the absence of HERV-KCON Env were noninfectious. Inoculation of cells from a small
panel of mammalian species revealed that several, including those of human, squirrel
monkey, murine, and feline origin, could be infected with HERV-KCON Env pseudotyped
HIV-1 VLPs (Figure 28B).
While attempts were made to generate infectious particles that contained both
HERV-KCON cores and Env proteins, infection events using this combination were
undetectable. Nevertheless, these experiments indicate that the HERV-KCON genome
contains all functional components required to complete an exogenous retroviral
replication cycle.
As mentioned previously, HERV-KCON is a betaretrovirus. Of the seven genera of
Retroviridae, lentiviruses are unique in their ability to infect non-diving cells. Most other
retroviruses depend on the cell cycle to dissolve the nuclear membrane for the PIC to
access the host genomic DNA for integration. How HERV-K accesses the host genome
was examined by treating HT1080 cells with aphidicolin, which blocks the cell cycle at
early S phase, prior to infection (Figure 29). When the target cells were effectively
blocked in cell cycle, HERV-KCON was unable to infect HT1080. This was in contrast to
HERV-KCON infection of untreated HT1080s or HIV-1 infection of treated HT1080 cells.
This data clearly demonstrates that HERV-K, like most nonlentiviral retroviruses,
depends on the cell cycle for successful infection.
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Figure 29 Cell cycle dependency of HERV-KCON
HT1080 cells were treated with 2µg/ml of aphidicolin 24 hours, then infected with HIV-1, MLV, or
HERV-KCON VLPs. The cells were treated with aphidicolin at the same concentration during the entire
experiment. For HIV-1 VLPs, 293T cells were transfected with CSGW and NL4-3 GPol plasmids. For
MLV VLPs, cells were transfected with CNCG and MLV GPol plasmids. For HERV-KCON VLPs, cells
were transfected with CCGBX, pCRVI/Con Gag-Prot-Pol, and pCR3.1/K108 Rec. All VLPs are
pseudotyped with VSVG. Successful cell cycle arrest and infection was checked via FACS.
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Chapter 3. Restriction factors and HERV-K

3.1 Introduction to restriction factors
Restriction factors are host proteins that help defend the host cell against virus
infections (Bieniasz, 2004b). Although also up-regulated by IFN, they are constitutively
expressed, potentially in any cell, providing an immediate front-line defense against
invading viruses (Bieniasz, 2004b). To date, three major groups of restriction factors
have been described for retroviruses; all were discovered in relation to HIV-1, but some
have been shown since to be active against other retroviruses and non-retroviruses as well
(Esnault et al., 2005; Harris et al., 2003; Jouvenet et al., 2009b; Turelli et al., 2004b;
Vartanian et al., 2008a; Yu et al., 2004b).
The first group of proteins, including Fv-1, TRIM5α and TRIM5-Cyp, target the
incoming viral core, although the exact mechanism of restriction is unclear (Bieniasz,
2004b; Johnson and Sawyer, 2009a). The second group of restriction factors is the
APOBEC3 cytidine deaminase family. APOBEC3G (A3G) was first described as an
antiretroviral factor capable of inhibiting Vif deficient HIV-1 (Sheehy et al., 2002), but
other APOBEC3 proteins have since been shown to have antiviral activity as well
(Bishop et al., 2004a; Dang et al., 2008; Dang et al., 2006; OhAinle et al., 2006; Yu et al.,
2004a; Zennou and Bieniasz, 2006). The major mechanism of restriction by A3G is likely
by extensive mutation of Cs to Us in the minus strand of the ssDNA viral genome during
reverse transcription (Bishop et al., 2004a; Harris et al., 2003; Mangeat et al., 2003;
Miyagi et al., 2007). The most recently described retroviral restriction factor is tetherin,
which tethers fully assembled and budded particles to the infected cell’s plasma
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membrane and prevents the virus from moving away and infecting a new cell (Neil et al.,
2008b; Van Damme et al., 2008a).
TRIM5α and A3G proteins have been under positive selection in primates for at
least 35 million years (Sawyer et al., 2004; Sawyer et al., 2005b), as has tetherin for at
least 25 million years (McNatt et al., 2009b). Likely, these proteins have been
functioning against many retroviruses and perhaps other viruses during that time
(Johnson and Sawyer, 2009a). As an ancient retrovirus that infected primate and Old
World monkey ancestors, HERV-KCON is an ideal candidate to test the retroviral activity
of these restriction factors in an effort to understand the long-standing interaction
between the proteins and retroviruses.

3.2 Effects of TRIM proteins on HERV-KCON infection
To test the sensitivity of HERV-K to retrovirus restriction factors that it might
encounter in human cells and might be responsible for attenuation or extinction of
replication therein, unmodified or human TRIM5α expressing hamster (CHO)-derived
cell lines were challenged with VSVG pseudotyped HERV-KCON. The human TRIM5α
expressing cell line was greater than 100-fold resistant to N-tropic MLV relative to the
control cell line or B-tropic MLV, confirming that the transduced human TRIM5α was
functioning as expected in the cell line (Figure 30A). Unlike MLV, HERV-KCON infected
unmanipulated and human TRIM5α -expressing cells with nearly identical efficiency
(Figure 30B). Additionally, CHO cells expressing rhesus macaque TRIM5α or the
unusual owl monkey variant of TRIM5 (TRIM-Cyp) were also similarly sensitive to
HERV-KCON infection compared to unmanipulated control cells (Figure 30B). This was
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despite the fact that CHO cells expressing rhesus monkey TRIM5α and owl monkey
TRIMCyp were about 30-fold and 100-fold, respectively, resistant to HIV-1 infection
compared to HIV-1 carrying an SIVMAC CA (Figure 30A). Whether HERV-K(HML-2)
has evolved to resist the effects of human TRIM5α and by chance is also resistant to
rhesus macaque TRIM5α and owl monkey TRIM-Cyp or is completely unaffected by
TRIM5 proteins is unknown.
Human TRIM5 exists as a gene cluster of four TRIM proteins on chromosome 11,
TRIM6, TRIM34, TRIM5, and TRIM22, which likely resulted from tandem gene
duplication (Sawyer et al., 2007). Like TRIM5, TRIM22 is up-regulated by IFN

Figure 30 Effect of TRIM5 proteins on HERV-KCON infection
A. Unmanipulated CHO cells or variants stably expressing human TRIM5α, rhesus monkey TRIM5α, or
owl monkey TRIM-Cyp were infected with VSVG pseudotyped retroviral vectors that are sensitive to one
or more of the TRIM5 proteins (N-MLV or HIV-1) or TRIM5-resistant controls (B-MLV or HIV-1
carrying SIVmac CA HIV(SCA)), as indicated. Two days postinfection, the percentage of GFP+ cells was
determined using FACS. B. The same panel of CHO-derived TRIM5-expressing CHO cell lines were
inoculated with VSVG pseudotyped HERV-KCON. Two days postinfection, GFP+ foci were quantified by
FACS.
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treatment and, unusually, has been under episodic positive selection in primates over the
past 23 million years (Bouazzaoui et al., 2006; Gongora et al., 2000; Sawyer et al., 2007).
TRIM22 also has been shown to reduce HIV-1 replication in primary human
macrophages and cell lines such as HOS and HeLa cells, but the mechanism by which
TRIM22 restricts the virus remains unclear (Barr et al., 2008; Bouazzaoui et al., 2006;
Gongora et al., 2000).
To test the restrictive potential of TRIM22 on HERV-KCON, CHO745 cells were
stably transduced with TRIM22 proteins from human, gorilla, rhesus macaque, owl
monkey, and squirrel monkey. The localization of these proteins, examined via confocal
microscopy of GFP tagged versions, shows that human, gorilla, rhesus macaque, and
squirrel monkey TRIM22 proteins are punctate and cytoplasmic (Figure 31A). Squirrel
monkey TRIM22 also existed as small ring structures within the nucleus. Owl monkey
TRIM22 is found as both punctate cytoplasmic form and as a large nuclear mass,
resembling the nucleolus. Regardless, when these cells were infected with HERV-KCON,
no change in infection was seen (Figure 31B), suggesting that TRIM22 proteins tested do
not restrict HERV-K between virus entry and integration.

3.3 Effect of tetherin on HERV-KCON release
Next, the effect of tetherin on HERV-K infection was tested. Tetherin was discovered as
the target of an HIV-1 accessory protein Vpu, the interaction which leads to increase
HIV-1 particle release (Neil et al., 2008b; Van Damme et al., 2008a). Expression of
tetherin seems to block the release of other virus particles as well (Jouvenet et al., 2009b).
How Vpu antagonizes the effects of tetherin is unknown. Co-expression of human

112

Figure 31 Localization and effect of TRIM22 on HERV-KCON infection
A. Confocal microscopy of PGSA cells stably transduced with human, gorilla, rhesus macaque, squirrel
monkey, and owl monkey TRIM22 proteins fused with an HA tag. The cells were permeabilized, fixed
with 4% PFA, and stained with anti-HA antibody. B. PGSA cells stably transduced with TRIM22 proteins
were infected with HERV-KCON VLPs and fixed two days after for FACS analysis. CCGBX packageable
genome was used to make the VLPs.
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tetherin with pCRVI/Con Gag-PR-Pol in 293T cells resulted in a dramatic decrease of
VLPs in the supernatant, from a ten-fold decrease at the lowest concentration of tetherin
tested to almost complete inhibition at the highest concentration (Figure 32) (Jouvenet et
al., 2009b). Co-expression of HIV-1 Vpu partially restored the amount of VLP in the
supernatant to within half of the level released when no tetherin was co-expressed (Figure
32).
This demonstrates that tetherin can effectively reduce the amount of HERV-K
particles produced from an infected cell. As the entire virus was not used in the
experiment, it is possible that proteins not expressed in pCRVI/Gag-PR-Pol such as Env
may have a Vpu-like activity to counter the antiviral effects of tetherin. Indeed, the Env
protein of HIV-2ROD10 strain has a Vpu-like ability to enhance retrovirus release (Bour
and Strebel, 1996). Whether HERV-KCON Env has similar ability has not been tested.
Furthermore, as tetherin targets a very wide array of enveloped viruses, it is unclear
whether HERV-K truly interacted with tetherin in the past, or is susceptible because of
tetherin’s general mechanism of action. Furthermore, as tetherin is only expressed in

Figure 32 Effect of tetherin on HERV-KCON VLP release
HERV-K particles were generated by transfecting 1.8 µg of CCGBX,
0.5 µg of pCRV1/ConGag-PR-Pol, and 0.5 µg of pCR3.1/Rec, along
with 0, 100, 200, or 400 ng of pCR3.1/Tetherin-HA, in the presence
or absence of pCR3.1/Vpu. Semi-quantitative analysis of western blot
was carried out by scanning using an Alpha Innotech imaging system
and rendering the blots as TIFF files. Band intensities (given in
arbitrary units) associated with released VLPs, at each amount of
transfected tetherin expression plasmid, were quantitated using Image
J software (W. S. Rasband, U.S. National Institutes of Health,
Bethesda, MD [http://rsb.info.nih.gov/ij/], 1997 to 2008). Histograms
of pixel intensity for each lane were generated using the plot lane
function in the Gels Analysis toolbox, and the area under the curve of
the histogram peak was then calculated.
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the presence of type-I IFN in most cells, if HERV-K does not induce an IFN response
during infection, then tetherin may not affect its replication in vivo at all (Neil et al.,
2007). Hence, it is difficult to conclude that HERV-KCON has influenced the evolution of
tetherin.

3.4 Effect of APOBEC proteins on HERV-KCON infection
Like tetherin, A3G was discovered as the target of an HIV-1 accessory protein
(Sheehy et al., 2002). While human A3G cannot block infection of HIV-1 due to the
actions of Vif, it may still counteract infection from other viruses which have not evolved
to avoid it. The effect of human APOBEC3 proteins on HERV-K infection was
determined. Although it would be optimal to test infection using physiologically relevant
APOBEC3 protein levels, the expression level of most APOBEC3 proteins in various
tissues is unknown. Moreover, the tissue tropism of HERV-K is unknown; hence it is
difficult to find the APOBEC expression level at which HERV-K naturally infects.
Instead, by titrating the amount of expression vector in the assays, APOBEC3 proteins
were expressed at various, and relatively low, levels that mimicked the range of protein
levels at which hA3G, hA3F, and hA3B inhibit HIV-1 infection in the absence of Vif
(Figure 33A). HERV-KCON VLPs were generated in 293T cells in the presence of each of
the C-terminally HA-tagged human APOBEC3 proteins. Western blot analysis of cell
lysates showed that APOBEC3 protein expression varied (Figure 33A), but the range of
expression levels for most of the proteins overlapped as a result of transfecting various
levels of the corresponding expression plasmids. However, hA3DE and hA3H were
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Figure 33 Expression and effect of human APOBEC3 proteins on HERV-KCON infection
A. Anti-HA (top panel) and anti-HERV-K CA (bottom panel) Western blot of 293T cell lysates transfected
with HERV-KCON, VSVG, and APOBEC-HA plasmids. B. Infection of CEM cells with HIV-1 (left panel)
or 293T cells with HERV-KCON virions, generated in the presence of the indicated APOBEC3-HA
proteins. Infectious units were quantified as GFP+ cells using fluorescence-activated cell sorter analysis 2
days postinfection, and are expressed as a percentage of the number of infected cells (typically 15 to 30%)
that were obtained in the absence of an APOBEC3 protein.
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comparatively poorly expressed. Importantly, HERV-K Gag was expressed equally in all
conditions. The only exception to this was at high levels of hA3B expression, which
appeared to slightly reduce the levels of HERV-K Gag expression, presumably due to
marginal toxicity. Fresh 293T target cells were infected with HERV-K virions generated
in the presence of each of the APOBEC3 proteins. As can be seen in Figure 33B, hA3A,
hA3B, and hA3F inhibited HERV-KCON infection by approximately fivefold at the
highest concentration tested. Only marginal inhibition of infection was seen with hA3G,
while hA3C, hA3DE, and hA3H did not inhibit infection. Clearly, the relative sensitivity
of HERV-K to the various APOBEC3 proteins differ greatly from that of HIV-1 (Figure
33B).

3.5 Hypermutated HERV-K proviruses in modern human DNA
While several APOBEC3 proteins appeared capable of inhibiting HERV-K
infection in vitro, to determine whether restriction of HERV-K infection might have
occurred in vivo, evidence of APOBEC3-induced mutation in HERV-K proviruses that
are present in modern human DNA was sought. Specifically, 16 human-specific fulllength HERV-K(HML-2) proviruses were examined and especially for biases in the
patterns of mutation therein, relative to the pseudo-ancestral HERV-KCON sequence.
Overall, G-to-A and C-to-T substitutions were the most abundant changes in the
proviruses as a whole (Figure 34A), as would be expected from genomic sequences that
are not under purifying selection. Fourteen HERV-K proviruses showed a comparatively
minor increase in the frequency of G-to-A changes and C-to-T changes relative to other
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Figure 34 Nucleotide changes in human-specific HERV-K proviruses relative to HERV-KCON
A. The numbers of changes of each type from the HERV-KCON to sequences in endogenous proviruses are
plotted. For comparison of sequences flanking HERV-K60 and HERV-KI, 2 kb of genomic sequence
immediately proximal to the 5’ and 3’ ends of the proviruses were compared for changes from chimpanzee
to the orthologous human sequence. For each sequence comparison, the numbers of changes were
normalized to enable direct comparison with the numbers of changes in the individual HERV-K60 and
HERV-KI proviruses. B. Graphical representation of nucleotide changes relative to HERV-KCON in the 16
human specific proviruses. Red, GG to AG; cyan, GA to AA; green, GC to AC; magenta, GT to AT; black,
non-G-to-A transitions; yellow, gaps in the sequence.
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changes (Figure 34A). However, two proviruses, HERV-K60 and HERV-KI, were
exceptional in the total quantity and type of changes. Overall, they exhibited similar
frequencies of C-to-T mutation as did the other 14 proviruses, but both HERV-K60 and
HERV-KI exhibited a very high frequency of G-to-A changes relative to the HERV-KCON
(Figure 34A and B). Indeed, each of these individual proviruses had more G-to-A
mutations than the other 14 proviruses combined; two-thirds and one-half of all the
changes in K60 and KI, respectively, were G-to-A mutations (Figure 34A).
To ensure that the exceptional properties of the two apparently hypermutated
proviruses were not due to their insertion into an unusually hypermutated region of the
human genome, 2 kb of flanking genomic sequence at each end of the two proviruses
were examined for evidence of hypermutation. Specifically, changes between the
equivalent loci in humans compared to chimpanzees were examined. This is a
conservative approach, since these HERV-K insertions are absent in chimpanzees and
have, therefore, been resident in the human genome for less time than the flanking
sequences have been diverging in the two species. As expected, G-to-A, C-to-T, and
reciprocal A-to-G and T-to-C changes were found to be most abundant in comparisons of
the human and chimpanzee flanking sequences (Figure 34A). However, G-to-A changes
did not greatly outnumber other changes, suggesting that that the apparent hypermutation
in the inserted proviruses occurred independently of the genomic context sequence, likely
prior to their integration.
In addition to the 16 aforementioned proviruses, additional human-specific partial
HERV-K sequences that lacked LTRs, as well as HERV-K proviruses (defined as group
N by Romano et al.) that were not human specific, and group N CERV-K proviruses
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(chimpanzee counterparts of HERV-K), including four chimpanzee-specific insertions,
were also examined, as were related group O proviruses. No evidence of hypermutation
was evident in these sequences (data not shown).

3.6 Flanking nucleotide characteristics of G-to-A changes in hypermutated HERV-K
proviruses.
A common cause of G-to-A and C-to-T substitutions in genomic DNA is
spontaneous cytosine deamination. This occurs most often after methylation of cytosines
in CG dinucleotides, followed by spontaneous deamination of 5-methylcytosine to a
thymine (CG to mCG to TG; altered nucleotide underlined). This series of events would
lead to an overabundance of plus-strand C-to-T changes with G in the +1 position relative
to the C-to-T mutation (CG to TG). Conversely, the same deamination event on the
minus strand would lead to plus strand G-to-A changes with an overabundance of C at
the -1 position relative to the mutated nucleotide (CG to CA). Indeed, in most of the
HERV-K proviruses examined (the 14 nonhypermutated proviruses), C-to-T changes
were significantly enriched for G in the +1 position (Figure 35A), and G-to-A changes
were significantly enriched for C in the -1 position (Figure 35B), suggesting most C to T
and G-to-A changes were a result of spontaneous cytosine deamination, as would be
expected of DNA elements that are long-term residents of the human genome.
To determine whether the excessive G-to-A changes present in HERV-K60 and
HERV-KI were indicative of APOBEC3- induced hypermutation, and if so, to determine
the identity of the responsible protein, the nucleotides flanking the G-to-A changes were
examined (Figure 36). At least some of the APOBEC3 proteins have signature
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Figure 35 Flanking nucleotides of C-to-T and G-to-A changes in non-hypermutated HERV-K
Nucleotide occurrence at five positions 5’ and 3’ to (A) C to T and (B) G-to-A changes was catalogued,
using the HERV-KCON sequence as a reference in non-hypermutated HERV-K proviruses. The absolute
number of times that each nucleotide occurred at each position relative to each change in the
nonhypermutated proviruses is plotted.
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dinucleotide preferences; for example, hA3B and hA3F prefer to deaminate cytosines
within TC dinucleotides, resulting in GA-to-AA mutations on the viral plus strand, while
hA3G exhibits a bias for deaminating CC dinucleotide, leading to plus-strand GG-to-AG
changes. In fact, of all the human APOBEC3 proteins, only hA3G exhibits the bias
toward GG-to-AG changes.
In both HERV-K60 and HERV-KI, a strong GG dinucleotide bias was detected at
G-to-A changes (Figures 36 and 37A). This preference indicates that hA3G was likely
responsible for the excessive G-to-A mutations in HERV-K60 and HERV-KI. In other
proviruses, and the genomic DNA flanking HERV-K60 and HERV-KI, no such
dinucleotide preference was detected (Figure 35B and data not shown). Furthermore, a
strong, statistically significant bias for GGG trinucleotides at G-to-A mutated positions
was also evident upon examination of the third nucleotide in all GG-to-AG substitutions
(Figure 37B). Notably, the GGG preference has been detected in previous studies of
hA3G with a Vif-deficient HIV-1 (Yu et al., 2004d), further supporting the notion that
hA3G was responsible for the excessive G-to-A mutations in HERV-KI and HERV-K60.

3.7 Hypermutation of HERV-K by APOBEC3 proteins during in vitro replication.
To test whether the in vivo hypermutation changes could be recapitulated in vitro,
HERV-KCON virions were generated in the presence of each human APOBEC3 protein
using the HERV-K packaging construct CCGBX-P (Figure 21). This construct contains
GFP as the marker and a 53 bp HIV-1 sequence (GATCTGAGCCTGGGAGCTCT CTG
GCTTGTGACTCTGGTAACTAGAGATCCCTC) 34 bps after the start of 3’ LTR to
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Figure 36 Flanking nucleotides of G-to-A changes in hypermutated HERV-K
Nucleotide occurrence at five positions 5’ and 3’ to G-to-A changes was catalogued, using the HERV-KCON
sequence as a reference. The absolute number of times that each nucleotide occurred at each position
relative to each G-to-A mutation in (A) HERV-K60 and (B) HERV-KI is plotted. The P value in panel B
for deviation from random nucleotides at +1 and +2 positions was > 0.0001, calculated using a chi-square
test of independence.
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Figure 37 Frequency of di- and trinucleotide for all G-to-A and GG-to-AG changes
Frequencies of each di- (A) and trinucleotide (B) for all G-to-A and GG-to-AG changes, respectively, in
HERV-K60 and HERV-KI are plotted as black bars. The expected numbers of G-to-A mutations in each
sequence context, based on di- and trinucleotide composition, of HERV-KCON is represented as a horizontal
gray line. The P value, for deviation from random di- and trinucleotide preference, was > 0.0001,
calculated by a chi-square test of independence.

allow selective amplification of newly synthesized HERV-K in a background of existing
HERV-K proviruses present in human cells. This extra sequence should be copied into
both LTRs during reverse transcription, and provide the means to distinguish de novo
integration events from endogenous HERV-K proviruses. As integration is largely
determined by the IN protein independently of the virus sequence, this extra sequence
should have minimal effect on the integration site preference (Lewinski et al., 2006).

124

HERV-K and APOBEC plasmids were transfected into 293T cells. Five hours
post transfection, the medium was replaced with fresh DMEM. Two days post
transfection, the supernatant was DNase treated at 37°C for an hour, then used to infect
fresh 293T cells. 11 hours post infection, the cells were harvested for total DNA
extraction using QiaAmp Blood and Tissue Kit (QIAGEN). A 762-bp sequence of
nascent HERV-KCON DNA was then amplified from the total DNA using primers
targeting the EGFP insert in the vector genome and the inserted HIV-1 sequence. Two
controls were done to establish the success of this strategy and to show that DNase
treatment reduced contaminating plasmid DNA in the virion preparations to
subdetectable levels. First, PCR amplifications were done using primers targeting the
plasmid backbone. Second, infections were done using virions harboring an inactivating
point mutation in the HERV-K reverse transcriptase. In both cases, PCR products were
not detected, indicating that the sequences generated following HERV-K infection
genuinely represented infection-dependent, de novo-synthesized HERV-K DNA, not a
transfer of residual transfected DNA.
hA3A, hA3B, hA3F, and hA3G were found to induce hypermutation of HERVKCON during in vitro infection. However the patterns and frequency of hypermutation
were different (Figure 38). In particular, nearly all HERV-K clones generated in the
presence of hA3G had G-to-A mutations, but each had a low to moderate number of
changes (median of six G-to-A changes per clone). Conversely, hA3A, hA3B, and hA3F
each induced hypermutation in a minority of clones, but hA3A and hA3B hypermutated
clones had a very high burden of mutations (37 changes for the sole hA3A hypermutated
clone, and a median of 43.5 G-to-A changes for hA3B hypermutated clones). Only a few
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Figure 38 Hypermutation of HERV-KCON during in vitro infection
All changes in HERV-KCON reverse transcripts relative to preinfection sequence were analyzed for +1 site
preference using HYPERMUT, and the sequences of 12 HERV-K clones generated during infection in the
presence of each APOBEC protein are represented as horizontal lines. Mutations are indicated as vertical
lines. Red, GG to AG; cyan, GA to AA; green, GC to AC; magenta, GT to AT; black, non-G-to-A
transitions.

changes were seen in HERV-K DNA generated in the presence of hA3F (median of four
changes per clone). Of the four human APOBEC3 proteins found to hypermutate HERVK in vitro, only hA3G exhibited the GG dinucleotide and GGG trinucleotide bias for the
generation of G-to-A mutations (Figures 38 and 39), as has previously been reported for
hA3G mutation of HIV-1 (Yu et al., 2004c). Moreover, hA3F and hA3B exhibited the
expected GA dinucleotide bias at positions where G-to-A mutations were generated
(Figures 38 and 39). hA3A also showed the same GA bias, with the caveat that only a
single HERV-KCON clone was found to be mutated by hA3A (Figures 38 and 39). Hence,

126

Figure 39 Flanking nucleotides of G to A changes incurred during in vitro infection of HERV-KCON
Flanking nucleotide sequence context surrounding mutations generated by APOBEC3 proteins during
HERV-K infection in the presence of hA3A, hA3B, hA3F, and hA3G. The numbers of times that each
nucleotide occurred at five positions 5’ and 3’ to each G-to-A change were plotted.

among all seven of the human APOBEC3 proteins, four appear intrinsically capable of
inducing hypermutation in HERV-K, but only hA3G was capable of hypermutating
HERV-K during in vitro infection with a characteristic bias that very closely resemble
mutations found in the endogenous HERV-K60 and HERV-KI proviruses (compare
Figures 36 and 39).
Moreover, when the 273 bp of HERV-KCON sequence that was analyzed in the
hA3G mutagenesis assay were compared with the corresponding sequence in HERV-K60
and HERV-KI, 10 out of the possible 75 G-to-A mutations were found in either or both

127

HERV-K60 and HERV-KI, while 15 out of the possible 75 G-to-A mutations were
represented in corresponding sequences that were mutated by hA3G during in vitro
infection (Figure 40). Notably, six of these G-to-A mutations were at identical positions,
a highly significant correlation (P = 0.003, Fisher’s exact test), lending further supporting
to the notion that hA3G was responsible for hypermutation of HERV-K60 and HERV-KI.

Figure 40 Comparison of in vivo and in vitro
mutations
Comparison of mutations relative to HERV-KCON that
appear in naturally hypermutated proviruses (HERVK60 and HERV-KI) and in the 273 nucleotides of
mutated HERV-K sequence generated in vitro in the
presence of hA3G. Changes relative to HERV-KCON are
represented graphically on horizontal lines and are color
coded according to the nucleotide appearing at the -1
site for HERV-K60 and HERV-KI and 12 HERV-K
clones generated during infection in the presence of
hA3G. Mutations are indicated as vertical lines. Red,
GG to AG; cyan, GA to AA; green, GC to AC; magenta,
GT to AT; black, non-G-to-A transitions; yellow, gaps
in sequence.
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Chapter 4. Integration of HERV-KCON

4.1 Introduction to retrovirus integration
Integration is one of two hallmark events of retrovirus replication. Where a
retrovirus integrates may affect its transcriptional efficiency, as well as the host cell’s
viability due to insertional mutagenesis. Each retrovirus has its own integration site
preference, but the preference usually relates to genomic features, such as CpG islands or
transcription units, rather than a specific sequence that the integrase recognizes. For
example, studies have shown that HIV-1 prefers to integrate into active transcription
units, MLV prefers CpG-rich promoter regions, while ASLV integrates relatively
randomly with a minor preference for transcription units (Barr et al., 2005; Mitchell et al.,
2004; Narezkina et al., 2004; Schröder et al., 2002b; Wu et al., 2003). The preference
based on genomic features means that the number of potential sites for integration is large
and predicting the exact insertion location is impossible, presenting an obvious drawback
for the use of retroviruses as vectors for gene therapy.
As no replicating HERV-K was available until recently, studies of HERV-K
integration have thus far focused on examining the resident proviruses in the human
genome sequence. Previous studies, and examination of the 404 insertions in this work
identified in Table 1 relative to chromosome size suggests that HERV-K accumulation is
not a random event, which would predict the number of insertions per chromosome to
positively correlate with chromosome size (Figure 8) (Medstrand et al., 2002; van de
Lagemaat et al., 2006; Villesen et al., 2004). Rather, HERV-K is found more frequently
outside of transcription units and when in genes, in reverse transcriptional orientation
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relative to the gene (Medstrand et al., 2002; Smit, 1999; van de Lagemaat et al., 2006;
Villesen et al., 2004). Whether this integration pattern reflects a true preference of
HERV-K or is a result of post-integration selection is unknown, but understanding the
preference will help assess the mutagenic potential of HERV-K.
The following work was conducted as a collaboration between the Bieniasz
laboratory and Bushman laboratory at University of Pennsylvania. The infection of 293T
and HT1080 cells, DNA extraction, and HML2(85) data set collection was conducted by
myself, the preparation of the DNA samples for the pyrophosphate mass sequencing by
Dr. Troy Brady, the MMTV data set was derived by Dr. Keshet Ronen, the analysis of de
novo insertions relative to genomic markers by Dr. Charles Berry (UCSD), and the
analysis of de novo insertions relative to endogenous HERVs by Dr. Troy Brady and Dr.
Nirav Malani.

4.2 HERV-K integration preference relative to genomic markers
The HERV-KCON single cycle infection system is an optimal system to test
integration preference. Attempts were made to find a germ cell-like cell line as target
cells, as these would most closely mimic the cell populations that would have been
infected to generate endogenous proviruses. Teratocarcinoma cells Tera-1, Tera-2, and
PA-1 were tested for their susceptibility to retrovirus infection, but they were all
relatively resistant to HERV-K infection (less than 10% GFP+ cells, data not shown).
Thus two human cell lines, 293T and HT1080, already known to be susceptible to
HERV-KCON infection, were used as target cells. Numerous studies of HIV-1, ASLV, and
MLV integration showed that the preference did not change between different cell lines,
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including cell lines of a different species, hence it is likely that using 293T and HT1080
cells will not result in a significant discrepancy relative to the native target cells (Barr et
al., 2006; Barr et al., 2005; Mitchell et al., 2004). Furthermore, 293T and HT1080 cells
are both human cell lines, but are derived from different organs (293T and HT1080 cell
lines are derived from fetal kidney and fibrosarcoma, respectively), but this difference did
not affect the integration site preference, further supporting the notion that these cell lines
are representative of natural HERV-K target cells for integration preference.
To approximate the native conditions of HERV-K infection as closely as possible
and enable use of human cells as target cells, CCGBX-P was used as the packaging
genome, the same construct used to identify APOBEC hypermutated HERV-K sequence
in Chapter 3.7. CCGBX-P and relevant HERV-K expression plasmids were transfected
into 293T cells for virus production. Two days post transfection, the supernatant was
treated with DNase for 1 hour at 37°C, then used to infect fresh target cells. The infection
efficiency determined by FACS was between 10-20%. The genomic DNA of target cells
was harvested two days post-infection and digested (MseI for 293T cells, MseI or ApoI
for HT1080 cells) and ligated to linker sequences. The integration sites were PCR
amplified using primers specific to the inserted HIV-1 sequence and linker sequence, and
the amplicons used for template in pyrophosphate mass sequencing. A total of 1565 de
novo integration sites (1064 sites from 293T cells, 501 sites from HT1080 cells) were
identified and characterized. Despite the different organ and gender origins of 293T and
HT1080 cells, comparison of integration relative to genomic markers did not show any
discrepancy between the two cell lines, except insertion into Y chromosome in HT1080
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cells that is not expected in 293T cell line, as it is derived from a female donor. Hence,
data for the two cell lines are combined for analysis below, except when noted.
Controls were derived for each HERV-KCON integration site. A large library of
random sites was generated in silico, then the distances to restriction enzyme recognition
sites were scored. Each experimental site was matched with three random control sites
that were positioned the same number of nucleotides from a restriction site for the
enzyme used to isolate the experimental site. That is, if an integration site was isolated
after cleavage with ApoI, and the distance from the ApoI site to the edge of the HERVKCon sequence was 80 bp, then three random control sites were drawn from the pool that
were also 80 bp from an ApoI site. Integration sites and matched random controls were
annotated for proximity to genomic features, and the distributions were compared. The
data is depicted as the ratio between observed HERV-KCON sites to control matches. A
ratio of 1 indicates that integration is random for the particular genomic feature, where as
a ratio more or less than 1 indicates a preference or an aversion for the genomic feature.
The genomic characteristics examined in retrovirus integration include
transcription units, gene density, gene expression, CpG islands, and DNase sites. Active
transcription units have been hypothesized to be potential integration sites due to either
the accessible nature of the genome during transcription, or the binding of viral proteins
with transcription factors associated with the region (Schröder et al., 2002a). Gene
density and gene expression are correlated features, as highly expressed genes tend to
reside in regions of high gene density. These genomic features correlate with HIV-1
integration (Mitchell et al., 2004; Schröder et al., 2002a; Wu et al., 2003). CpG islands
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and DNase sites are indicators of promoter regions, and correlate with MLV integration
(Bird et al., 1985; Lander et al., 2001; Mitchell et al., 2004; Wu et al., 2003).
HERV-KCON integration showed a minor but significant preference for
transcription units, and correlated positively with gene density and expression (Figure
41A, D, E). More significantly, HERV-KCON displayed a two and a half fold increased
preference for proximity to CpG islands and a two-fold preference for proximity to
DNase sites over matched controls (Figure 41B, C), which is similar but more subdued
than the integration preference of MLV. Integration site information derived from studies
of other viruses is analyzed together with the data derived from this study of HERV-K to
give a relative perspective. The source of data is listed in Table 3. Notably, the retrovirus
to which HERV-K is the most closely related whose integration preference has been
analyzed is MMTV. Despite their sequence similarity, the integration preferences of
these two retroviruses of the same genera seem to be different. The difference between
HERV-K and MMTV is unlike the integration preference of two other related
retroviruses, HIV-1 and EIAV, whose preference are highly similar (Hacker et al., 2006).
Insertions were also examined by chromosome (Figure 42). The null hypothesis
of de novo insertions equaling the random insertions was statistically rejected (p < 10-16),
indicating that insertions do not correlate to the size of the chromosome. Chromosomes 1,
17 and 19 were highly favored, and chromosomes 4, 13, 18, X, Y were heavily
disfavored. Earlier in this work, the number of endogenous HERV-K as a ratio to the size
of chromosome was presented (Figure 8). In that data set, the insertions were heavily
favored in chromosome 19 and disfavored in chromosomes 13, 15, and X. The de novo
HERV-K integration preference discussed above may explain some of these
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Figure 41 Integration target site selection of HERV-KCON relative to other retroviruses
Values are reported as the proportion of integration events divided by random events. The bar at 1.0
represents the expected random distribution. The statistical significance of differences from the matched
random controls is shown by the asterisks next to the legends. (*) 0.05 > P > 0.01; (**) 0.01 > P > 0.001;
(***) P < 0.001. A. Integration frequency within RefSeq genes. B. Integration frequency as a function of
gene density. The X-axis shows six bins of increasing gene density from lowest (left) to highest (right). C.
Integration frequency relative to gene expression. All genes tested in 293T cells using the Affymetrix 133
array were divided into eight equal bins, then the proportions of integration sites in genes at each activity
level were quantified and compared with random. The X-axis shows bins of increasing expression rank
from lowest (left) to highest (right). D. Integration frequency relative to CpG islands, scored as the
proportion of integration sites within 2 kb of an annotated CpG island. E. Integration frequency relative to
sites of DNase I cleavage (Crawford et al. 2004), scored as the proportion of integration sites within 2 kb of
an annotated cleavage site.
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Table 3 Integration data sets used

(Ciuffi et al., 2005; Faschinger et al., 2008; Lander et al., 2001; Marshall et al., 2007; Miller et al., 2005;
Mitchell et al., 2004)

Integration frequency (inserts/matches)

3.0
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Figure 42 Integration target site selection of HERV-KCON by chromosome
Values are reported as the proportion of integration events divided by random events. A ratio of 1.0
represents the expected random distribution. The statistical significance (p) of differences from the matched
random controls is less than 10-16.
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characteristics. HERV-KCON’s preference to integrate into transcription units and
promoter regions, which should also be affiliated with transcription units, and
chromsome 19’s characteristic as most gene dense chromosome in the human genome,
explains why chromosome 19 is highly favored for HERV-K insertions (Grimwood et al.,
2004). In contrast, chromosome 13 contains the fewest endogenous HERV insertions and
HERV-KCON insertions likely because it has the lowest gene density of all chromosomes
(Dunham et al., 2004). As insertions will be under selection pressure independent from
the integration preference later on, it is not surprising that the distribution of de novo
HERV-KCON and endogenous HERV-K differ.
Both sex chromosomes are known for their high density of repeat elements. The
two sex chromosomes, X and Y, were originally a pair of autosomes that have evolved
into sex chromosomes over the past 300 million years (Ross et al., 2005). They now have
diverged so far that only 5% of the Y chromosome overlap with sequences in X
chromosome (Graves, 2006a; Skaletsky et al., 2003). Hence, unlike autosomal
chromosomes, X chromosome only undergoes homologous recombination in females,
while Y chromosome does not, except the 5% of its sequence that still resembles X
chromosome (Ross et al., 2005). The heavy disfavoring for both de novo integration and
endogenous insertions into X chromosome may be due to the low density of genes
relative to autosomal chromosomes (estimated 1098 genes, 7.1 genes per Mb) (Ross et al.,
2005). The reduced amount of homologous recombination, an opportunity to eliminate
unwanted sequences, may explain the high quantity of other HERVs on the X
chromosome despite the low level of HERV-K de novo integration. A more detailed
analysis of Chromosome Y is presented later.
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4.3 HERV-KCON integration preference relative to endogenous HERV-K integration sites

For various biologically interesting reasons, the pattern of HERV-K insertions in
the human genome may not match that generated following HERV-KCON infection. To
analyze the differences, the sites of de novo HERV-KCON insertions were compared with
those of two groups of endogenous proviruses: the HERV-K(HML-2) subfamily, and
HERV-K superfamily. For the HERV-K(HML-2) data set, sequences with 85% matches
to the HERV-KCON LTR sequences were collected, marking the most recently acquired
and evolutionarily youngest HERV-K (HML-2) elements. This dataset was termed
termed HML2(85) and contained a total of 402 integration sites. The 85% cutoff was
determined by comparison of the percent nucleotide identity among HML-2 elements,
which ranges from 99% to 85%, with the percent identity between HML-2 and the next
closest HERV-K subfamily, HML-1, which ranges between 70% and 80% (Medstrand
and Blomberg, 1993a). For the HERV-K superfamily data set, RepeatMasker
(http://www.repeatmasker.org) was used to generate a large set of all Class II HERV
related sequences in the human genome (ERV2 data set; 10,573 integration sites). The
ERV2 set combines all subfamilies of the HERV-K superfamily (HML1 through
HML10), including both old and young ERV2s.
Integration of each data set relative to transcription units, CpG islands, DNase
sites, gene expression, gene density, and GC content were examined. As previously noted,
HERV-KCON has a minor preference for integration in transcription units (Figure 41A and
43A). HML2(85) and ERV datasets, however, have a clear preference for integration
outside transcription units (Figure 43A), a statistically significant difference with HERV-

137

KCON data set. HERV-KCON showed a two-fold preference over random matched controls
for CpG islands, while HML2(85) and ERV2 showed a one and a half fold and just over
one fold preference over controls (Figure 43B). For DNase sites, HERV-KCON had a twofold preference, while HML2(85) and ERV2 were disfavored from DNase I sites (Figure
43C). The preference of HERV-KCON increases gradually proportionally to GC content,
while the peak and decline before the highest GC content group, and ERV2 peaks before
HML(85) data set and declines as well (Figure 43D). Hence, for all genome feature
examined, a general pattern emerged where HERV-KCON data set displayed a preference
at one end of a range and the ERV2 data set at another, with HML2(85) having an
intermediate phenotype between the two data sets. This suggests a two-step model of
HERV accumulation where HERV-K integrates according to its preference, then the
proviruses are selected upon over time. Hence, HML-2(85) data set may represent
insertions that had the phenotype of HERV-KCON insertions before, and will become like
the ERV2 data set later on.
The preference for gene density increased proportionally for all data sets, with the
biggest increase for HERV-KCON and smaller increases for the older data sets (Figure
43E). Gene expression also correlated positively with HERV-KCON integration, but were
disfavored by HML2(85) and ERV2 data sets, except at the highest gene expression
group for HML(85), where integration was preferred at one and a half fold over controls
(Figure 43F). Combined with the HERV-KCON’s preference for transcription units, these
data suggest that after integration into gene dense regions, HERV-K elements which have
inserted into expressed parts of gene dense region are selected out. Hence, in gene dense
regions, HERV-K will accumulate outside of genes over time.
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Figure 43 Integration of HERV-KCON versus resident ERV2 elements
Values are reported as the proportion of integration events divided by random events. The bar at 1.0
represents the expected random distribution. The statistical significance of differences between data sets is
shown by the asterisks next to the legends: (*) 0.05 > P > 0.01; (**) 0.01 > P > 0.001; (***) P < 0.001. A.
Integration frequency relative to transcription units as defined by the RefSeq database. B. Integration
frequency relative to CpG islands. C. Integration frequency relative to DNAse I cleavage sites, 2-kb
windows. D. Integration frequency relative to G/C content, 5-kb windows. E. Integration frequency relative
to gene density. F. Integration frequency relative to gene activity. In this plot, Affymetrix microarray
analysis was used to rank the activity of all genes queried, then the ranks were distributed into eight bins.
The genes hosting integration events were then distributed into the bins and the frequencies compared with
matched random controls.
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Figure 44 HERV-K integration into the Y
chromosome
Values are reported as the proportion of integration
events divided by random events. The bar at 1.0
represents the expected random distribution. The
statistical significance of differences between data sets is
shown by the asterisks next to the legends: (*) 0.05 > P >
0.01; (**) 0.01 > P > 0.001; (***) P < 0.001. Only the
HT1080 data set was used in this analysis, as it is
derived from a male cell line, while 293T cells are not.

The Y chromosome has been noted previously to contain an extraordinarily high
quantity of repeat elements, including an average of 14 HERVs per Mb (Graves, 2006b;
Kim et al., 2004b; Kunkel et al., 1976; Skaletsky et al., 2003; Villesen et al., 2004). To
test whether the abundance of HERVs in the Y chromosome is caused by a natural
integration preference or an accumulation post selection, the de novo insertion of HERVKCON was examined. Compared to matched random controls, HERV-KCON insertions in
Y chromosome were underrepresented but the difference did not reach statistical
significance (Figure 44). The HML2(85) data set displayed a one and a half fold
preference to insert over random matches, but ERV2 integration sites were enriched on
the Y chromosome five fold over random matches, in agreement with studies of other
HERVs (Kim et al., 2004b; Villesen et al., 2004). The small number of HERV-KCON
insertions in Y chromosome is expected based on its preference for transcription units
and CpG islands and the dearth of genes in the Y chromosome. The low number of de
novo insertions suggests that the high quantity of resident HERVs in Y chromosome is
not due to a natural preference of integration. Y chromosome is a small, gene poor
chromosome of 60 Mbs, of which 95% of the sequence does not participate in
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homologous recombination, and therefore, unlike other chromosomes, lacks a potential
method to eliminate deleterious insertions, which may explain the abundance of HERVs
(Graves, 2006b). Furthermore, like the analysis relative to genomic markers, the pattern
for the three data sets has a gradient pattern, suggesting that the HML2(85) data set
represents a intermediate state between the de novo integrations and the more ancient
ERV2 integrations.
Lastly, the orientation of insertions into transcription units was examined. Similar to
other HERVs described, ERV2 and HML2(85) were integrated with a heavy bias in the
opposite transcriptional orientation relative to the gene (Figure 45).

Figure 45 Proviral orientation of de novo HERV-KCON vs resident HERVs
A. Diagram showing proviral orientations and the potential for transcriptional disruption by
provirusencoded transcription signals. (SD) Splice donor; (SA) splice acceptor; (PolyA) polyA signal. B.
Transcriptional orientation of ERV2, HML2(85), and HERV-KCON sequences found within gene-coding
regions as defined by the RefSeq database.
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Surprisingly, the bias was stronger for the HML2(85) data set than ERV2 data set.
This phenotype may attest to the presence and the stronger influence of splice acceptors
and donors and premature polyA signals in the younger group. The ERV2 group contains
members with more sequence deterioration, and may include insertions without effective
SA and SD sites and polyA signals, hence may be less detrimental to the transcript
expression, and thus under less pressure to be negatively selected from the population.
In contrast to HML2(85) and ERV2, HERV-KCON showed no preference in
orientation when inserted in a gene. This is perhaps the strongest evidence of a two-step
model of HERV-K genomic accumulation. Integration likely occurs according to the
actual preference of HERV-K, as determined here using HERV-KCON, then over time
individual insertions are negatively selected based on their negative influences on host
survival, such as abnormal gene expression due to integration into or near a gene. What
remains in the host genome is a result of constant ‘cleansing’ of detrimental repeat
elements at the population level.
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IV. DISCUSSION

Endogenous retroviruses are fossils of ancient infections that contain hidden
information about host-pathogen interactions, genomic rearrangements, and history of
population migration and speciation. The first human endogenous retroviruses were
discovered in the early 1980s: a type-C-like endogenous retrovirus similar to MLV and
Baboon endogenous retrovirus (BaEV), and a type-D-like endogenous retrovirus similar
to MMTV (Callahan et al., 1982; Martin et al., 1981; May et al., 1983). These two
HERVs are now known as HERV-E and HERV-K, which belong to the genera
gammaretroviruses and betaretroviruses, respectively (Ono, 1986; Steele et al., 1984).
Further studies showed that HERV-K is in fact a family of closely related viruses, and is
now referred to as the HERV-K superfamily (Franklin et al., 1988). Of the ten
subfamilies of HERV-K, the HERV-K(HML-2) subfamily is of particular interest
because it is believed to be the youngest of all HERVs known, and thought perhaps to
include replication competent members.
This body of work has focused on the replication of HERV-K(HML-2), and its
interaction with antiretroviral restriction factors. In Chapter 1, the HERV-K(HML-2)
elements in the human genome gathered by BLAST search are presented, with details on
their location. Many of these elements have been previously described or characterized
(Barbulescu et al., 1999; Belshaw et al., 2005a; Belshaw et al., 2004; Macfarlane and
Simmonds, 2004; Romano et al., 2006). Characterization of two proviruses, K113 and
K108, is also presented. Chapter 2 describes the derivation of HERV-KCON, a consensus
sequence of ten human specific proviruses and the establishment of a single-cycle
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infection system using this virus. Known anti-retroviral factors are tested against HERVKCON in Chapter 3, along with a more extensive analysis of the previous and current
interactions between HERV-KCON and APOBEC3G protein. Lastly, where HERV-KCON
prefers to integrate is described in Chapter 4, as well as the comparison of de novo
integrations with those of endogenous HERV-K elements.

Chapter 1.
In this chapter, a BLAST search of the human genome for endogenous HERV-K
insertions using either the LTR sequence or the amino acid sequence of HERV-KCON Gag
is presented (Table 1, Table 2). These collections of insertions likely reflect HERV-K
infections of hominoid and Old world monkey ancestors after the divergence from New
world monkeys. A previous study found 553 HERV-K(HML-2) insertions, but as the
identity of the insertions or the criteria for distinguishing HML-2 from other HERV-K
subfamilies is not discussed in the previous study, a comparison is not possible (Belshaw
et al., 2005a). Similar to other HERVs, 90% of insertions are solo-LTRs and 10% are
associated with complete or partial internal sequence (41 of 404 insertions, Table 2). The
404 insertions are integrated across all chromosomes and largely correlate with the size
of the chromosome except for chromosome 19, which as more insertions than expected
by size, and chromosomes 13, 15, and X, which have less than expected. These
exceptions are discussed later.
No naturally occurring replication competent provirus has been identified, and the
replication potential of the best candidate, K113, has been disappointing. However, the
apparent expression of HERV-K proteins in teratocarcinoma-derived cell lines may yield
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some useful information about the nature of the factor or factors that induce transcription
from HERV-K LTR and the natural tropism of HERV-K. A recent publication which
examined the identity of HERV-K(HML-2) transcripts in Tera-1 teratocarcinoma cell line
via sequencing, eight proviruses were identified as major contributors of transcripts
encoding either Gag or Env sequences (Ruprecht et al., 2008). Consistent with this study
and the finding that HERV-K proteins are expressed in teratocarcinoma cells, K113 LTR
was more active in NCCIT teratocarcinoma cell line than 293T cell line (Figure 9). The
heterokaryon experiment shows that the factor or factors are dominant and present in the
NCCIT cells, but its identity is still unknown. Discovery of this factor or factors may
narrow down the list of potential natural target cells, as its expression is likely be a
requirement for a productive infection. The low level expression induced in the
overexpression of YY2 does not account for the much larger induction in teratocarcinoma
cell lines detected by Knossl et al, and hence unlikely to be the sole or the main factor
responsible for the upregulation in transcription from HERV-K LTR.
Despite the efforts to induce higher levels of transcription by insertion of a CMVP
and a functional Env of K108, CMVP-K113 and CMVP-K113K108 constructs did not
produce detectable levels of Gag by Western blotting (data not shown). The expression of
Rec in trans enhanced Gag expression, but it was still difficult to detect via Western
blotting. This shows that Rec is expressed and that K108 Rec and RcRE of K113 and
K108 are functional, but there are likely other defects in the proviruses which results in
efficient expression of Gag.
The undetectable level of Gag from a full length genome and the lack of
replication of K113 may be due to multiple factors. Aside from the low level of activity
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of K113 LTR in 293T cells and the nonfunctional Env, K113 also has a substitution in
CA (I516M), which greatly reduces viral particle formation in the context of HERVKCON Gag (Heslin et al., 2009). Furthermore, K113 RT is inactive, although its activity
can be restored by changing six amino acids that differ from RT sequence of HERV-K10
(Beimforde et al., 2008). Hence, despite its complete nucleotide sequence, K113 is
defective on multiple levels, and is demonstrably inactive.
In contrast, K108 has become more promising in its replication potential since its
discovery. The K108 locus, also known as HERV-K(C7) and HERV-K(HML2-HOM), is
composed of two almost identical proviruses that share an internal LTR (Reus et al.,
2001). K108 alleles contain three major mutations, a stop codon in Gag, a frameshift in
Prot, and a YIDD to CIDD in the highly conserved RT, in various combinations (Mayer
et al., 1999a; Reus et al., 2001). Its LTRs differ from each other by six nucleotides,
suggesting that it inserted more than a million years ago (Mayer et al., 1999a). For these
reasons, K108 was thought to be incapable of replication. However, against expectation,
the CIDD mutation does not inactivate RT (Figure 24). The most common allele of K108
lacks the stop codon and frameshift mutations, which are clearly inactivating mutations,
and only includes the CIDD RT mutation (Reus et al., 2001). Given that the Env and Rec
proteins of K108 are functional (Dewannieux et al., 2005), and Gag-Prot-Pol ORFs are
complete in some alleles, K108 may now represent the most likely candidate for a
replication competent HERV-K.
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Chapter 2. Derivation of HERV-KCON and the single-cycle infection system
Here, a HERV-K provirus whose sequence resembles that of an ancestral humanspecific HERV-K(HML-2) was constructed. All viral proteins encoded by this provirus
were demonstrated to be capable of functioning in the context of a retroviral replication
cycle. While some recent studies have reconstituted “live” viruses from synthetic DNA
(Cello et al., 2002; Tumpey et al., 2005), this and a similar study of HERV-K published
nearly simultaneously (Dewannieux et al., 2006) are the first examples in which the
replication cycle of a virus has been reconstituted using a group of sequences that
represent ancient fossils and are demonstrably defective. The methods used here are
conceptually similar to those applied to the reconstitution of the transposable element
Sleeping Beauty, in which a functional Tc1/mariner-type transposon present only in
defective forms in fish DNA was reconstituted (Ivics et al., 1997). Successful
reconstitution in that study was achieved using a majority consensus sequence to
synthesize an active transposase protein and selecting cis-acting sequences from a
representative element that closely resembled those of the majority consensus sequence
(Ivics et al., 1997).
It was not obvious what the optimal approach to reconstitute functional HERV-K
sequences would be, since variation in HERV-K sequence could arise through natural
variation via error-prone reverse transcription, mutational degradation after deposition in
the primate germ-line, or cytidine deamination before, during, or after during initial
germ-line deposition (see below). Moreover, it was possible that the population of
proviruses accessible to us in modern DNA represented a highly biased sample of
HERV-K genomes where defects might have been positively selected during primate
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evolution. Thus, rather than attempt reconstruct the evolutionary history of HERV-K in
primates, a conservative approach to reconstitute functional sequences was adopted,
selecting ten proviruses that were most similar to K113, reasoning that these were the
least likely to have undergone substantial sequence degradation. As described earlier, all
of the selected proviruses were unique to human DNA, and some were polymorphic in
humans, suggesting comparatively recent replication. While it was possible that all of the
selected proviruses would have a common lethal defect, this appeared not to be the case.
Indeed, by compiling a simple majority consensus sequence, individual lethal defects
represented in the group of proviruses that contribute to the consensus sequence were
successfully removed, allowing replication of the consensus genome in a bona fide
reverse transcription–dependent manner that resulted in the stable integration of HERVKCON genomes into target cells.
Assembly of HERV-K virions at the plasma membrane is notable (Figures 19 and
20), given that the exogenous retroviruses that are most closely related to HERV-K
include mouse mammary tumor virus and Mason-Pfizer monkey virus, both of which are
betaretroviruses that assemble complete capsids within the cytoplasm of infected cells.
Nonetheless, previous analyses have suggested that the small number of human cell lines
that express HERV-K exhibit plasma membrane localized assembly intermediates (Bieda
et al., 2001; Boller et al., 1993b), as was observed here for HERV-KCON. Moreover,
previous work has shown that a single amino acid mutation in MPMV Gag protein can
change its assembly characteristics from cytoplasmic to plasma membrane associated
assembly (Rhee and Hunter, 1990b). Thus, it should not be surprising that HERV-K
assembly appears morphologically different to that of its betaretrovirus relatives.
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Chapter 3. Restriction factors and HERV-K
In recent years, several gene products with antiretroviral activity have been
identified, such as TRIM5, tetherin, and the APOBEC3 family of proteins. Positive
selection pressure has been placed on many of these genes during primate evolution
(Conticello et al., 2005; McNatt et al., 2009b; Sawyer et al., 2004; Sawyer et al., 2005b;
Song et al., 2005). As HERV-K has been repeatedly colonizing the genomes of Old
World primates since the divergence of Old and New World monkeys approximately 35
million years ago, it is a potential source of recurrent selective pressure on primate hosts
(Bannert and Kurth, 2004).
HERV-K infection was not inhibited by the TRIM5 proteins that were tested
(Figure 30). In the case of human TRIM5α, this was not unexpected, because HERVKCON was derived from human-specific proviruses that must, by definition, have
replicated in humans at some point in their evolution and may, therefore, have evolved
resistance to human TRIM5α. However, HERV-KCON was also resistant to rhesus
monkey TRIM5α and also TRIM-Cyp, a form of TRIM5 that is unique to owl monkeys
(Nisole et al., 2004b; Sayah et al., 2004b), a New World monkey species that does not
carry HERV-K. At present, therefore, there is no evidence that TRIM5 proteins and
HERV-K have exerted reciprocal evolutionary pressure during primate evolution.
However, analysis of CA sequences reconstructed from more ancient groups of HERV-K
proviruses and inserted into HERV-KCON, as well as inclusion of more TRIM5α variants,
may be illuminating. The studies described herein suggest that such approaches to study
interactions between ancient retroviruses and their hosts should be feasible.
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Unlike TRIM5α, tetherin was able to restrict HERV-KCON virus release (Figure
32). Thus far, tetherin seems capable of restricting release of particles from all viruses
tested, including retroviruses from six of seven genera, as well as Marburg and Ebola
filoviruses and the arenavirus Lassa virus (Jouvenet et al., 2009a; Neil et al., 2008a;
Sakuma et al., 2009). However, most of these assays were conducted using viral
structural proteins rather than full length viruses. Hence, any anti-tetherin activity in other
parts of these viruses will not be detected. Indeed, some SIVs that do not encode for Vpu
seem to use another accessory protein, Nef, to counter the effects of tetherin (Jia et al.,
2009; Zhang et al., 2009). It is possible that other enveloped viruses have their own
mechanism of counteracting tetherin.
The study of the interaction between APOBEC proteins and HERV-K has been
more illuminating. When comparing full-length human-specific HERV-K proviruses to
HERV-KCON, an abundance of G-to-A and C-to-T substitutions were found (Figure 34).
These substitutions, the most common change found in genomes (Lander et al., 2001),
can occur when DNA methyltransferase methylates cytosines in CG dinucleotides to 5methylcytosine, which spontaneously deaminates to thymine, resulting in a CG-to-TG
change. These methylation events, important for development via genomic imprinting
and X chromosome inactivation, can also silence retroelements. This effect has been
demonstrated in mice, where knocking out DNA methyltransferase Dnmt1 or Dnmt3L
leads to transcriptional activation of mouse retroelements intracisternal A particles and
LINE-1 (Bourc'his and Bestor, 2004; Walsh et al., 1998). In addition, previous studies of
a selection of HERV-K LTRs in the teratocarcinoma cell line Tera-1 showed that
methylation and transcription are inversely related (Lavie et al., 2004). Given these two

150

facts, one would expect to find that HERV-K proviruses would be cytosine methylated by
the host, and consequently G-to-A and C-to-T mutations should be abundant. This was
indeed the case, and in 14 of 16 HERV-K proviruses examined, the CG dinucleotide
methylation/spontaneous deamination pathway appeared to be the major source of G-to-A
and C-to-T mutations (Figure 35).
Another common cause of G-to-A, and less frequently C-to-T (Bishop et al.,
2004b), changes in viral DNA is APOBEC3-mediated cytidine deamination. Fortuitously,
the two events are easily distinguished. DNA methyltransferases methylate cytosines in
CG dinucleotides, while APOBEC proteins deaminate cytosines in XC dinucleotides,
where X can differ depending on the APOBEC protein that is responsible for deamination.
Hence, by examining the nucleotides immediately 5' and 3' to the mutated cytosine, one
can largely assign G-to-A and C-to-T changes to either mechanism. One exception is
when both DNA methyltransferase and APOBEC preferred nucleotides flank the altered
cytosine, such as CCG trinucleotides, where CC represents the dinucleotide preference of
hA3G and CG the preference of DNA methyltransferase. However, exclusion of these
ambiguous samples in the analyses did not alter the conclusions.
The characteristics of HERV-K hypermutation found both in vivo and in vitro
match several of the characteristics previously observed in the context of APOBECinduced mutations in other retrovirus infections. First, G-to-A mutations constituted a
large fraction of the total mutations in HERV-K60 and HERV-KI (Figures 34 and 36), as
has previously been found for hypermutated viral sequences in HIV- and HBV-infected
patients (Janini et al., 2001; Simon et al., 2005; Suspene et al., 2006; Vartanian et al.,
1991). Furthermore, the GGG trinucleotide preference found during in vitro HERV-K
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infection in the presence of hA3G has been documented in HIV-1 infection assays by
several groups (Figures 36 and 37) (Bishop et al., 2004a; Wiegand et al., 2004; Yu et al.,
2003). The combination of these two major characteristics found in HERV-K60 and
HERV-KI, plus the failure of any other human APOBEC3 protein to induce a similar
pattern of mutation during HERV-K replication in vitro, makes a strong argument for
hA3G as the sole source of hypermutation in ancient HERV-K proviruses.
Another reported characteristic of viral hypermutation by hA3G is the gradient of
changes along the viral genome. This characteristic is thought to derive from the positiondependent length of time that the nascent viral DNA is in the form of single-stranded
DNA, the preferred nucleic substrate of hA3G. However, this was not observed in the
HERV-K60 and HERV-KI sequences (data not shown). The reasons for this are unclear
at present. Nonetheless, the ability to fairly precisely recreate the hypermutation patterns
present in ancient proviruses specifically using hA3G during in vitro HERV-K replication
assays suggests that the interaction between this protein and HERV-K occurred and was
physiologically and evolutionarily relevant. HERV-K is therefore an eminently
reasonable candidate for an infectious agent that has applied selective pressure on A3G
during primate evolution. However, it is notable that HERV-K is one of a number of
agents that could potentially have imposed selective pressure on antiretroviral defenses.
Other abundant endogenous retroelements, such as Alu and LINE-1 elements in humans,
have also been shown to be restricted by APOBEC3 proteins (Bogerd et al., 2006b; Chiu
et al., 2006; Hulme et al., 2007; Niewiadomska et al., 2007; Stenglein and Harris, 2006),
and these elements as well as other exogenous and endogenous retroviruses may also
have contributed to the expansion and positive selection that is evident in APOBEC3
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genes. Indeed, among the ancient retroviruses, only those that colonized the germ line are
accessible to this type of analysis, and it is completely unknown what fraction of ancient
retroviruses that replicated in ancestral primates are fossilized in modern DNA.
Nonetheless, A3G has been under positive selection for many millions of years (Sawyer
et al., 2004), and HERV-K could, potentially, have contributed to this pressure.
Given that HERV-K(HML-2) appears intrinsically mutable by hA3G and a
hypermutated provirus is likely to be less harmful than an intact provirus and hence more
likely to become fixed in a host genome, it is perhaps surprising that only 2 out of 16
HERV-K human-specific proviruses and none of 4 chimpanzee-specific proviruses were
clearly hypermutated. Several factors may have contributed to this, and perhaps the most
important influence would be viral tropism. The appearance of a hypermutated provirus in
human DNA indicates that HERV-K likely replicated in an A3G-expressing maternal or
paternal tissue immediately prior to deposition of the provirus into the germ line.
Conversely, the deposition of a nonhypermutated virus suggests that the preceding
generations involved replication in APOBEC3G-negative tissues. The simplest
explanation for the appearance of hypermutated and nonhypermutated proviruses in the
human genome is that HERV-K replicated in both A3G-expressing and nonexpressing
somatic cells prior to germ line infection.
Moreover, the frequency of hypermutated proviruses in modern genomes may not
reflect the frequency at which hypermutation occurred during ancient infections. Indeed,
while hypermutation would generally inactivate a particular provirus, hypermutation itself
is unlikely to be always necessary or sufficient to result in fixation of the element, where
chance-influenced mechanisms, such as drift or bottlenecking, may play a dominant role
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in provirus fixation. Of note, older HERV-K sequences belonging to group O as defined
by Romano et al. (Romano et al., 2006) did not exhibit signs of hypermutation compared
to HERV-KCON. Moreover, a previous study of endogenous murine leukemia viruses also
found that only a minority of proviruses were overtly hypermutated, perhaps for the same
aforementioned reasons.
While there was a reasonable qualitative correlation between the appearance of
APOBEC3-induced G-to-A mutations and infection inhibition during in vitro HERV-K
replication, there was a notable lack of a quantitative correlation between the burden of
mutations and the extent to which infection was inhibited. Specifically, hA3A, hA3B, and
hA3F caused mutation in a minority of nascent HERV-K reverse transcripts yet inhibited
infection to a greater degree than hA3G, which mutated the majority of nascent HERV-K
DNA molecules (Figure 38). Since no evidence of hA3A, hA3B, or hA3F hypermutation
was found in endogenous proviruses, inhibition of HERV-K infection by these cytidine
deaminases may be physiologically irrelevant or might occur primarily via mechanisms
that would not leave remnants of the viral encounter with the APOBEC protein, such as
inhibition of DNA synthesis or integration (Bishop et al., 2006; Guo et al., 2006; Holmes
et al., 2007; Mbisa et al., 2007; Yang et al., 2007).
The lack of strong inhibition of HERV-K infection by hA3G in the single-cycle
replication assay should not be overinterpreted as suggesting that hA3G lacks antiHERV-K activity in vivo. As documented here and elsewhere, A3G appears to have
evolved to target GG dinucleotides, especially GGG trinucleotides. This property makes it
a particularly efficient mutator of tryptophan codons. G-to-A mutation of tryptophan
codons invariably leads to the generation of new stop codons, which would almost always
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be lethal to a retrovirus, even if a provirus were successfully established with a relatively
low burden of A3G-induced mutation. Importantly, the HERV-K infection assay requires
a single cycle of infection by a reporter virus that encodes the commonly used EGFP as
the reporter gene. EGFP contains only a single tryptophan, and thus a moderate level of
hA3G-induced mutations might not score as strong inhibition during an in vitro singlecycle infection assay but would abolish further rounds of replication in an in vivo
spreading infection. Indeed, HERV-K60 and HERV-KI represent clear examples of viral
sequences that have been fossilized in the human genome in defective form as a
consequence of hA3G-induced hypermutation.

Chapter 4. Integration of HERV-KCON
Here, a study of integration target site selection by HERV-KCON and its
relationship to the distribution of fixed HERV sites in the human genome is reported.
Sites of HERV-KCON integration were slightly enriched in transcription units, in genedense regions, and in a collection of features associated with gene activity (Figure 41).
The endogenous HERV-K elements, ERV2 and HML2(85), showed a very different
distribution and were enriched outside genes (Figure 43). The HERV-K(HML-2),
represented by the HML2(85) data set, showed a pattern intermediate between the older
HERV-K superfamily ERV2 sites and the de novo integrated HERV-KCON (Figures 43
and 45). These data support a two-step model for accumulation of fixed HERV elements
in the human genome, in which integration targeting preferences dictated the initial
placement of integration sites, while subsequent purifying selection eliminated the
majority of insertions because they were deleterious to host viability.
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Previous studies have reported differing distributions among the distinct HERV
element families and investigated the mechanisms that mediate gene disruption upon
integration (Mager et al., 1999; Smit, 1999; van de Lagemaat et al., 2006). These studies
support the idea that strong splice sites and poly(A) sites within HERV elements can
disrupt gene transcription, as has been seen with other genomic parasites (Britten, 1996;
Jordan et al., 2003; van de Lagemaat et al., 2006). However, these studies did not identify
a distinctive distribution pattern for the most recently integrated HERV sequences. This
study used homology searching to form a collection of the most similar, hence youngest,
genomic HERV-K(HML-2) elements, and it was by analyzing this collection that the
intermediate distribution of HML2(85) sequences between the older ERV2 elements and
newly integrated HERV-KCON was detected. In contrast to the relationship to genomic
features, the orientation bias within genes is evident and similar for both the HML2(85)
and ERV2 data sets. This is consistent with the idea that particularly disruptive proviruses
integrated within genes may be removed relatively quickly by purifying selection.
Previous studies of retroviral integration targeting have shown that retroviruses
from the same genus tend to share the same targeting patterns, but HERV-KCON appears
to be an exception. HERV-KCON is most closely related to exogenous betaretroviruses,
and its integrase protein sequence clusters with MMTV, a prototype betaretrovirus rather
than integrases from other retroviral genera (data not shown). As discussed above,
HERV-KCON integration is more frequent in gene-rich regions and genomic features
associated with active transcription, somewhat resembling MLV (Wu et al., 2003).
Surprisingly, the reported MMTV distribution is almost perfectly random (Faschinger et
al., 2008). The only other data set with such a random distribution is AAV, but AAV is
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believed to become integrated at cellular DNA double-strand breaks by the action of
cellular DNA repair enzymes (Rutledge and Russell, 1997; Song et al., 2001). MMTV, in
contrast, encodes an integrase protein, and MMTV integration events show the usual
sequence features associated with retroviral integration. It will be useful to obtain more
data on integration site distributions from the betaretrovirus genus to clarify this puzzling
observation.
Another previously noted surprising difference between the members of
betaretroviridae is the location of assembly. Assembly of related betaretrovirus MPMV
takes place at a perinuclear region (Rhee and Hunter, 1987), whereas HERV-K assembly
takes place at the plasma membrane. These two phenotypic differences (assembly and
integration targeting) within betaretroviridae suggest that the genus may not be
monophyletic. Thus, although the integration targeting data for HERV-KCON seems likely
to model trends for all of the HERV-K elements, it is uncertain to what extent, if any, the
data for HERV-KCON models the other HERV families that most closely resemble
exogenous retroviruses of other genera.
The two-step model for HERVs accumulation is likely operating on endogenous
retroviruses and other integrating elements of many vertebrates (Bushman, 2001; Han
and Boeke, 2005; Kazazian, 2004). In a previous study, Barr et al. compared de novo
ASLV integration events in chicken cells to fixed proviruses in the chicken germline that
were derived from the same retroviral group (Barr et al., 2005). They found that de novo
ASLV integration showed a modest preference for transcription units, while fixed ASLVs
in the germline accumulated outside of transcription units. Fixed ASLVs in the germline
also showed an orientation bias, so that proviruses within genes tended to accumulate in
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opposite transcriptional orientation relative to the host gene, while the de novo
integration events showed no such bias. Similar biases in endogenous provirus
accumulation have also been observed in mouse and rat (Barr et al., 2005; van de
Lagemaat et al., 2006). These findings suggest that purifying selection is operating
similarly on the endogenous retroviruses inhabiting the genomes of many vertebrates
(Barr et al., 2005; Brookfield, 2005; Cutter et al., 2005; Lowe et al., 2007; Roy-Engel et
al., 2005).

Other questions
Is HERV-K still replication competent?
The findings from the HERV-K sequence data, such as the purifying selection on
ORFs, supports the idea that HERV-K has been replicating until recent evolutionary time
(Belshaw et al., 2005a; Costas, 2001). However, so far all insertions have been identified
via manual screening of cell lines, a handful of human samples, or BAC libraries and
mining the genomic sequence data, meaning that only a few individuals’ genomes have
been screened. To identify a replication competent virus, more polymorphic elements
need to be identified, as replication competent virus is likely to be among these sequences,
if it exists at all. However, currently, the detection method is limited, as mass sequencing
of individuals is expensive, and various blotting techniques are less sensitive.
Furthermore, even after a wide array of human individuals and populations have been
screened, proving de novo infection by HERV-K will be difficult, as it will require
identification of an insertion in an offspring that does not exist in either parent. Hence,
proof of natural replication of HERV-K in vivo is still currently unlikely.
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Which cells did HERV-K infect?
ERVs must infect germ cells or germ cell progenitors to become endogenized, but
it is unclear whether these are the natural or rare targets. If cells other than germ cells and
progenitors are HERV-K’s most common target cells, then the virus may be capable of
horizontal transmission to new, unrelated hosts. This idea is based on the concept of
purifying selection. If HERV-K infects somatic cells but does not infect new individuals,
the infection in the somatic cells will be lost once the host dies, as no effective additional
copies of the virus have been generated. In other words, if the somatic infection had not
occurred, there would be no difference to the virus population. Without replication, there
is no selection to retain the sequence, and the somatic cell tropism will likely be lost over
time. However, if upon infection of somatic cells, the virus can transmit to a new host,
the propagation and hence selection to retain sequences important for exogenous life
cycle may be retained. What these other natural target cells may be is entirely unknown.
Another factor in question in identifying the target cell is the gender of the host.
Unlike most somatic cells such as CD4+ T cells of HIV-1, gametogenesis is a gender
specific process; thus, HERV infection may be gender specific. It is certain that male
germ cells and/or progenitors are infected, as Y chromosome harbors HERV insertions.
The insertions found on X chromosome may have occurred in either male or female host,
hence it is not possible to rule out female germ cells as potential targets.
The stage of germ cell development at which HERV-K infection occurs is also
difficult to identify. The transcriptional activity of HERV-K LTR in teratocarcinomaderived cell lines, a tumor in the testes which includes pluripotent germ cells, suggests
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that HERV-K LTR activity may be linked to earlier parts of germ cell development.
Furthermore, study of HERV-K LTR in human and mouse teratocarcinoma cells showed
higher LTR activity relative to nonteratocarcinoma cells, which was lost after
differentiation of teratocarcinoma cell lines, suggesting that there may be an unknown
point in development after which the LTR become inactive (Casau et al., 1999). Also, in
HERV-K LTR transgenic mice, the LTR was active in the testes, especially in the
undifferentiated spermatocytes (Casau et al., 1999). In human samples, HERV-K(HML-2)
elements were expressed at low levels in both the testes and ovary (Seifarth et al., 2005).
Collectively, the LTR seems to be more active in the earlier male germ cell development
stages than later, and suggests that the virus may be more replication competent during
this time.

Can HIV-1 become endogenized?
As a retrovirus, it is possible that HIV-1 can also become endogenized by either
infecting developing or mature gametes. In oocytes, in vitro incubation of oocytes and
cell free HIV-1 does not result in infection; in vivo infection is unknown (Baccetti et al.,
1999). In males, HIV-1 is found in semen soon after infection (Tindall et al., 1992).
Furthermore, virus DNA can be detected in sperm at various stages of development
(spermatogonia, spermatids, and spermatocytes) from testes of HIV-1 infected men via
PCR in situ hybridization and PCR (Muciaccia et al., 1998; Nuovo et al., 1994). In
animal models, viral RNA and proteins are found in testes and epipididymis of pig-tail
macaques (Macaca nemestrina) infected with SIVmac251or SHIVmn229, suggesting that
these locations of spermatogensis contain productively infected cells (Shehu-Xhilaga et
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al., 2007). A caveat to these studies is the potential of presence by cell-free virus or
infected lymphocytes. HIV-1 may also infect spermatozoa in the semen, where cell-free
virus is found (Krieger et al., 1991). Spermatozoa purified from other cells and semen
fluid have been shown to contain HIV-1 DNA, but no direct evidence of a provirus has
been shown (Muciaccia et al., 2007) [reviewed in (Cardona-Maya et al., 2006)]. Hence,
infection of spermatozoa and progenitors is still inconclusive.
Another problem of endogenization of HIV-1 is the lack of CD4, the HIV-1 Env
receptor, in both gametes (Baccetti et al., 1999; Gil et al., 1995). As an alternate,
mannose receptor CD206 has been identified from solubilized spermatozoa proteins as
binding partners of cell free HIV-1 virus particles or HIV-1 Env protein, and proposed to
act as the receptor on spermatozoa in the absence of CD4 (Bandivdekar et al., 2003;
Fanibunda et al., 2008). Mannose receptor has already been shown to mediate HIV-1 Env
binding in astrocytes, macrophages, and dendritic cells, although in the latter two cell
types, this binding is thought to mediate virus transfer to CD4+ T cells, rather than
inducing infection in macrophages and DCs (Liu et al., 2004; Nguyen and Hildreth, 2003;
Turville et al., 2001). In astrocytes, the interaction between HIV-1 Env and mannose
receptor is thought to enable infection (Liu et al., 2004). However, there is no direct
evidence of spermatozoa infection via the mannose receptor. Hence, thus far, there is no
direct evidence that HIV-1 will become endogenized.
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